Gamma-diketones for treatment and prevention of aging skin and wrinkles.
Abstract
The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

Term
8.9 yearsleft in the term
Expires 20 August 2035.
- Priority
- Filed
- Granted
- Today
- Expires
3 claims: 2 independent, 1 dependent
- 1CLAIMS REIVINDICACIONES 1.- A cosmetic method for improving the aesthetic appearance of a subject's skin, the method is characterized in that it comprises administering to the subject an effective amount of a compound of Formula I. or a dermatologically acceptable salt thereof:l.-Un método cosmético para mejorar la apariencia estética de una piel de sujeto, el método está caracterizado porque comprende administrar al sujeto una cantidad efectiva de u.n compuesto de la Fórmula I. o una sal dermatológicamente aceptable del mismo: en donde: where: el anillo A es un heteroarilo de 7-12 miembros, con la condición de que un átomo de carbono en el anillo se una al carbono de carbonilo;ring A is a 7-12 membered heteroaryl, provided that one carbon atom in the ring attaches to the carbonyl carbon;Ring 8 is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, provided that one carbon atom in the ring attaches to the carbonyl carbon: el anillo 8 se selecciona del grupo que consiste de fenilo y un heteroarilo de 5-6 miembros, con la condición de que un átomo de carbono en el anillo se una al carbono de carbonilo: R1 es un sustituyente unido al anillo A y se selecciona independientemente en cada ocurrencia del grupo que consiste en Ci-6 alquilo no substituido, haloalquilo, haluro, -OR3 y CN;R1 is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of Ci-6 unsubstituted alkyl, haloalkyl, halide, -OR3 and CN;R2 es un sustituyente unido al anillo 8 y se selecciona independientemente en cada ocurrencia del grupo que consiste en Gi-s alquilo no substituido, -CHs'OH, -CHsNCR^h, -Ci-s haloalquilo, haluro, -OR3 y CN;R2 it is a substituent attached to ring 8 and is independently selected at each occurrence from the group consisting of Gi-s unsubstituted alkyl, -CHs'OH, -CHsNCR ^ h, -Ci-s haloalkyl, halide, -OR3 and CN;cada Ra se selecciona independientemente del grupo que each Rto is independently selected from the group that 330 it consists of H, -Ci and unsubstituted alkyl, and haloalkyl;330 consiste en H, -Cí e alquilo no substituido, y haloalquilo;cada R3b se selecciona independientemente del grupo que consiste en H y~C<..s alquilo no substituido;each R3b is independently selected from the group consisting of H and ~ C <.. s unsubstituted alkyl;cada n es 0 a 10;y each n is 0 to 10;Y 5 each m is 0 to 5. 5 cada m es 0 a 5.
- 3.ci 3..ci Br Br H, o una sal dermatológicamente aceptable del mismo. H, or a dermatologically acceptable salt thereof. 11. method according to any of claims 1 to 10, further characterized in that the improvement in aesthetic appearance is improvement of one or more of skin tone, radiance, clarity, tightness, skin firmness, fatness, flexibility, softness, texture of skin, foot texturing! and wetting. 11.método conformidad con cualquiera de las reivindicaciones 1 a 10, caracterizado además porque la mejora en apariencia estética es mejora uno o más de tono de piel, radiancia, claridad, tirantez, firmeza de la piel, gordura, flexibilidad, suavidad, textura de la piel, texturización de la píe! y humectación. apariencia de contornos de ía piel, apariencia de mejillas hundidas. appearance of contours of the skin, appearance of sunken cheeks. Appearance of sunken, loose or dark circles under the skin, brilliance, thickness of the psel, and elasticity of the skin. apariencia de círculos hundidos, holgados u obscuros bajo lo i u sí re piel, brillantez, grosor de la psel, y elasticidad re s i lie nc¡a de la piel. El método de conformidad con cualquiera de reivindicaciones 1 a 10, caracterizado además porque la mejora apariencia estética es la reducción y/o prevención de líneas expresión o arrugas. The method according to any of claims 1 to 10, further characterized in that the improved aesthetic appearance is the reduction and / or prevention of expression lines or wrinkles. 13,- El método de conformidad con cualquiera reivindicaciones 1 a 10, caracterizado además oorque la mejora de las apariencia estética es la. reducción y/o prevención de decoloración 13. The method according to any of claims 1 to 10, further characterized because the improvement of the aesthetic appearance is the. reduction and / or prevention of discoloration 358 of the skin. 358 de la piel. 14. The method according to any of claims 1 to 10, further characterized in that the compound is formulated to be administered as a cosmetic composition;14.- Ei método de conformidad con cualquiera de las reivindicaciones 1 a 10, caracterizado además porque el compuesto está formulado para ser administradle como una composición cosmética;15. The method according to claim 14, further characterized in that the cosmetic composition is a topical composition. 15.- El método de conformidad con la reivindicación 14, caracterizado además porque la composición cosmética es una composición, tópica.
Independent claims2
4,160 paragraphs in 59 sections, as filed
DIVISIONAL DEPUTY DIRECTOR OF PATENT FUND EXAMINATION BIOTECHNOLOGICAL, PHARMACEUTICAL AND CHEMICAL AREAS
<img file="MX368248B_D0001.tif" />
EMELIA HERNÁNDEZ PRIEGO
Original string:
EMELIA HERNANDEZ PRIEGO | 00001000000405397295 | Administration Service
Tr¡butar¡a | 56 || MX / 2019/88238 | MX / a / 2017/002285 | Patent title PCT | 1223 | GAGV | Page (s) 2 | XLLYP + wPmhkN27YOudXETObVx1 A =
Digital stamp:
DJos6WB9umBBKqzdlHmyqSho3SulKJdg11NUnC6Fri9jOTCcfN / ysTSG8ztSyW14L / pyP¡Lv2W2nncbmomfHrTxyJD oXkr6Fsxz80qL2cxlKHvMÓxylwgcGtaZiolBCjjByGpqdC¡aVyg7Obz5 / 4qCa0tRsUsFgZ + 88q087m02AnJER / e6sa
NDOBcpe1QZBZcFJ93jOWp5o1Rtc58vpOTmesTQjPWknYBQ1jczq5IBRb8SMeu9yevzXyE7HURMUbajhT8HOZFGKXWXKQX5KXQXP5 / YPVM1QBXQ05
Additional information on the next page.
MX 2019'88238
GAMMA-DICETONES FOR TREATMENT AND PREVENTION OF AGED SKIN AND WRINKLES
Related requests
This application claims the benefit of provisional US Application No. 62 / 039,786, filed on August 20, 2014, which is incorporated herein by reference in its entirety.
Background of the Invention
Technical field
The present description refers to compounds, cosmetic or dermopharmaceutical compositions comprising the same and methods for using the compounds or compositions to treat, protect and / or improve the aesthetic condition and / or appearance of the skin, for example, treating, preventing, improve, reduce and / or eliminate expression lines and / or skin wrinkles, or improve the appearance of expression lines and / or skin wrinkles, the methods comprising the application of the described compounds or compositions.
Background
The mammalian epidermis and its appendages (for example, hair, nails, sebaceous and sweat glands) provide a barrier to keep harmful elements out of the body and essential body fluids inside. As the first line of defense against various physical trauma to the environment, the epidermis must protect itself as well as the underlying tissues. The epidermis is also exposed to mutagenic ultraviolet radiation. In hairless or sparse regions, such as most human skin, the epidermis is thicker than that of hairy skin, and in these locations the skin functions primarily in a protective role. The constant assaults on the epidermis need self-renewal, making the epidermis a good example of an adult tissue that experiences continuous and rapid flow.
Aged skin differs from young skin in both appearance and function. The aged epidermis is devoid of keratinocytes and is physically thinner, but mainly from the erasure of the epithelial ridges. In addition to weight loss, aging slows wound healing, prolongs epidermal rotation, and impairs barrier formation. The skin appears thin, wrinkled, bruised, and rough. Wrinkles and bruises can also result from age-related changes in the dermis. The dermis is also characteristically thinner in older people. Aging fibroblasts are less likely to synthesize normal amounts of collagen, elastin, laminin glycosaminoglycans, and fibronectin. The dermis may, in such cases, lack elasticity, strength, container support, remodeling capabilities, and base substances. For example, epithelial ridges can be erased and basal cells may no longer deploy hairy projections into the dermis. Epidermal cell turnover is reduced by up to 50% in the elderly compared to the young. For example, the amounts of melanocytes can decrease 8-20% per decade. There are fewer Langerhans cells in the elderly, and those present frequently deteriorate functionally. Collagen synthesis decreases, for example, up to 30% within 4 years of menopause in women. The numbers of collagen and elastic fibers also decrease. The dermis may also become less echogenic on ultrasound, consistent with changes in collagen and elastic tissues.
Brief description of the invention
The present disclosure relates to compounds, compositions comprising the same, and methods of using the compounds or compositions to treat, protect, and / or alter (eg, improve) the condition and / or aesthetic appearance of the skin, including, for example , treat, prevent, improve, reduce and / or eliminate expression lines and / or wrinkles of the skin and / or improve the aesthetic appearance of expression lines and / or wrinkles of the skin, caused by, for example, cellular senescence, environmental damage or dermatoheliosis. The description also relates to methods for stimulating skin cell turnover, promoting fibroblast proliferation, and / or synthesizing elastin, collagen, proteoglycans, or new connective tissue, thereby reducing wrinkles, restoring elasticity, resilience, and / or flexibility of the skin.
The compounds and compositions described herein can be used for cosmetic uses, dermopharmaceutical uses, or both cosmetic and dermopharmaceutical uses. A "cosmetic" as used herein can be contacted with the skin, such as by being rotated, emptied, sprayed, sprayed onto the skin, or otherwise introduced into or onto the skin, and is intended to improve the aesthetic appearance of the skin, such as when cleaning, beautifying, promoting attractiveness, or altering, for example, improving, the aesthetic appearance of the contacted skin. A cosmetic benefit is usually visual or aesthetic and can be evaluated using subjective or objective tests.
A "dermopharmaceutical" as used herein, can be similarly contacted with the skin and is intended to be used in the treatment, mitigation or prevention of a skin disease or disorder and / or is intended to affect the structure or a function of the skin. A dermopharmaceutical normally has a physiological, pharmacological and / or therapeutic effect on the skin. A dermopharmaceutical can result in an improved aesthetic appearance of the skin by virtue of its physiological, pharmacological, or therapeutic effects. A dermopharmaceutical benefit can be evaluated using subjective or objective tests.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for improving the condition and / or aesthetic appearance of the skin, wherein the composition comprises a compound according to formula I, II, Illa, lllb and / or
IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition to alter the aesthetic appearance of skin associated with or affected by, or to prevent or reduce, wrinkles, dry skin, sensitive skin, or dermatological symptoms caused by ineffective homeostatic regulation of healthy skin, wherein the composition comprises a compound according to formula I, II, Illa, IIIb and / or IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for altering the aesthetic appearance of skin associated with or affected by wrinkles, sagging and / or loss of skin elasticity, wherein the composition comprises a compound according to formula I , II, Illa, lllb and / or IV.
In another embodiment, the description refers to the use of a compound according to formula I, II, Illa, lllb and / or IV to alter the aesthetic appearance of skin associated with or affected by wrinkles and / or expression lines, skin lean, a lack of elasticity and / or skin tone, thinning of the dermis, degradation of collagen fibers, sagging skin, thinned skin and / or internal skin breakdown following exposure to ultraviolet radiation.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition to alter the aesthetic appearance of the skin associated with or affected by, or to treat or prevent, a skin condition / disorder accompanied by a loss of skin elasticity, in where compassion comprises a compound according to formula I, II, Illa, lllb and / or
IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for altering the aesthetic appearance of skin associated with or affected by, or for treating or preventing, acne, wherein the composition comprises a compound according to formula I, II, Illa, lllb and / or IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for treating or preventing deterioration in skin viscoelasticity, wherein the composition comprises a compound according to formula I, II, Illa, lllb and / or IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for treating or preventing vitiligo (a skin condition in which there is a loss of brown color (pigment) from skin areas), wherein the composition comprises a compound of according to formula I, II, Illa, lllb and / or IV.
In one embodiment, the disclosure provides methods of increasing cell or tissue regeneration. Such methods include administering to a vertebrate subject in need thereof, a compound according to formula I, II, Illa, lllb and / or IV, or a dermatologically acceptable salt thereof.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for activating or promoting the proliferation and / or mobility of skin keratinocytes and / or dermis fibroblasts, for example, to perform skin regeneration, wherein the composition comprises a compound according to formula I, II, Illa, IIIb and / or IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for increasing or improving epidermal cell repair activity, eg, in a human, wherein the composition comprises a compound according to formula I, II, Illa, lllb and / or IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for increasing or improving the barrier function and / or viability of the skin, wherein the composition comprises a compound according to formula I, II, Illa, lllb and / or IV.
In one embodiment, the present disclosure provides a cosmetic or dermopharmaceutical composition for increasing fibroblast proliferation, keratinocyte proliferation and / or collagen expression, or reducing collagenase activity, wherein the composition comprises a compound according to formula I, II, Illa, lllb and / or IV.
In another embodiment, the disclosure relates to the use of a compound according to formula I, II, Illa, lllb and / or IV as a medicament for treating or preventing a wound healing disorder in a mammal.
In another embodiment, the disclosure refers to the use of a compound according to formula I, II, Illa, lllb and / or IV as a medicament for treating or preventing a wound, such as an ulcer in a mammal.
Some embodiments provided herein include cosmetic or dermopharmaceutical compositions comprising one or more of the compounds provided herein and a dermatologically acceptable carrier.
An embodiment provided herein includes compounds of formula I:
<img file="MX368248B_D0002.tif" />
or a dermatologically acceptable salt thereof.
In some forms of formula I:
Ring A is a 7-12 membered heteroaryl, provided that a carbon atom on the ring is attached to the carbonyl carbon;
Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, provided that one carbon atom in the ring is attached to the carbonyl carbon;
R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of Ci.<sub>6</sub> unsubstituted alkyl, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN;
R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of
Cve unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -C<sub>V3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN;
each R<sup>3</sup> is independently selected from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl and -Ci_<sub>3</sub> haloalkyl;
each R<sup>3b</sup> is independently selected from the group consisting of H and C ^ to unsubstituted alkyl;
each n is 0 to 10; and each m is 0 to 5.
Another embodiment provided herein includes compounds of formula II:
<img file="MX368248B_D0003.tif" />
or a dermatologically acceptable salt thereof.
In some forms of formula II:
Ring C is a 5-6 membered heteroaryl, provided that one carbon atom on the ring is attached to the carbonyl carbon;
Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, provided that one carbon atom on the ring is attached to the carbonyl carbon;
R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of Ci.e unsubstituted alkyl, -C1.3 haloalkyl, halide, -OR<sup>and</sup> and CN;
R<sup>5</sup> is a substituent attached to ring D and is independently selected at each occurrence from the group consisting of Ci.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>5b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>6</sup> and CN;
each R<sup>6</sup> is independently selected from the group consisting of H, -C<sub>V</sub>8 unsubstituted alkyl and -C1.3 haloalkyl;
each R<sup>eb</sup> is independently selected from the group consisting of H and C<sub>13</sub> unsubstituted alkyl;
each q is 0 to 4; and each p is 0 to 5.
Another embodiment provided herein includes compounds of formula III:
(R<sup>8</sup>)<sub>p</sub> '£ Λύ °
III or a dermatologically acceptable salt thereof.
In some forms of formula III:
R<sup>7</sup> is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of Cve unsubstituted alkyl, -CH2OH, -CH2N (R<sup>9a</sup>) 2, -Ci.<sub>3</sub> haloalkyl, halide, -OR<sup>9</sup> and CN;
R<sup>8</sup> is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of Ci-e alkyl, -CH2OH, -CH2N (R<sup>9a</sup>) 2> -C ^ haloalkyl, halide, -OR<sup>9</sup> Y
CN;
each R<sup>9</sup> is independently selected from the group consisting of H, -Ove unsubstituted alkyl and -C1.3 haloalkyl;
each R<sup>9a</sup> is independently selected from the group consisting of H and C<sub>13</sub> unsubstituted alkyl; and each q is 1 to 5; and each p is 0 to 5.
Another embodiment provided herein includes compounds of formula Illa:
<img file="MX368248B_D0004.tif" />
Illa or a dermatologically acceptable salt thereof.
In some forms of the Illa formula:
R<sup>10</sup> is selected from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, <sup>_</sup>Ci-3 haloalkyl, halide, -OR<sup>13</sup> and CN;
R<sup>11</sup> is selected from the group consisting of -C ^ unsubstituted alkyl, -CH2OH, -CH2N (R<sup>13b</sup>) 2, -Ci.3 haloalkyl, halide, -OR<sup>13</sup> and CN;
R<sup>12</sup> is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of Cve unsubstituted alkyl, -CH2OH, -CH2N (R<sup>13b</sup>) 2, -C ^ a haloalkyl, halide, -OR<sup>13</sup> and CN;
each R<sup>13</sup> is independently selected from the group consisting of -C ^ g unsubstituted alkyl and -C<sub>V3</sub> haloalkyl;
each R<sup>13b</sup> it is independently selected from the group consisting of H and -Ci.<sub>3</sub> unsubstituted alkyl; and each q is 0 to 5.
Another embodiment provided herein includes compounds of formula lllb:
<img file="MX368248B_D0005.tif" />
II Ib or a dermatologically acceptable salt thereof.
In some modalities of lllb formula:
R<sup>14</sup> is selected from the group consisting of -Ci.<sub>and</sub> unsubstituted alkyl and -C-_<sub>3</sub> haloalkyl;
R<sup>15</sup> is selected from the group consisting of -Ci.<sub>and</sub> unsubstituted alkyl and -Ci_<sub>3</sub> haloalkyl;
R<sup>16</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of Cve unsubstituted alkyl, CH2OH, -CH2N (R<sup>17b</sup>) 2, -Ci.3 haloalkyl, halide, -OR<sup>17</sup> and CN;
each R<sup>17</sup> is independently selected from the group consisting of -C ^ e unsubstituted alkyl and -C<sub>13</sub> haloalkyl;
each R<sup>17b</sup> is independently selected from the group consisting of H and C<sub>13</sub> unsubstituted alkyl; and each q is 0 to 5.
Another embodiment provided herein includes compounds of formula IV:
IV or a dermatologically acceptable salt thereof.
In some forms of formula IV:
ring F is <sup>r</sup> ring G is selected from the group consisting of R<sup>1</sup>* <sub>R</sub>19b
<img file="MX368248B_D0006.tif" />
and a heteroaryl (R<sup>19d</sup>)<sub>z</sub> 5-6 membered, with the proviso that a carbon atom on the heteroaryl ring binds to the carbonite carbon;
each R<sup>18</sup> is a substituent attached to ring F and is independently selected at each occurrence from the group consisting of C1.3 haloalkyl, halide, -OR<sup>20</sup> and CN;
R<sup>19th</sup> is a substituent attached to the para position of phenyl and is selected from the group consisting of H, -C2.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>21</sup>) 2, -C1.3 haloalkyl, F, Br, I, -OR<sup>20</sup> and CN;
R<sup>19b</sup> is a substituent attached to the meta or ortho position of phenyl and is selected from the group consisting of H, -C<sub>2</sub>.<sub>and</sub> unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>21</sup>)<sub>2</sub>, -Ci.<sub>3</sub> haloalkyl, halide, -OR<sup>20</sup> and CN;
r<sup>19c</sup> is a phenyl-linked substituent and is independently selected at each occurrence from the group consisting of CH2OH, -CH2N (R<sup>21</sup>) 2, -0, .3 haloalkyl, halide, -OR<sup>20</sup> and CN;
R<sup>19d</sup> is a substituent attached to the heteroaryl ring and is independently selected at each occurrence from the group consisting of -CH2OH, -CH2N (R<sup>21</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>20</sup> and CN;
each R<sup>20</sup> is independently selected from the group consisting of H, -C<sub>3</sub>.<sub>6</sub> unsubstituted alkyl and -C1.3 haloalkyl;
each R<sup>21</sup> is independently selected from the group consisting of H and -C1.3 unsubstituted alkyl;
k is 0 to 5;
p is 0 to 13;
r is 1 to 5;
z is 0 to 4.
Some embodiments include stereoisomers of a compound of formula I, II, Illa, lllb and / or IV.
Some embodiments include prodrugs of a compound of formula I, II, Illa, lllb and / or IV. For example, prodrugs of a compound of formula I, II, Illa, lllb and / or IV can be prodrug polymer conjugates for delayed release or prolonged release.
Also provided herein are cosmetic or dermopharmaceutical compositions comprising a compound of formula I, II, Illa, lllb and / or IV and a dermatologically acceptable carrier, diluent or excipient.
It is understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the description as claimed.
Detailed description of the drawings
The figure is a linear graph showing the average change in roughness of the skin baseline of test subjects after topical treatment of the periorbital areas using compound # 222 (0.05% in oil, 005% in PEG, 0.15% in oil and 0.15% in PEG). The roughness was determined by Visioscan. Each data point is the average of 20 or 21 test subjects.
Figure 2 is a line graph showing the average percentage of wrinkle reduction of the skin baseline of test subjects after topical treatment of the periorbital areas by compound # 222 (0.05% in oil, 0.05% in PEG 0.15% in oil and 0.15% in PEG). Wrinkle reduction was determined by Visioscan. Each data point is the average of 20 or 21 test subjects.
Detailed description of the invention
Provided herein are γ-diketones useful for treating, protecting and improving the cosmetic condition and / or appearance of the skin, for example, treating, preventing, improving, reducing and / or eliminating and / or improving the appearance of fine lines. and / or wrinkles of the skin. The inventors have discovered that in some embodiments, the application of the γ-diketones provided herein may increase collagen replacement and retention and may, in some embodiments, also increase cell proliferation of the epidermis and dermis.
Cosmetic or dermopharmaceutical compositions comprising one or more compounds according to formulas I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf, III, Illa, lllb, lile, Hld and / or IV, or a dermatologically acceptable salt and a dermatologically acceptable carrier are also provided herein.
Compounds
Some embodiments of the present disclosure include compounds of formula (I):
<img file="MX368248B_D0007.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some embodiments of formula I, ring A is a 7-12 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some embodiments of formula I, ring A is a 7-12 membered heteroaryl, wherein a carbon atom in the benzene ring is attached to the carbonyl carbon.
In some embodiments of formula I, ring A is a 7-12 membered heteroaryl, wherein a carbon atom in the heteroaromatic ring is attached to the carbonyl carbon.
In some embodiments of formula I, ring A is a 7-12 membered heteroaryl, wherein a carbon atom in the heterocyclic aliphatic ring is attached to the carbonyl carbon.
In some embodiments of formula I, ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, provided that one carbon atom in the ring is attached to the carbonyl carbon.
In some forms of formula I, R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -C ^ unsubstituted alkyl, Ci.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula I, R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -Ci_<sub>and</sub> unsubstituted alkyl, Ci_3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula I, R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of H, -C<sub>b5</sub> unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -0, .3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula I, R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of -C, .e unsubstituted alkyl, CH2OH, -CH2N (R<sup>3b</sup>) 2, -Ci-<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula I, each R<sup>3</sup> is independently selected from the group consisting of H, -C<sub>V6</sub> unsubstituted alkyl and -Ci_<sub>3</sub> haloalkyl.
In some forms of formula I, each R<sup>3b</sup> is independently selected from the group consisting of H and -C<sup>1</sup>’<sup>3</sup> unsubstituted alkyl.
In some forms of formula I, n is 0 to 10. In some forms of formula I, n is 1 to 10.
In some modalities of formula I, m is 0 to 5.
In some modalities of formula I, m is 1 to 5.
In some embodiments of formula I, ring A is a 9-membered bicyclic heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
In some embodiments of formula I, ring A is a 10-membered bicyclic heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
In some embodiments of formula I, ring A is selected from the group consisting of:
<img file="MX368248B_D0008.tif" />
Otherwise designated, the carbonyl carbon of formula I can bond with an unsubstituted carbon in ring A.
In some embodiments of formula I, ring A is selected from the group consisting of:
<img file="MX368248B_D0009.tif" />
where the carbonyl carbon of formula I can bond with any unsubstituted carbon in ring A.
In some embodiments of formula I, ring A is selected from the group consisting of:
<img file="MX368248B_D0010.tif" />
<img file="MX368248B_D0011.tif" />
wherein the carbonyl carbon of formula I can bond with any unsubstituted carbon in ring A.
In some embodiments of formula I, the ring is selected from the group consisting of:
<img file="MX368248B_D0012.tif" />
<img file="MX368248B_D0013.tif" />
<img file="MX368248B_D0014.tif" />
wherein the carbonyl carbon of formula I can bond with any unsubstituted carbon in ring A.
In some embodiments of formula I, ring A is selected from the group consisting of
<img file="MX368248B_D0015.tif" />
<img file="MX368248B_D0016.tif" />
<img file="MX368248B_D0017.tif" />
<img file="MX368248B_D0018.tif" />
<img file="MX368248B_D0019.tif" />
<img file="MX368248B_D0020.tif" />
<img file="MX368248B_D0021.tif" />
wherein the carbonyl carbon of formula I can bond with any unsubstituted carbon in ring A.
In some embodiments of formula I, ring A is selected from the group consisting of
<img file="MX368248B_D0022.tif" />
<img file="MX368248B_D0023.tif" />
<img file="MX368248B_D0024.tif" />
<img file="MX368248B_D0025.tif" />
wherein the carbonyl carbon of formula I can bond with any unsubstituted carbon in ring A.
In some embodiments of formula I, ring A is selected from the group consisting of
<img file="MX368248B_D0026.tif" />
<img file="MX368248B_D0027.tif" />
where the carbonyl carbon of formula I can bond with any unsubstituted carbon in ring A.
In some embodiments of formula I, ring A is selected
<img file="MX368248B_D0028.tif" />
In some embodiments, ring A is selected from the group consisting of
<img file="MX368248B_D0029.tif" />
<img file="MX368248B_D0030.tif" />
Some formula modalities
I include compounds of formula (la):
<img file="MX368248B_D0031.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some modalities of formula la, ring A is
<img file="MX368248B_D0032.tif" />
In some embodiments of formula la, ring B is selected from the group consisting of
<img file="MX368248B_D0033.tif" />
<sub>R</sub>2b
<img file="MX368248B_D0034.tif" />
<img file="MX368248B_D0035.tif" />
<img file="MX368248B_D0036.tif" />
<img file="MX368248B_D0037.tif" />
<img file="MX368248B_D0038.tif" />
<img file="MX368248B_D0039.tif" />
<img file="MX368248B_D0040.tif" />
(R<sup>2</sup>·), (R<sup>2f</sup>)<
<img file="MX368248B_D0041.tif" />
(R<sup>20</sup>).
<img file="MX368248B_D0042.tif" />
(R<sup>2e</sup>) t (R<sup>2e</sup>k
In some modalities of formula la, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -Ci-3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities, of formula la, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -C <.<sub>and</sub> unsubstituted alkyl, -Cv <sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula la, R<sup>2nd</sup> is a substituent attached to the para position of phenyl and is selected from the group consisting of -Ci.e unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -Ci_<sub>3</sub> haloalkyl, Cl, Br, I, -OR<sup>3rd</sup>and CN.
In some modalities of formula la, R<sup>2b</sup> is a substituent attached to the meta or ortho position of phenyl and is selected from the group consisting of -Ci.e unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, Ο<sub>μ3</sub> haloalkyl, halide, -OR<sup>3rd</sup> and CN.
In some modalities of formula la, R<sup>2 C</sup> is a phenyl-linked substituent and are independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl, CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -Cva haloalkyl, halide, -OR<sup>3</sup> and CN; m is 2 to 5.
In some modalities of formula la, R<sup>2d</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of -Cve unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C ^ s haloalkyl, halide, -OR<sup>3</sup> and CN; s is 1 to 4.
In some modalities of formula la, R<sup>2e</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of -Cb8 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -Ci_<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN; t is 1 to 4.
In some modalities of formula la, R<sup>2e</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of H, -Ci_e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C- |.<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN; t is 0 to 4.
In some modalities of formula la, R<sup>2e</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of -Ci_e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -Ci_<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN; u is 1 to 3.
In some modalities of formula la, R<sup>2 g</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of H, -Ci_6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN; v is 1 to 3.
In some modalities of formula la, R<sup>29</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of -Cb6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -Cvs haloalkyl, halide, -OR<sup>3</sup> and CN; v is 0 to 3.
In some modalities of formula la, R<sup>3</sup> is independently selected from the group consisting of H, -C<sub>b6</sub> unsubstituted alkyl and -C<sub>13</sub> haloalkyl.
In some modalities of formula la, each R<sup>3rd</sup> is independently selected from the group consisting of -C<sub>2</sub>.<sub>6</sub> unsubstituted alkyl and -Ci_<sub>3</sub> haloalkyl.
In some modalities of formula la, each R<sup>3b</sup> is independently selected from the group consisting of H and -C<sub>13</sub> unsubstituted alkyl.
In some modalities of formula la, each W is independently N or C.
In some modalities of formula la, at least two W must be N.
In some modalities of formula la, each U is independently N or C.
In some modalities of formula la, at least one U must be N and at least one U must be C.
In some modalities of formula la, G is NH or O.
In some modalities of formula la, each J is independently N or C.
C.
In some modalities of formula la, at least one J must be
In some modalities of formula la, n is 0 to 7.
In some modalities of formula la, n is 1 to 7.
In some modalities of select from the group consisting of the ring is formulated
<img file="MX368248B_D0043.tif" />
FF and <sup>F</sup>
TO
<img file="MX368248B_D0044.tif" />
B se
In some modalities of formula la, the ring
<img file="MX368248B_D0045.tif" />
CN
<img file="MX368248B_D0046.tif" />
In some modalities of formula la, the ring
B se
<img file="MX368248B_D0047.tif" />
<img file="MX368248B_D0048.tif" />
<img file="MX368248B_D0049.tif" />
In some embodiments of formula la, ring B is selected from the group consisting of
<img file="MX368248B_D0050.tif" />
<img file="MX368248B_D0051.tif" />
In some modalities of formula la, ring B is
<img file="MX368248B_D0052.tif" />
<img file="MX368248B_D0053.tif" />
select from the group consisting of
<img file="MX368248B_D0054.tif" />
<img file="MX368248B_D0055.tif" />
In some formula modalities select from the group consisting of
<img file="MX368248B_D0056.tif" />
<img file="MX368248B_D0057.tif" />
<img file="MX368248B_D0058.tif" />
<img file="MX368248B_D0059.tif" />
<img file="MX368248B_D0060.tif" />
In some modalities of formula la, ring B is
<img file="MX368248B_D0061.tif" />
<img file="MX368248B_D0062.tif" />
select from the group consisting of
<img file="MX368248B_D0063.tif" />
<img file="MX368248B_D0064.tif" />
In some modalities of formula la, ring B is
<img file="MX368248B_D0065.tif" />
<img file="MX368248B_D0066.tif" />
In some modalities of formula la, t is 0.
In some modalities of formula la, at least one R<sup>2e</sup> it is a halide.
In some forms of formula the.
at least one
R<sup>2e</sup> it is
In some modalities of formula la, at least one
R<sup>2e</sup> it is
Cl.
In some types of formula, minus one
R<sup>2e</sup> it is
I.
In
In
OMe.
I.
CF<sub>3</sub>.
OMe.
In
In
In
In
In
In
In
In
In
In
In some modalities of formula la, at least one
R<sup>2e</sup> it is
Oh
some modalities of formula la, some modalities of formula la, some modalities of formula la, at least one minus R<sup>2e</sup> minus an R<sup>2e</sup>
R<sup>2</sup>® is is CF<sub>3</sub>.
it's CN.
some modalities of formula la, t is 1 and R<sup>2e</sup> is F.
some modalities of formula la, t is 2 and both R<sup>2e</sup> some modalities of formula la, t is 1 and R<sup>2</sup>® is Me.
some modalities of formula la, t is 2 and both R<sup>2e</sup> some modalities of formula la, t is 1 and R<sup>2e</sup> is CF<sub>3</sub>.
some modalities of formula la, t is 2 and both R<sup>2e</sup> some modalities of formula la, t is 1 and R<sup>2</sup>® is OMe.
some modalities of formula la, t is 2 and both R<sup>2e</sup> some modalities of formula la, t is 2 and an R<sup>2e</sup> is F other R<sup>2e</sup> is Me.
In some modalities of formula la, t is 2 and an R<sup>2e</sup> is F other R<sup>2</sup>® is CF<sub>3</sub>.
are are are are and he and he
In some modalities of formula la, t is 2 and an R<sup>2e</sup> is F and the other R<sup>2e</sup> is OMe.
In some modalities of formula la, t is 1 and R<sup>2e</sup> it's CN.
In some modalities of formula la, t is 2 and both R<sup>2e</sup> they are CN.
In some modalities of formula la, t is 2 and an R<sup>2e</sup> is F and the other R<sup>2e</sup> it's CN.
In some modalities of formula la, at least one R<sup>2e</sup> is -C ,.
I rent.
In some modalities of formula la, at least one R<sup>2e</sup> is -C ,.
I rent.
In some modalities of formula la, at least one R<sup>2e</sup>eis -C1.4 alkyl.
In some modalities of formula la, at least one R<sup>2e</sup> is -Cv alkyl.
In some modalities of formula la, at least one R<sup>2e</sup> is -C<sub>b</sub><sub>6</sub> I rent.
In some modalities of formula la, at least one R<sup>2e</sup> is -C<sub>2</sub>. and alkyl.
In some modalities of formula la, at least one R<sup>2e</sup> is -C<sub>3</sub>. and alkyl.
In some modalities of formula la, at least one R<sup>2e</sup> is -C<sub>4</sub>. <sub>6</sub> I rent.
In some modalities of formula la, at least one R<sup>2e</sup> is -C<sub>2</sub>.
I rent.
In some modalities of formula la, at least one R<sup>2e</sup> is -C<sub>3</sub>.
I rent.
In some modalities of formula la, at least one R<sup>2f</sup> it is halide.
In some modalities of formula la, at least one
R<sup>2f</sup> it is
F.
In some modalities of formula la, at least one R<sup>2f</sup> is Cl.
In some modalities of formula la, at least one R<sup>2f</sup> is Me.
In some modalities of formula la, at least one R<sup>2f</sup> it's OH.
In some modalities of formula la, at least one R<sup>2f</sup> it is
OMe.
In some modalities of formula la, at least one R<sup>2f</sup> is CF<sub>3</sub>.
In some modalities of formula la, at least one R<sup>2f</sup> it's CN. In some modalities of formula la, u is 1 and R<sup>2f</sup> is F.
In some modalities of formula la, u is 2 and both R<sup>2f</sup> are 15 F.
In some modalities of formula la, u is 1 and R<sup>2f</sup> is Me.
In some modalities of formula la, u is 2 and both R<sup>2f</sup> are Me.
In some modalities of formula la, u is 1 and R<sup>2f</sup> is CF<sub>3</sub>.
In some modalities of formula la, u is 2 and both R<sup>2f</sup> are
CF<sub>3</sub>.
In some modalities of formula la, u is 1 and R<sup>2f</sup> is OMe.
In some modalities of formula la, u is 2 and both R<sup>2f</sup> are
OMe.
In some modalities of formula la, u is 2 and an R<sup>2f</sup> is F and the other
R<sup>2f</sup> is Me.
In some modalities of formula la, is
2and a
R<sup>2f</sup> is F and the other
R<sup>2f</sup> is CF<sub>3</sub>.
In some forms of formula it is
2and a
R<sup>2f</sup> is F and the other
CN.
other
R<sup>2f</sup> is OMe.
In
In
In some some some
R<sup>2f</sup> it's CN.
For rent.
For rent.
For rent.
For rent.
For rent.
In the rent.
In the rent.
In some some some some some some some some modalities of the formula the is
R<sup>2f</sup> it's CN.
modalities of formula ia, u is 2 and both R<sup>2f</sup> Modalities Modalities Modalities Modalities Modalities Modalities Modalities Modalities Modalities are of formula of of of the, u is 2 and an R<sup>2f</sup> is F and the formula formula formula la, la, la, at least at least minus a one
R<sup>2f</sup>
R<sup>2f</sup>
R<sup>2f</sup> is is is of formula la, at least one R<sup>2f is</sup> formula formula formula formula
-Ci-2
-Ci-<sub>3</sub>
-C1-4
-C1-5 la, la, la, at least minus minus at least one one one one
R<sup>2f</sup> is -Cf.e
R<sup>2f</sup>
R<sup>2f</sup>
R<sup>2f</sup> is is is
-C<sub>2</sub>.
-C<sub>3</sub>.
-c<sub>4</sub>.
β alkyl.
In some modalities of formula la, at least one R<sup>2f</sup> is -C<sub>2</sub>. 5 alkyl.
In some modalities of formula la, at least one R<sup>zf</sup> is -C<sub>3</sub>.
I rent.
In some modalities of formula la, v is 0.
In some modalities of formula la, v is 1.
In some modalities of formula la, v is 2.
In some modalities of formula la, at least one R<sup>29</sup> it is halide.
In some modalities of formula la, at least one R<sup>29</sup> is F.
In some modalities of formula la, at least one R<sup>29</sup> is CL
In some modalities of formula la, at least one R<sup>2 g</sup> is Me.
In some modalities of formula la, at least one R<sup>29</sup> it's OH.
In some modalities of formula la, at least one R<sup>2 g</sup> is OMe.
In some modalities of formula la, at least one R<sup>2 g</sup> is CF<sub>3</sub>.
In some modalities of formula la, at least one R<sup>29</sup> it's CN.
In some modalities of formula la, v is 1 and R<sup>2 g</sup> is F.
In some modalities of formula la, v is 2 and both R<sup>2 g</sup> are
F.
In some modalities of formula la, v is 1 and R<sup>2 g</sup> is Me.
In some modalities of formula la, v is 2 and both R<sup>2 g</sup> are
I.
In some modalities of formula la, v is 1 and R<sup>2 g</sup> is CF<sub>3</sub>.
In some modalities of formula la, v is 2 and both R<sup>2 g</sup> are
CF<sub>3</sub>.
In some modalities of formula la, v is 1 and R<sup>20</sup> is OMe.
In some modalities of formula la, v is 2 and both R<sup>2 g</sup> they are OMe.
In some modalities of formula la, v is 2 and an R<sup>2 g</sup> is F and the other R<sup>29</sup> is Me.
In some modalities of formula la, v is 2 and an R<sup>2 g</sup> is F and the other R<sup>2 g</sup> is CF<sub>3</sub>.
In some modalities of formula la, v is 2 and an R<sup>2 g</sup> is F and the other R<sup>2 g</sup> is OMe.
In some modalities of formula la, v is 1 and R<sup>2 g</sup> it's CN.
In some modalities of formula la, v is 2 and both R<sup>2 g</sup> they are CN.
In some modalities of formula la, v is 2 and an R<sup>2 g</sup> is F and the other R<sup>2 g</sup> it's CN.
In some modalities of formula la, at least one R<sup>2 g</sup> is -Cv alkyl.
In some modalities of formula la, at least one R<sup>2 g</sup> is -C).
I rent.
In some modalities of formula la, at least one R<sup>2 g</sup> is -Ci.
I rent.
In some modalities of formula la, at least one R<sup>2g is</sup> -Ci_<sub>5 </sub>I rent.
In some modalities of formula la, at least one R<sup>29</sup> is -C<sub>v</sub><sub>6</sub> I rent.
In some modalities of formula la, at least one R<sup>29</sup> is -C<sub>2</sub>. to alkyl.
In some modalities of formula la, at least one R<sup>29</sup> is -C<sub>3</sub>. <sub>6</sub> I rent.
In some modalities of formula la, at least one R<sup>29</sup> is -C<sub>4</sub>. to alkyl.
In some modalities of formula la, at least one R<sup>29</sup> is -C<sub>2</sub>. <sub>5</sub> I rent.
In some modalities of formula la, at least one R<sup>2 g</sup> is -C<sub>3</sub>.
<sub>4</sub> I rent.
Some formula modalities
I include compounds of formula (Ib):
or you go out
<img file="MX368248B_D0067.tif" />
dermatologically acceptable, or prodrugs thereof.
In some formula modalities
Ib, the ring is
<img file="MX368248B_D0068.tif" />
In some formula modalities
Ib, the ring is selected from the group consisting of phenyl and a heteroaryl of
5-6 members, where a carbon atom in the ring is attached to the carbonyl carbon atom.
In some forms of formula Ib, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>s</sub> unsubstituted alkyl, <sup>_</sup>Ci-3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Ib, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -C<sub>16</sub> unsubstituted alkyl, -Ci_3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Ib, each R<sup>2</sup> it is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of H, -C ^ e alkyl, CH2OH, -CH2N (R<sup>3b</sup>)2 C<sub>13</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Ib, each R<sup>2</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C16 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -Cvs haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Ib, each R<sup>3</sup> is independently selected from the group consisting of H, -Ci_<sub>s</sub> unsubstituted alkyl and -C ^ to haloalkyl.
In some forms of formula Ib, each R<sup>3b</sup> it is independently selected from the group consisting of H and -C ^ unsubstituted alkyl.
In some embodiments of formula Ib, each M is independently selected from the group consisting of N, C, S, and O.
In some forms of formula Ib, both M are not O.
In some forms of formula Ib, both M's are not C.
In some modalities of formula Ib, m is 0 to 5.
In some forms of formula Ib, m is 1 to 5.
In some forms of formula Ib, n is 0 to 10.
In some modalities of formula Ib, n is 1 to 10.
In some embodiments of formula Ib, ring A is selected from the group consisting of
<img file="MX368248B_D0069.tif" />
<img file="MX368248B_D0070.tif" />
<img file="MX368248B_D0071.tif" />
Some formula modalities
They include compounds of formula (le):
<img file="MX368248B_D0072.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some modalities of formula le, ring A is
In some embodiments of formula le, ring b is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of formula le, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci.<sub>s</sub> unsubstituted alkyl, -Ci-<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -C<sub>vs</sub> unsubstituted alkyl, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of H, -C ^ g unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>)2 C<sub>13</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of -CVe unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>3</sup> is independently selected from the group consisting of H, -Ci_<sub>and</sub> unsubstituted alkyl and -C1.3 haloalkyl.
In some modalities of formula le, each R<sup>3b</sup> is independently selected from the group consisting of H and -Ci_<sub>3</sub> unsubstituted alkyl.
In some embodiments of formula le, each M is independently selected from the group consisting of N, C, S, and O.
In some embodiments of the formula le, if one M is C, the other M is selected from the group consisting of N, S, and
OR.
In some modalities of formula le, it is 0 to 5.
In some modalities of formula it is 1 to 5.
In some modalities of formula c, n is 0 to 10.
In some modalities of the formula le, n is 1 to 10.
In some modalities of formula le, ring A is selected
<img file="MX368248B_D0073.tif" />
In some embodiments of formula I include compounds of formula (Id):
<img file="MX368248B_D0074.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some forms of formula Id, ring A is
<img file="MX368248B_D0075.tif" />
In some forms of formula Id, ring B is <sub>R</sub>2b
<img file="MX368248B_D0076.tif" />
select from the group consisting of <sup>R2a</sup>
<img file="MX368248B_D0077.tif" />
R<sup>2 C</sup> (R<sup>2dd</sup>) w
<img file="MX368248B_D0078.tif" />
and a heteroaryl (R<sup>2ee</sup>)<sub>Y</sub> 5-6 membered, where one carbon atom in the ring binds to carbonyl carbon.
In some forms of formula Id, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Id, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -C<sub>b6</sub> unsubstituted alkyl, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Id, R<sup>2nd</sup> is a substituent attached to the para position of phenyl and is selected from the group consisting of H, -Ci, and unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C1. 3 haloalkyl, Cl, Br, I, -OR<sup>3rd</sup>yCN.
In some forms of formula Id, R<sup>2b</sup> is a substituent attached to the phenyl meta position and is selected from the group consisting of H, -C2.6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C1. 3 haloalkyl, F, I, -OR<sup>3</sup> and CN.
In some forms of formula Id, R<sup>2 C</sup> is a substituent attached to the ortho phenyl position and is selected from the group consisting of -C-i_<sub>6</sub> unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -C ^ a haloalkyl, F, Br, I, -OR<sup>3</sup> and CN.
In some forms of formula Id, R<sup>2dd</sup> is a phenyl-linked substituent and is independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl, CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -Ci_<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN; w is 1 to 5.
In some forms of formula Id, R<sup>2ee</sup> it is a substituent attached to the heteroaryl ring and is independently selected at each occurrence from the group consisting of -Ci.<sub>6</sub> unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN; y is 0 to 3.
In some forms of formula Id, R<sup>2 C</sup> it's an F.
In some
In some
In some
In some
In some
In some
In some
In some
In some
In some
In some
In some modalities modalities modalities modalities modalities modalities modalities modalities modalities modalities modalities formula formula formula formula formula formula formula formula formula formula formula formula formula
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
Go, R<sup>2 C</sup> is a
I.
Oh
OMe.
CF<sub>3</sub>.
CN.
-Cj_2 alkyl.
-Ci.<sub>3</sub> I rent.
-Ci-4 alkyl.
-Cvs alkyl.
-Ci_6 alkyl.
—C<sub>2</sub>.e rent.
—C<sub>3</sub>.g alkyl.
In some formula modalities
Go
R<sup>2 C</sup> It's a c<sub>4</sub>.<sub>and</sub> I rent.
In some formula modalities
Go
R<sup>2 C</sup> It's a c<sub>2</sub>-5 alkyl.
In some formula modalities
Id, r2C is a
-C<sub>3</sub>.<sub>4</sub> I rent.
In some formula modalities
Go, at least one
R<sup>2dd</sup> it is
In some formula modalities
Go, at least one
R<sup>2dd</sup> it is
Cl.
In some formula modalities
Go, at least one
R<sup>2dd</sup> it is
I.
In some forms of
Oh
In some OMe modalities.
In some forms of CF<sub>3</sub>.
In some types of CN.
formula Id, at least one R<sup>2dd</sup> is formula Id, at least one R<sup>2dd</sup> is formula Id, at least one R<sup>2dd</sup> is formula Id, at least one R<sup>2dd</sup> it is
In some modalities of formula Id, w is 2 to 5.
In some forms of formula Id, w is 1.
In some forms of formula Id, w is 2.
In some modalities of formula Id, w is 1 and R<sup>2dd</sup> is F.
In some forms of formula Id, w is 2 and both R<sup>2dd</sup> They are f.
In some modalities of formula Id, w is 1 and R<sup>2dd</sup> is Me.
In some forms of formula Id, w is 2 and both R<sup>2dd </sup>are Me.
In some modalities of formula Id, w is 1 and R<sup>2dd</sup> is CF<sub>3</sub>.
In some forms of formula Id, w is 2 and both R<sup>2dd</sup> are CF<sub>3</sub>.
In some modalities of formula Id, w is 1 and R<sup>2dd</sup> is OMe.
In some forms of formula Id, w is 2 and both R<sup>2dd </sup>they are OMe.
In some modalities of formula Id, w is 2 and an R<sup>2dd</sup> is F and the other R<sup>2dd</sup> is Me.
In some modalities of formula Id, w is 2 and an R<sup>2dd</sup> is F and the other R<sup>2dd</sup> is CF<sub>3</sub>.
In some modalities of formula Id, w is 2 and an R<sup>2dd</sup> is F and the other R<sup>2dd</sup> is OMe.
In some modalities of formula Id, w is 1 and R<sup>2dd</sup> it's CN.
In some forms of formula Id, w is 2 and both R<sup>2dd </sup>they are CN.
In some modalities of formula Id, w is 2 and an R<sup>2dd</sup> is F and the other R<sup>2dd</sup> it's CN.
<td>In some formula modalities</td><td>Go, at least an R<sup>2dd</sup> it is -</td>
Ci.<sub>2</sub> I rent.
<td>In some formula modalities</td><td>Go, at least an R<sup>2dd</sup> it is -</td>
Cva alkyl.
<td>In some formula modalities</td><td>Go, at least an R<sup>2dd</sup> it is -</td>
C<sub>b4</sub> I rent.
<td>In some formula modalities</td><td>Go, at least an R<sup>2dd</sup> it is -</td>
Ci-5 alkyl.
<td>In some formula modalities</td><td>Go, at least an R<sup>2dd</sup> it is -</td>
Cve alkyl.
In some formula modalities
Go, at least one
R<sup>2dd</sup> it is
C<sub>2</sub>.e rent.
In some formula modalities
Go, at least one
R<sup>2dd</sup> it is
C<sub>3</sub>.e rent.
C4-6
C<sub>2</sub>_5
C3.4
In some formula modalities
Go, at least one
R<sup>2dd</sup> it's alkyl.
In some formula modalities
Go, at least one
R<sup>2dd</sup> it's alkyl.
In some formula modalities
Go, at least one
R<sup>2dd</sup> it's alkyl.
In some modalities of formula Id y is 0.
In some modalities of formula Id y is 1.
In some modalities of formula Id y is 2.
In halide.
Oh
OMe.
CF<sub>3</sub>.
In
In
In
In
In
In
In some forms of Id formula, at least one R<sup>2ee</sup> is some some some some some some some formula modalities formula modalities formula modalities modalities modalities modalities modalities of of of of
Go to
Go to
Go to formula formula formula formula
Go
Go
Go
Go, minus minus minus al al al un a minus minus minus minus
R<sup>2ee</sup>
R<sup>2ee</sup>
R<sup>2ee</sup> a one a one is is is
Cl.
I.
R<sup>2ee</sup>
R<sup>2ee</sup>
R<sup>2ee</sup>
R<sup>2ee</sup> is is is is
CN.
In some modalities of formula Id y is 1 and R<sup>2ee</sup> is F.
In some modalities of formula Id y is 2 and both R<sup>2ee</sup> They are f.
In some modalities of formula Id y is 1 and R<sup>2ee</sup> is Me.
In some modalities of formula Id y is 2 and both R<sup>2ee</sup> are Me.
In some modalities of formula Id y is 1 and R<sup>2ee</sup> is CF<sub>3</sub>.
In some modalities of formula Id y is 2 and both R<sup>2ee</sup> are
CF<sub>3</sub>.
In some modalities of formula Id y is 1 and R<sup>2ee</sup> is OMe.
In some modalities of formula Id y is 2 and both R<sup>2ee</sup> are
OMe.
In some modalities of formula Id y is 2 and an R<sup>2ee</sup> is F and the other R<sup>2ee</sup> is Me.
In some modalities of formula Id y is 2 and an R<sup>2ee</sup> is F and the other R<sup>2ee</sup> is CF<sub>3</sub>.
In some modalities of formula Id y is 2 and an R<sup>2ee</sup> is F and the other R<sup>2ee</sup> is OMe.
In some modalities of formula Id y is 1 and R<sup>2ee</sup> it's CN.
In some modalities of formula Id y is 2 and both R<sup>2ee</sup> they are CN.
In some modalities of formula Id y is 2 and an R<sup>2ee</sup> is F and the other R<sup>2ee</sup> it's CN.
In some forms of Id formula, at least one R<sup>2ee</sup> is 45
C<sub>12</sub> I rent.
In some formula modalities
Go, at least one
R<sup>2ee</sup> it is
Cv3 alkyl.
In some formula modalities
Go, minus one
R<sup>2ee</sup> it is
C<sub>14</sub> I rent.
In some formula modalities
Go, minus one
R<sup>2ae</sup> it is
Ci.5 alkyl.
In some formula modalities
Go, at least one
R<sup>2ee</sup> it is
Cve alkyl.
In some formula modalities
Go, minus one
R<sup>2ee</sup> it is
C<sub>2</sub>-6 alkyl.
In some formula modalities
Go, at least one
R<sup>2ee</sup> it is
C<sub>3</sub>_e rent.
In some formula modalities
Go, at least one
R<sup>2ee</sup> it is
C<sub>4</sub>.<sub>and</sub> I rent.
In some formula modalities
Go, at least one
R<sup>2ee</sup> it is
C<sub>2</sub>.<sub>5</sub> I rent.
In some formula modalities
Go, minus one
R<sup>2ee</sup> it is
C<sub>3</sub>_4 alkyl.
In some formula modalities
Go, every R<sup>3</sup> it is independently selected from the group consisting of H, -Cve unsubstituted alkyl and -C ^ haloalkyl.
In some forms of formula Id, each R<sup>3rd</sup> is independently selected from the group consisting of H, -C<sub>2</sub>.<sub>6</sub> unsubstituted alkyl and -Ci.<sub>3</sub> haloalkyl.
In some forms of formula Id, each R<sup>3b</sup> it is independently selected from the group consisting of H and -Ci.<sub>3</sub> unsubstituted alkyl.
In some modalities of formula Id, Q is S or NH.
In some modes of formula Id, n is 0 to 5.
In some forms of formula Id, n is 1 to 5.
In some embodiments of formula Id, ring A is selected from the group consisting of
<img file="MX368248B_D0079.tif" />
In some forms of formula Id, R<sup>2nd</sup> it's H.
In some forms of formula Id, R<sup>2b</sup> it's H.
In some forms of formula Id, w is 0.
Some forms of the formula include compounds of formula (le):
<img file="MX368248B_D0080.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some modalities of formula le, ring A is
<img file="MX368248B_D0081.tif" />
In some embodiments of formula le, ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of formula le, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of Η, unsubstituted alkyl, -Ci-<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -Ci.<sub>6</sub> unsubstituted alkyl, -C1-3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of H, -C18 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -0 ^ 3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of -Cve unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 21 -Ci_<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula le, each R<sup>3</sup> it is independently selected from the group consisting of H, -Ci.<sub>and</sub> unsubstituted alkyl and -C-i_<sub>3</sub> haloalkyl.
In some modalities of formula le, each R<sup>3b</sup> is independently selected from the group consisting of H and -Cv<sub>3</sub> unsubstituted alkyl.
In some embodiments of formula le, each W is independently N or C.
In some modalities of formula le, at least one W must be N.
In some modalities of the formula le, Q is S or NH.
In some modalities of the formula le, m is 0 to 5.
In some modalities of formula le, m is 1 to 5.
In some modalities of the formula le, n is 0 to 4.
In some modalities of formula le, n is 1a 4.
In some embodiments of formula le, ring A is selected from the group consisting of
<img file="MX368248B_D0082.tif" />
Some formula modalities include compounds of formula (If):
<img file="MX368248B_D0083.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some modalities of the If formula, ring A is
<img file="MX368248B_D0084.tif" />
In some embodiments of the If formula, ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some If formula modalities, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -C ^ unsubstituted alkyl, ~ Ci-3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some If formula modalities, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -Cbj haloalkyl, halide, -OR<sup>3</sup> and CN.
In some If formula modalities, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of H, -Ci, and unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>)2 C<sub>13</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some If formula modalities, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -Ci_<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some If formula modalities, each R<sup>3</sup> is independently selected from the group consisting of Η, -Ο<sub>Ί</sub>.<sub>6</sub> unsubstituted alkyl and -C ^ haloalkyl.
In some If formula modalities, each R<sup>3b</sup> it is independently selected from the group consisting of H and -C-.<sub>3</sub> unsubstituted alkyl.
In some modalities of the If formula, each W is independently N or C.
In some modalities of the If formula, m is 0 to 5.
In some modalities of the If formula, m is 1 to 5.
In some modalities of the If formula, n is 0 to 5.
In some modalities of the If formula, n is 1 to 5.
In some modalities of the If formula, ring A is selected from the group consisting of
<img file="MX368248B_D0085.tif" />
Some forms of the formula include compounds of the formula (Ig):
<img file="MX368248B_D0086.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some embodiments of formula Ig, ring A is
<img file="MX368248B_D0087.tif" />
In some modalities of formula Ig, ring B is <sub>R</sub>2b
<img file="MX368248B_D0088.tif" />
select from the group consisting of R<sup>2nd</sup>
<img file="MX368248B_D0089.tif" />
R<sup>2b</sup> (R<sup>2 C</sup>) m
<img file="MX368248B_D0090.tif" />
and a heteroaryl (R<sup>2d</sup>)<sub>s</sub> 5-6 membered where a carbon atom in the ring binds to the carbonyl carbon.
In some forms of the Ig formula, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci.<sub>and</sub> unsubstituted alkyl, -Cj.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of the Ig formula, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -Ci.<sub>and</sub> unsubstituted alkyl, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Ig, R<sup>2nd</sup> is a bonded substituent for the para position of phenyl and is selected from the group consisting of -Ci.6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>)2 C<sub>13 </sub>haloalkyl, F, I, -OR<sup>3</sup><sub>Y</sub>CN.
In some forms of formula Ig, R<sup>2b</sup> is a substituent attached to the phenyl meta or ortho position and is selected from the group consisting of -C2.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula Ig, R<sup>2 C</sup> is a phenyl-linked substituent and is independently selected at each occurrence from the group consisting of -Cve unsubstituted alkyl, CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -Cj.3 haloalkyl, halide, -OR<sup>3</sup> and CN; m is 2-5.
In some forms of formula Ig, R<sup>2d</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>, -Ο ,.<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN; s is 1-3.
In some forms of formula Ig, R<sup>2d</sup> is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of -Cve unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C- |.<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN; s is 0-4.
In some forms of the Ig formula, each R<sup>3</sup> 15 is independently selected from the group consisting of H, -C ,.<sub>6</sub> unsubstituted alkyl and -0, .3 haloalkyl.
In some forms of the Ig formula, each R<sup>3b</sup> is independently selected from the group consisting of H and -0, .3 unsubstituted alkyl.
In some embodiments of formula Ig, Q is selected from the group consisting of O, S, and NH.
In some modalities of the Ig formula, n is 0 to 5.
In some modalities of the Ig formula, n is 1 to 5.
In some embodiments of formula Ig, ring A is selected from the group consisting of
<img file="MX368248B_D0091.tif" />
<img file="MX368248B_D0092.tif" />
NH
In
In
In
In
CH<sub>2</sub>Oh
In some some some some some
CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>.
In some
CH<sub>2</sub>NH<sub>2</sub>.
In some
CH<sub>2</sub>NHMe
In some
CH<sub>2</sub>NMe<sub>2</sub>.
In some
CH<sub>2</sub>NHEt
In some
CH<sub>2</sub>N (Me) (Et).
In some
CH<sub>2</sub>NEt<sub>2</sub>.
formula modalities formula modalities formula modalities modalities modalities modalities modalities modalities modalities modalities de de de de de de de lg, R<sup>2nd</sup> lg, R<sup>2nd</sup> lg, R<sup>2nd</sup> formula formula formula formula formula formula formula formula
Some modalities of formula I formula (Ih):
es es es lg, al g, al lg, al lg, al lg, al lg, al lg, al lg, al un un un
F.
Oh
OMe.
minus minus minus minus minus minus minus one one one one one one one
R2d
R<sup>2d</sup>
R<sup>2d</sup>
R2d <sub>R</sub>2d
R2d
R<sup>2d</sup>
R2d is is is is is is is is include compounds of (R<sup>1</sup>) n ·
<img file="MX368248B_D0093.tif" />
(R<sup>2</sup>) m
Ih or salts, dermatologically acceptable salts, or prodrugs thereof.
In some embodiments of formula Ih, ring A is
<img file="MX368248B_D0094.tif" />
In some embodiments of formula Ih, ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of formula Ih, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>5</sub> unsubstituted alkyl, - <7-3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula Ih, each R<sup>1</sup> it is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -C<sub>vs</sub> unsubstituted alkyl, -Ci_3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula Ih, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C ^ s haloalkyl, halide, -OR<sup>3</sup> Y
CN.
In some modalities of formula Ih, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of -CV6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -Ci_<sub>3</sub> haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula Ih, each R<sup>3</sup> is independently selected from the group consisting of Η, -Ο ·.<sub>0</sub> unsubstituted alkyl and -Ci_<sub>3</sub> haloalkyl.
In some modalities of formula Ih, each R<sup>3b</sup> is independently selected from the group consisting of H and a -C<sub>1</sub>.<sub>3</sub> unsubstituted alkyl.
In some modalities of formula Ih, each W is independently
No.
In some modalities of formula Ih, at least one W must be
N.
In some embodiments of formula Ih, it is selected from the group consisting of O, S, and NH.
In some formula modalities
Ih it's
5.
In some formula modalities
Ih it's
5.
In some formula modalities
Ih, it's 0 to 4.
In some formula modalities
Ih, it's 1 to 4.
In some formula modalities
Ih, ring A is selected from the group consisting of
<img file="MX368248B_D0095.tif" />
Some formula modalities
I include compounds of formula (Ii):
<img file="MX368248B_D0096.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
<img file="MX368248B_D0097.tif" />
, where a carbon atom in the ring is attached to the carbonyl carbon.
In some embodiments of formula II, ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of formula Ii, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -Cvj haloalkyl, halide, -OR<sup>3</sup> and CN.
In some modalities of formula Ii, each R<sup>1</sup> is a substituent attached to ring A and is independently selected at each occurrence from the group consisting of -C -,. β unsubstituted alkyl, -Cvs haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula l, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of H, -Ci_6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula li, each R<sup>2</sup> is a substituent attached to ring B and is independently selected at each occurrence from the group consisting of -Ci.6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>3b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>3</sup> and CN.
In some forms of formula li, each R<sup>3</sup> is independently selected from the group consisting of Η, -Ομ<sub>β</sub> unsubstituted alkyl and -C1.3 haloalkyl.
In some forms of formula li, each R<sup>3b</sup> is independently selected from the group consisting of H and -Ο<sub>ν3</sub> unsubstituted alkyl.
In some embodiments of formula li, each W is independently N or C.
In some forms of formula li, at least one W is C.
In some embodiments of formula li, Q is selected from the group consisting of O, S, and N.
In some forms of formula li, m is 0 to 5.
In some modalities of formula li, m is 1 to 5.
In some modalities of formula li, n is 0 to 7.
In some forms of formula li, n is 1 through 7.
In some embodiments of formula li, ring A is selected from the group consisting of
In some modalities of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, "Cj-3 haloalkyl is CF<sub>3</sub>.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, R<sup>1</sup> is selected from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3</sub> and CN.
In some modalities of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, n is 0.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, at least one R<sup>1</sup> it is a halide.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, at least one R<sup>1</sup> is F.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, at least one R<sup>1</sup> is Cl.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, at least one R<sup>1</sup> is Me.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, at least one R<sup>1</sup> it's OH.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is OMe.
In some modalities and II, at least one R<sup>1</sup> is CF<sub>3</sub>.
In some modalities and II, at least one R<sup>1</sup> it's CN.
In some modalities and Ii, n is 0 to 8.
In some modalities and Ii, n is 0 to 6.
In some modalities and Ii, n is 0 to 4.
In some modalities and Ii, n is 0 to 2.
In some modalities and II, R<sup>1</sup> is F; and n is 1.
In some modalities and II, R<sup>1</sup> is F; and n is 1 or 2.
In some modalities and II, R<sup>1</sup> is F, and n is 3 or 4.
In some modalities and II, R<sup>1</sup> is OH; and n is 1 or 2.
In some modalities and II, R<sup>1</sup> is OMe; and n is 1 or 2.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le , Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih of formula I, la, Ib you Id, le, If, Ig, Ih of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> it is -0 ^ 2 alkyl.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is -Ci.3 alkyl.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is -0 ^ 4 alkyl.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is -C ^ s alkyl.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is -C<sub>16</sub> I rent.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is -C<sub>2</sub>.<sub>6</sub> I rent.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is -C<sub>3</sub>.<sub>6</sub> I rent.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, at least one R<sup>1</sup> is -C<sub>4</sub>.<sub>and</sub> I rent.
In some modalities, each R<sup>1</sup> is the same.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and Ii, R<sup>1</sup> es is independently selected at each occurrence from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3</sub> and CN; and n is 1 or 2.
In some embodiments of formula I, Ib, le, le, If, Ih and Ii, ring B is phenyl.
In some embodiments of formula I, Ib, le, le, If, Ih, and Ii, ring B is a 5-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
In some embodiments of formula I, Ib, le, le, If, Ih and Ii, ring B is a 6-membered heteroaryl containing 1-2 nitrogen atoms.
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2e</sup>, R<sup>2f</sup>, or R<sup>29</sup> is -CH<sub>2</sub>Oh
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>2 C</sup> is -CH<sub>2</sub>Oh
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH<sub>2</sub>Oh
In some forms of formula I, Ib, le, le, If, ig, Ih and Ii, at least one R<sup>2</sup> is -CH<sub>2</sub>Oh
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2e</sup>, R<sup>2f</sup>, or R<sup>29</sup> is -CH2N (R<sup>3b</sup>)2.
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>2 C</sup> is -CH2N (R<sup>3b</sup>)2.
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH2N (R<sup>3b</sup>)2.
In some forms of formula I, Ib, le, le, If, Ig, Ih and Ii, at least one R<sup>2</sup> is -CH2N (R<sup>3b</sup>)2.
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2e</sup>, R<sup>2f</sup>, or R<sup>29</sup> is -CH<sub>2</sub>NH<sub>2</sub>.
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>2 C</sup> is -CH<sub>2</sub>NH<sub>2</sub>.
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH<sub>2</sub>NH<sub>2</sub>.
In some forms of formula I, Ib, le, le, If, Ig, Ih and Ii, at least one R<sup>2</sup> is -CH<sub>2</sub>NH<sub>2</sub>.
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2e</sup>, R<sup>2</sup>*, or R<sup>29</sup> is -CH<sub>2</sub>NHMe.
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>2 C</sup> is -CH<sub>2</sub>NHMe.
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH<sub>2</sub>NHMe.
In some forms of formula I, Ib, le, le, If, Ig, Ih and Ii, at least one R<sup>2</sup> is -CH<sub>2</sub>NHMe.
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2e</sup>, R<sup>2f</sup>, or R<sup>29</sup> is -CH<sub>2</sub>NMe<sub>2</sub>.
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>2 C</sup> is -CH<sub>2</sub>NMe<sub>2</sub>.
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH<sub>2</sub>NMe<sub>2</sub>.
In some forms of formula I, Ib, le, le, If, Ig, Ih and Ii, at least one R<sup>2</sup> is -CH<sub>2</sub>NMe<sub>2</sub>.
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2</sup>®, R<sup>2f</sup>, or R<sup>29</sup> is -CH<sub>2</sub>NHEt.
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>20</sup> is -CH<sub>2</sub>NHEt
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH<sub>2</sub>NHEt
In some forms of formula I, Ib, le, le, If, Ig, Ih and Ii, at least one R<sup>2</sup> is -CH<sub>2</sub>NHEt.
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2e</sup>,
R<sup>2f</sup>, or R<sup>29</sup> is -CH<sub>2</sub>N (Me) (Et)
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>2 C</sup> is -CH<sub>2</sub>N (Me) (Et).
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH<sub>2</sub>N (Me) (Et)
In some forms of formula I, Ib, le, le, If, Ig, Ih and Ii, at least one R<sup>2</sup> is -CH<sub>2</sub>N (Me) (Et).
In some modalities of formula la, at least one R<sup>2d</sup>, R<sup>2e</sup>, R<sup>2f</sup>, or R<sup>29</sup> is -CH<sub>2</sub>NEt<sub>2</sub>.
In some modalities of formula la, Id and Ig, at least one R<sup>2nd</sup>, R<sup>2b</sup>, or R<sup>2 C</sup> is -CH<sub>2</sub>NEt<sub>2</sub>.
In some forms of Id formula, at least one R<sup>2dd</sup> or R<sup>2ee </sup>is -CH<sub>2</sub>NEt<sub>2</sub>.
In some forms of formula I, Ib, le, le, If, Ig, Ih and Ii, at least one R<sup>2</sup> is -CH<sub>2</sub>NEt<sub>2</sub>.
In some forms of formula I, Ib, le, le, If, Ih and Ii, at least one R<sup>2</sup> is independently selected at each occurrence from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3</sub> and CN.
In some modalities of formula I, Ib, le, le, If, Ih and Ii, m is 0.
In some forms of formula I, Ib, le, le, If, Ih and II, at least one R<sup>2</sup> it is halide.
In some forms of formula I, Ib, le, le, If, Ih and Ii, at least one R<sup>2</sup> is F.
In some forms of formula I, Ib, le, le, If, Ih and Ii, at least one R<sup>2</sup> is Cl.
In some forms of formula I, Ib, le, le, If, Ih and Ii, at least one R<sup>2</sup> is Me.
In some forms of formula I, Ib, le, le, If, Ih and II, at least one R<sup>2</sup> it's OH.
In some forms of formula I, Ib, le, le, If, Ih and Ii, at least one R<sup>2</sup> is OMe.
In some forms of formula I, Ib, le, le, If, Ih and Ii, at least one R<sup>2</sup> is CF<sub>3</sub>.
In some forms of formula I, Ib, c, le,
Ih and Ii, at least an R<sup>2</sup> it's CN.
In some forms of formula I,
Ib, le, le, If, Ih and II, m is a 4.
In some modalities of formula I, Ib, le, le, If, Ih and Ii, m is a 2.
In some forms of formula I, Ib, lo, le, If, Ih and II, m is
1.
In some forms of formula I, Ib, le, le, If, Ih and Ii, m is
2.
In some forms of formula I, Ib, le, le, If, Ih and Ii, R<sup>2</sup> is F; and m is 1.
In some forms of formula I, Ib, le, le, If, Ih and Ii, R<sup>2</sup> is F; and m is 2.
In some forms of formula I, Ib, le, le, If, Ih and Ii, R<sup>2</sup> it is
I; and m is 1.
In some formula modalities
Ib, le, le, If,
Ih
R<sup>2</sup> it is
I; and m is 2.
In some formula modalities
Ib, le, le, If,
Ih
R<sup>2</sup> it is
CF<sub>3</sub>; ym
In some formula modalities
Ib,
If,
Ih
R<sup>2</sup> it is
CF<sub>3</sub>; and m is 2.
In some
OMe; and m is 1.
In some
OMe; and m is 2.
In some
I; and m is 2.
In some modalities of formula modalities of formula modalities of formula modalities
CF<sub>3</sub>; and m is 2.
In some modalities
OMe; and m is 2.
In some modalities
Ib,
Ib,
Ib, le, le, le, le, le, of formula of formula of formula
Ib,
Ib,
Ib, le,
If,
If,
If,
If,
If,
If,
Ih
Ih
Ih
Ih
Ih
Ih
CN; and m is 1.
In some formula modalities
Ib, lo, le,
If,
Ih
CN; and m is 2.
In some formula modalities
Ib, le, le,
If,
Ih
F and CN; and m is 2.
In some forms of formula I, Ib, le, le, minus an R<sup>2</sup> is -C- |.<sub>2</sub> I rent.
In some forms of formula I, Ib, le, le,
If,
If,
R<sup>2</sup> it is
R<sup>2</sup> it is
R<sup>2</sup> it is
R<sup>2</sup>
R<sup>2</sup>
R<sup>2</sup>
R<sup>2</sup>
R<sup>2</sup>
Ih and li,
Ih and li, is is is is is at least an R<sup>2</sup> is -Ci.3 alkyl.
In some forms of formula I, Ib, le, le, lf,
Ih minus an R<sup>2</sup> is -Ci_<sub>4</sub> I rent.
In some forms of formula I, Ib, le, le, lf,
Ih at least an R<sup>2</sup> is -C ^ s alkyl.
In some forms of formula I, Ib, le, lf,
Ih minus an R<sup>2</sup> is -C ^ e alkyl.
In some forms of formula I, Ib, lf,
Ih at least an R<sup>2</sup> is -C<sub>2</sub>.<sub>and</sub> I rent.
In some forms of formula I, Ib, le, lf,
Ih at least an R<sup>2</sup> is -C<sub>3</sub>.<sub>6</sub> I rent.
In some forms of formula I, Ib, le, lf,
Ih at least an R<sup>2</sup> is -C<sub>4</sub>.<sub>and</sub> I rent.
In some modalities of formula la,
Ib, le,
Go, le, lf,
Ig, Ih li, R<sup>3</sup> is -Ci.<sub>2</sub> I rent.
In some modalities of formula la,
Ib,
Go, le, lf,
Ig, Ih li, R<sup>3</sup> is -Cj.3 alkyl.
In some formula modalities
Ib,
Go, le, lf,
Ig, Ih li, R<sup>3</sup> is -Ci.4 alkyl.
In some modalities of formula la,
Ib, le,
Go, le, lf,
Ig, Ih li, R<sup>3</sup> is -Ci.5 alkyl.
In some modalities of formula la,
Ib,
Go, le, lf,
Ig, Ih li, R<sup>3</sup> is -Ci.<sub>and</sub> I rent.
In some forms of formula I, the,
Ib, le,
Go, le, lf,
Ig, Ih and II, R<sup>3</sup> and / or R<sup>3rd</sup>eis -C<sub>2</sub>.<sub>and</sub> I rent.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, R<sup>3</sup> and / or R<sup>3rd</sup> is -C<sub>3</sub>.<sub>6</sub> I rent.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, R<sup>3</sup> and / or R<sup>3rd</sup> is -C<sub>4</sub>.e rent.
In some forms of formula I, la, Ib, le, Id, le, If, Ig, Ih and li, R<sup>3</sup> and / or R<sup>3rd</sup> is -C<sub>2</sub>.5 alkyl.
In some forms of formula I, la, Ib, le, Id, le, If,
Ig, Ih and li, R<sup>3</sup> and / or R<sup>3rd</sup> is -C<sub>3</sub>.<sub>4</sub> I rent.
In some embodiments of formula I, Ib, le, le, If, Ih and li, ring B is a 6-membered phenyl or heteroaryl; R<sup>2</sup> is selected from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3</sub> and CN; m is 1; and R<sup>2</sup> binds to an ortho carbon of the 6-membered ring.
In some embodiments of formula I, Ib, le, le, If, Ih and li, ring B is a phenyl; R<sup>2</sup> is selected from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3</sub>; and CN; m is 1; and R<sup>2</sup> binds to an ortho position of the phenyl ring.
In some embodiments of formula I, Ib, le, le, If, Ih and li, ring B is a pyridine; R<sup>2</sup> is selected from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3</sub> and CN; m is 1; and R<sup>2</sup> binds to an ortho carbon of the pyridine ring.
In some forms of formula I, Ib, le, le, If, Ih and li,
<img file="MX368248B_D0098.tif" />
<img file="MX368248B_D0099.tif" />
<img file="MX368248B_D0100.tif" />
carbonite carbon of formula I, Ib, le, le, If, Ih and Ii, can bond with any unsubstituted carbon in ring B.
In some forms of formula I, Ib, le, le, If, Ih and Ii,
<img file="MX368248B_D0101.tif" />
is selected from the group consisting of:
<img file="MX368248B_D0102.tif" />
<img file="MX368248B_D0103.tif" />
<img file="MX368248B_D0104.tif" />
<img file="MX368248B_D0105.tif" />
carbonite carbon of formula I, Ib, le, le, If, Ih and Ii, can bond with any unsubstituted carbon in ring B.
In some forms of formula I, Ib, le, le, If, Ih and Ii,
<img file="MX368248B_D0106.tif" />
(R<sup>2</sup>) m is selected from the group consisting of:
F Me
YY &. Y. (Y. and ..
<img file="MX368248B_D0107.tif" />
where the carbonyl carbon of formula I, Ib, le, le, If, Ih and can bond with any unsubstituted ring B carbon.
In some forms of formula I,
Ib, le, le, If, el
<img file="MX368248B_D0108.tif" />
(R<sup>2</sup>) m (F) m
<img file="MX368248B_D0109.tif" />
(NC)<sub>m</sub>
<img file="MX368248B_D0110.tif" />
is selected from the group that
Ih and it consists of
<img file="MX368248B_D0111.tif" />
<img file="MX368248B_D0112.tif" />
(F<sub>3</sub>C><sub>m</sub>—H
<img file="MX368248B_D0113.tif" />
(MeO)<sub>m</sub>
<img file="MX368248B_D0114.tif" />
(I),
<img file="MX368248B_D0115.tif" />
; and m is 1 or 2.
<img file="MX368248B_D0116.tif" />
(R<sup>2</sup>) m
<img file="MX368248B_D0117.tif" />
is selected from the group consisting
<img file="MX368248B_D0118.tif" />
S 'of
<img file="MX368248B_D0119.tif" />
In some forms of formula I, Ib, le, le, If, Ih and Ii,
<img file="MX368248B_D0120.tif" />
m is 0.
(R<sup>2</sup>) m is selected from the group
In some forms of
<img file="MX368248B_D0121.tif" />
(R<sup>2</sup>) m<sup>N</sup> (R ') m consisting of
<img file="MX368248B_D0122.tif" />
; and formula I, Ib, le, le, If,
Ih and Ii, is selected from the group consisting of <sup>(r2)</sup>™ and <sup>(R2, m</sup> ; and m is 0 to 2.
In some forms of formula I, Ib, le, le, If,
<img file="MX368248B_D0123.tif" />
(R<sup>2</sup>) m is selected from the group consisting
<img file="MX368248B_D0124.tif" />
; and m is 0.
In
In
In
In
In
In
In
In (R<sup>2</sup>)<sub>m</sub> from
<img file="MX368248B_D0125.tif" />
some formula modalities some some some some some some some la and Id,
R<sup>2nd</sup> is to Cl.
modalities of formula modalities of formula modalities of formula modalities of formula modalities of formula modalities of formula la, la, la,
Go
Go
Go
Go
Go
Id lg, R<sup>2nd</sup> lg, R<sup>2nd</sup> lg, R<sup>2nd</sup> lg, R<sup>2nd</sup> lg, R<sup>2nd</sup> lg, R<sup>2nd</sup> is is is is is is
I.
CF<sub>3</sub>.
CN.
I.
CF<sub>3</sub>.
a CN.
modalities of formula la, Id and lg, R<sup>2nd</sup> is a -Ci_<sub>2</sub> I rent.
In some modalities of formula la,
Id ig, R<sup>2nd</sup> is a
-Ci-3 alkyl.
In some modalities of formula la,
Id ig, R<sup>2nd</sup> is a
-Cl-4 alkyl.
For rent.
For rent.
For rent.
For rent.
For rent.
For rent.
For rent.
In
In
In
In
In
In some some some some some some some modalities modalities modalities modalities modalities modalities of of of of of of formula formula formula formula formula formula formula some modalities of formula some some some some some la, la, la, la, la,
Go
Go
Go
Go
Go
Go
Id modalities modalities modalities of formula formula formula formula formula modalities
Ig, R<sup>2nd</sup>
Ig, R<sup>2nd</sup>
Ig, R<sup>2nd</sup> ig, R<sup>2nd</sup>
Ig, R<sup>2nd</sup>
Ig, R<sup>2nd</sup> ig, R<sup>2nd</sup> is a
-C1-5 is is is is is is and Ig, R<sup>2b</sup> is a la, Id and Ig, R<sup>2b</sup> is the and Ig, R<sup>2b</sup> it's a la, R<sup>2b</sup> it's a Me.
Id and Ig, R<sup>2b</sup> is a
Id and Ig, R<sup>2b</sup> is a a a a a a “0-1-6 —C<sub>2</sub>-6 ~ C<sub>3</sub>-6 - C4-6 —C<sub>2</sub>-5 —C3.4 halide.
an F.
Cl.
Oh
OMe.
In some
In some
In some
In some
In some
In some
In some modalities modalities modalities modalities modalities modalities of formula of formula of formula of formula of formula of formula of formula of formula la, Id and Ig, R la, Id and Ig, R la, R<sup>2b</sup> it's a la, R<sup>2b</sup> it's a la, R<sup>2b</sup> it's a la, R<sup>2b</sup> it's a la, R<sup>2b</sup> is a is a CF<sub>3</sub>. <sup>b</sup> it's a CN. -0, .2 alkyl. -C ,.<sub>3</sub> I rent. -C, .4 alkyl. -C ,.<sub>5</sub> I rent. -Cve rent.
In some formula modalities
Go
Ig, R<sup>2b</sup> it is a —C2-6 alkyl.
In some modalities of formula la,
Go
Ig, R<sup>2b</sup> it is a —C3.6 alkyl.
In some modalities of formula la,
Go
Ig, R<sup>2b</sup> it is a —C4-6 alkyl.
In some modalities of formula la,
Go
Ig, R<sup>2b</sup> It is a "C2-5 alkyl.
In some modalities of formula la,
Go
Ig, R<sup>2b</sup> it is a ~ C3.4 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> it is halide.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is F.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is CL
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> it is
I.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> it's OH.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is OMe.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is CF<sub>3</sub>.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> it's CN.
1.
2.
1.
2.
In
In
In
In
In
In
In
In
In some some some formula modalities formula modalities formula modalities some formula modalities some some some some some the other R<sup>2 C</sup> it is
In some the other R<sup>2 C</sup> it is
In some the modalities of formula modalities of formula modalities of modalities of modalities of
I.
cf modalities<sub>3</sub>.
speak formula formula formula formula formula ig.
ig.
ig.
ig.
R<sup>2 C</sup>
R<sup>2 C</sup> r<sup>2 C</sup>
R<sup>2 C</sup> is is is is to F.
Fy
I
Me and Ig, R<sup>2 C</sup> is CF<sub>3</sub> la and Ig, R<sup>2 C</sup> is CF<sub>3</sub> la la la la la is 2.
is is
Ig, R<sup>2 C</sup> is OMe
Ig, R<sup>2 C</sup> is OMe
Ig, m
Ig, m
Ig. m is is is a a is is r2<sub>C</sub> r2C <sub>R</sub>2<sub>C</sub> is is is
F and the other R<sup>2 C</sup> is OMe.
In some modalities of formula la and Ig, R<sup>2 C</sup> is CN and m is 1.
In some modalities of formula la and Ig, R<sup>2 C</sup> is CN and m is 2.
In some modalities of formula la and Ig, m is 2 and an R<sup>2 C</sup> is F and the other R<sup>2 C</sup> it's CN.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is Ci-2 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> it is <sup>-</sup>Ci-3 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is -Ci-4 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is -Ci-<sub>5</sub> I rent.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is -Cve alkyl.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is -C<sub>2</sub>-e rent.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is -C<sub>3</sub>.<sub>and</sub> I rent.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is -C<sub>4</sub>.<sub>and</sub> I rent.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> is -C<sub>2</sub>.5 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2 C</sup> it is
-C3.4 alkyl.
In some modalities of formula la and lg, at least one R<sup>2d</sup> it is halide.
In some modalities of formula la and lg, at least one R<sup>2d</sup> is F.
In some modalities of formula la and lg, at least one R<sup>2d</sup> is Cl.
In some modalities of formula la and lg, at least one R<sup>2d</sup> is Me.
In some modalities of formula la and lg, at least one R<sup>2d</sup> it's OH.
In some modalities of formula la and lg, at least one R<sup>2d</sup> is OMe.
In some modalities of formula la and lg, at least one R<sup>2d</sup> is CF<sub>3</sub>.
In some modalities of formula la and lg, at least one R<sup>2d</sup> it's CN.
In some modalities of formula la and lg, s is 1 and R<sup>2d</sup> is F.
In some modalities of formula la and lg, s is 2 and both R<sup>2d </sup>They are f.
In some modalities of formula la and lg, s is 1 and R<sup>2d</sup> is Me.
In some modalities of formula la and lg, s is 2 and both R<sup>2d </sup>are Me.
In some modalities of formula la and lg, s is 1 and R<sup>2d</sup> is CF<sub>3</sub>.
In some modalities of formula la and lg, s is 2 and both R<sup>2d </sup>are CF<sub>3</sub>.
In some modalities of formula la and Ig, s is 1 and R<sup>2d</sup> is OMe.
In some modalities of formula la and Ig, s is 2 and both R<sup>2d </sup>they are OMe.
In some modalities of formula la and Ig, s is 2 and an R<sup>2d</sup> is F and the other R<sup>2d</sup> is Me.
In some modalities of formula la and Ig, s is 2 and an R<sup>2d</sup> is F and the other R<sup>2d</sup> is CF<sub>3</sub>.
In some modalities of formula la and Ig, s is 2 and an R<sup>2d</sup> is F and the other R<sup>2d</sup> is OMe.
In some modalities of formula la and Ig, s is 1 and R<sup>2d</sup> it's CN.
In some modalities of formula la and Ig, s is 2 and both R<sup>2d </sup>they are CN.
In some modalities of formula la and Ig, s is 2 and an R<sup>2d</sup> is F and the other R<sup>2d</sup> it's CN.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> is -C<sub>12</sub> I rent.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> is -Ci_3 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> is -Ct.4 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> is -Ci-<sub>5</sub> I rent.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> is -Cv<sub>and</sub> I rent.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> is -C<sub>2</sub>-e rent.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> is -C<sub>3</sub>.<sub>6</sub> I rent.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> it is
-C4-6 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> it is
-C<sub>2</sub>-5 alkyl.
In some modalities of formula la and Ig, at least one R<sup>2d</sup> it is
-C3.4 alkyl.
Some embodiments of the present disclosure include compounds of formula (II):
<img file="MX368248B_D0126.tif" />
or salts, dermatologically acceptable salts, or drugs thereof.
In some embodiments of formula II, ring C is a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some embodiments of formula II, ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some forms of formula II, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -0, .3 haloalkyl, halide, -OR<sup>6</sup> and CN.
In some forms of formula II, each R<sup>4</sup> is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of -Ci_<sub>6</sub> unsubstituted alkyl, -Ci_3 haloalkyl, halide, -OR<sup>6</sup> and CN.
In some forms of formula II, each R<sup>5</sup> is a substituent attached to ring D and is independently selected at each occurrence from the group consisting of H, -Ci.6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>) 2, -C- |.<sub>3</sub> haloalkyl, halide, -OR<sup>6</sup> and CN.
In some forms of formula II, each R<sup>5</sup> is a substituent attached to ring D and is independently selected at each occurrence from the group consisting of -CV6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>) 2, -C- |.<sub>3</sub> haloalkyl, halide, -OR<sup>6</sup> and CN.
In some forms of formula II, each R<sup>6</sup> it is independently selected from the group consisting of H, -Ci.<sub>and</sub> unsubstituted alkyl and -Ci.3 haloalkyl.
In some forms of formula II, each R<sup>6b</sup> is independently selected from the group consisting of H and -Ci_<sub>3</sub> unsubstituted alkyl.
In some Formula II modalities, each q is 0 to 4.
In some modalities of formula II, each q is 1 to 4.
In some Formula II modalities, each p is 0 to 5.
In some Formula II modalities, each p is 1 to 5.
In some embodiments of formula II, ring C is a 5-membered heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
In some forms of formula II
<img file="MX368248B_D0127.tif" />
<img file="MX368248B_D0128.tif" />
of the group consisting of
<img file="MX368248B_D0129.tif" />
<sup>X</sup>N ' <sup>X</sup>N
In
In
<img file="MX368248B_D0130.tif" />
<img file="MX368248B_D0131.tif" />
; and p is 0 to 2.
some formula modalities some formula modalities
II, p is 0.
<img file="MX368248B_D0132.tif" />
is (R<sup>4</sup>) P
<img file="MX368248B_D0133.tif" />
In some embodiments of formula II, ring C is a 6-membered heteroaryl ring containing 1-2 nitrogens.
In some embodiments of formula II,
<img file="MX368248B_D0134.tif" />
Oh £ h ζ ^ Η ¡£ h of the group consisting of <sup>(R</sup>'p, <sup>(R) p</sup> , <sup>(R4) p</sup> Y <sup>(R,</sup>p; and p is a 2.
In some forms of formula II,
<img file="MX368248B_D0135.tif" />
(R *) P is
<img file="MX368248B_D0136.tif" />
In some forms of formula II, each R<sup>4</sup> is independently selected from the group consisting of F, Cl, Me, OMe, OH,
CF<sub>3</sub> and CN.
In some embodiments of formula II, ring C is selected from the group consisting of:
<img file="MX368248B_D0137.tif" />
In some embodiments of formula II, ring D is a 6-membered phenyl or heteroaryl; R<sup>5</sup> is selected from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3</sub> and CN; q is 1; and R<sup>5</sup> binds to an ortho carbon of the 6-membered ring.
In some embodiments of formula II, ring D is a phenyl, R<sup>5</sup> is selected from the group consisting of F, Cl, Me, OMe, OH, CF<sub>3 </sub>and CN; q is 1; and R<sup>5</sup> binds to an ortho position of the phenyl ring.
In some embodiments of formula II, ring D is a pyridine, R<sup>s</sup> is selected from the group consisting of F, Cl, Me, OMe,
OH CF<sub>3</sub> and CN; q is 1; and R<sup>5</sup> binds to an ortho carbon of the pyridine ring.
In some forms of formula II,
<img file="MX368248B_D0138.tif" />
is selected from the group consisting of:
<img file="MX368248B_D0139.tif" />
<img file="MX368248B_D0140.tif" />
<img file="MX368248B_D0141.tif" />
<img file="MX368248B_D0142.tif" />
h; wherein the carbonyl carbon of formula II can bond with any unsubstituted carbon in ring D; and q is o 2.
In some forms of formula II, q is 0.
In some forms of formula II,
<img file="MX368248B_D0143.tif" />
is selected from the group consisting of:
<img file="MX368248B_D0144.tif" />
<img file="MX368248B_D0145.tif" />
Carbonyl carbon of formula II can bond with any unsubstituted carbon on ring D.
In some forms of formula II,
<img file="MX368248B_D0146.tif" />
is selected from the group consisting of:
<img file="MX368248B_D0147.tif" />
where the carbonyl carbon of formula II can bond with any unsubstituted carbon in ring D.
Some embodiments of formula II include compounds of formula (Ha):
<img file="MX368248B_D0148.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
<img file="MX368248B_D0149.tif" />
In some forms of formula lia, ring C is
In some embodiments of formula lia, ring D is selected from the group consisting of
<img file="MX368248B_D0150.tif" />
<img file="MX368248B_D0151.tif" />
Carbon atom in the ring binds to carbonyl carbon.
In some modalities of formula Ha, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -Ci-<sub>3</sub> haloalkyl, halide, -OR<sup>6</sup> and CN.
In some modalities of formula Ha, each R<sup>4</sup> is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of -Ci_<sub>s</sub> alkyl, -C<sub>b3 </sub>haloalkyl, halide, -OR<sup>6</sup> and CN.
In some forms of formula Ha, R<sup>5th</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl, CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>6th</sup> and CN; j is 1 to 5.
In some forms of formula Ha, R<sup>5b</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -Ci.e unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>)2 C<sub>V</sub>3 haloalkyl, F, I, -OR<sup>6th</sup> and CN; k is 1 to 4.
In some forms of formula lia, R<sup>Sc</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -Ci, and unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -Ci-<sub>3</sub> haloalkyl, halide, -OR<sup>6</sup> and CN; x is 1 to 3.
In some forms of formula Ha, R<sup>Sc</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl, CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>6b</sup>)<sub>2</sub>, "Ci-3 haloalkyl, halide, -OR<sup>6</sup> and CN; x is 0 to 3.
In some modalities of formula Ha, x is 0.
In some forms of formula Ha, R<sup>5 d</sup> is a ring-linked substituent and are independently selected at each occurrence from the group consisting of -Ci_e unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>6</sup> and CN; z is 1 or 2.
In some forms of formula Ha, R<sup>5e</sup> is a ring-attached substituent and are independently selected at each occurrence from the group consisting of H, -Cve unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>6</sup> and CN; s is 1 to 3.
In some forms of formula Ha, R<sup>5e</sup> is a ring-linked substituent and are independently selected at each occurrence from the group consisting of -C-.e unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -Cva haloalkyl, halide, -OR<sup>6</sup> and CN; s is 0 to 3.
In some modalities of formula Ha, each R<sup>6</sup> is independently selected from the group consisting of H, -C ^ e unsubstituted alkyl, and -Ci.<sub>3</sub> haloalkyl.
In some modalities of formula lia, each R<sup>6th</sup> is independently selected from the group consisting of H, -C<sub>2</sub>.<sub>and</sub> unsubstituted alkyl and -Cvs haloalkyl.
In some modalities of formula lia, each R<sup>6b</sup> it is independently selected from the group consisting of H and -C1.3 unsubstituted alkyl.
In some formula modalities
Ha, every
A is independently N or C.
In some modalities of formula Ha, at least two A's must be N.
In some modalities of formula independently N or C.
lia, each one is
In some forms of formula Ha, at least
N and at least one J must be C.
In some forms of formula lia, independently N or C.
In being C.
In
In
In
In a J every U must be is some modalities of formula Ha, at least one U must some some some modalities of formula modalities of formula modalities of formula
He has,
He has,
He has,
Q is O or N.
some modalities of formula select from the group consisting of (R *), (R<sup>50</sup>) is 0 is 1 to 4.
to 4.
ring D is
He has,
<img file="MX368248B_D0152.tif" />
(R<sup>5b</sup>) k
<img file="MX368248B_D0153.tif" />
(R<sup>M</sup>) z
<img file="MX368248B_D0154.tif" />
(R<sup>5</sup>®), (R *).
(R *), (R *),
<img file="MX368248B_D0155.tif" />
<img file="MX368248B_D0156.tif" />
<img file="MX368248B_D0157.tif" />
N
<img file="MX368248B_D0158.tif" />
(R<sup>8</sup>®),
<img file="MX368248B_D0159.tif" />
(R<sup>8</sup>®)^
N
<img file="MX368248B_D0160.tif" />
(R<sup>8</sup>®),
<img file="MX368248B_D0161.tif" />
<img file="MX368248B_D0162.tif" />
<img file="MX368248B_D0163.tif" />
<img file="MX368248B_D0164.tif" />
<img file="MX368248B_D0165.tif" />
where a carbon atom in the ring is attached to the carbonyl carbon.
In some embodiments of formula Ha, ring D is selected from the group consisting of:
<img file="MX368248B_D0166.tif" />
<img file="MX368248B_D0167.tif" />
NC
<img file="MX368248B_D0168.tif" />
<img file="MX368248B_D0169.tif" />
Some formula modalities
II include compounds of formula (llb):
<img file="MX368248B_D0170.tif" />
(R<sup>6</sup>)<sub>what</sub> llb or salts, dermatologically acceptable salts, or prodrugs thereof.
In some embodiments of formula llb, ring C is A
In some embodiments of formula llb, ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein one carbon atom in the ring is attached to the carbonyl carbon.
In some forms of formula llb, each R<sup>4</sup> is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of Η, unsubstituted alkyl, -0 ^ 3 haloalkyl, halide, -OR<sup>6th</sup> and CN.
In some forms of formula llb, each R<sup>4</sup> is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of -C ^ unsubstituted alkyl, -Ci-<sub>3</sub> haloalkyl, halide, -OR<sup>6th</sup> and CN.
In some forms of formula llb, each R<sup>s</sup> is a substituent attached to ring D and is independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>eb</sup>) 2, -Ο<sub>Ί</sub>_<sub>3</sub> haloalkyl, halide, -OR<sup>6</sup> and CN.
In some forms of formula llb, each R<sup>5</sup> is a substituent attached to ring D and is independently selected at each occurrence from the group consisting of -Ο, .β unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>) 2, -C ^ s haloalkyl, halide, -OR® and
CN.
In some forms of formula llb, each R<sup>6</sup> is independently selected from the group consisting of H, -C ,.<sub>8</sub> unsubstituted alkyl and -C ^ to haloalkyl.
In some forms of formula llb, each R<sup>ea</sup> is independently selected from the group consisting of -C ^ e unsubstituted alkyl and -C · ^ haloalkyl.
In some forms of formula llb, each R<sup>eb</sup> it is independently selected from the group consisting of H and -C1.3 unsubstituted alkyl.
In some forms of formula llb, each
A is independently
No.
In some modalities of formula llb, at least two A's must be N.
In some formula modalities
Hb, is
3.
In some formula modalities
Hb, is
3.
In some formula modalities
Hb, is
5.
In some formula modalities
Hb, is
5.
C se
In some formula modalities
Hb, the ring
<img file="MX368248B_D0171.tif" />
In some embodiments of formula II and llb, ring D is phenyl.
In some forms of formula II and llb,
<img file="MX368248B_D0172.tif" />
select from the group consisting of
<img file="MX368248B_D0173.tif" />
<img file="MX368248B_D0174.tif" />
<img file="MX368248B_D0175.tif" />
<img file="MX368248B_D0176.tif" />
(MeO)<sub>what</sub>—N—
<img file="MX368248B_D0177.tif" />
<img file="MX368248B_D0178.tif" />
In some forms of formula II and llb,
<img file="MX368248B_D0179.tif" />
<img file="MX368248B_D0180.tif" />
select from the group consisting of
<img file="MX368248B_D0181.tif" />
In some embodiments of formula II and llb, ring D is a 5-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
In some forms of formula II
<img file="MX368248B_D0182.tif" />
group consisting of select from
<img file="MX368248B_D0183.tif" />
<img file="MX368248B_D0184.tif" />
<img file="MX368248B_D0185.tif" />
<img file="MX368248B_D0186.tif" />
In some forms of formula II and Ilb,
<img file="MX368248B_D0187.tif" />
is selected from the group consisting of
<img file="MX368248B_D0188.tif" />
In some embodiments of formula II and Ilb, ring D is a 6-membered heteroaryl containing 1-2 nitrogen atoms.
In some forms of formula II and Ilb,
<img file="MX368248B_D0189.tif" />
select from the group consisting of (R ') q; and q is 0 to 2.
In some forms of se
<img file="MX368248B_D0190.tif" />
select from the group consisting of
<img file="MX368248B_D0191.tif" />
<img file="MX368248B_D0192.tif" />
<img file="MX368248B_D0193.tif" />
In some forms of formula II and Ilb, at least one R<sup>5</sup> it is
-CH<sub>2</sub>Oh
In some forms of formula llb, at least one
R<sup>5</sup> it is
-CH<sub>2</sub>N (R<sup>3b</sup>)<sub>2</sub>.
In some formula modalities
Hb, at least one
R<sup>5</sup> it is
-CH<sub>2</sub>NH<sub>2</sub>.
In some
-CH<sub>2</sub>NHMe.
In some
-CH<sub>2</sub>NMe<sub>2</sub>.
In some
-CH<sub>2</sub>NHEt
In some
-CH<sub>2</sub>N (Me) (Et)
In some
-CH<sub>2</sub>NEt<sub>2</sub>.
modalities modalities modalities modalities modalities formula formula formula formula formula
II
In some forms of formula llb,
Hb,
Hb,
Hb,
Hb, at least minus minus minus minus one
R<sup>5</sup> is a
R<sup>5</sup> it's a one a
R<sup>5</sup> it is
R<sup>5</sup> it is
R<sup>5</sup> it is
II and llb, each R<sup>s</sup> is independently selected from the group consisting of F, Cl, Me,
OMe, OH, CF<sub>3</sub> and CN.
In
In
In
In
In
In
In some some some some some some some formula modalities formula modalities formula modalities formula modalities formula modalities formula modalities formula modalities
II some modalities of formula llb, R<sup>5</sup> llb,
Hb,
Hb,
Hb, llb, llb,
Hb is a halide.
R<sup>5</sup>
R<sup>5</sup>
R<sup>5</sup>
R<sup>s</sup>
R<sup>5</sup>
R<sup>5</sup>
R<sup>5</sup> is is is is is is is
Cl.
I.
Oh
OMe.
CF<sub>3</sub>.
CN.
In some forms of formula II and llb, q is 1-4.
In some forms of formula II and llb, q is 1-2.
In some forms of formula II and llb, q is 0.
In some forms of formula II and llb, q is 1.
In some forms of formula II and llb, q is 2.
In some forms of formula II and llb,
In some forms of formula II and llb,
In some forms of formula II and llb,
In some forms of formula II and llb,
R<sup>5</sup> is F, and q is 1.
R<sup>5</sup> is F; and q is 2.
R<sup>5</sup> is Me; and q is 1.
R<sup>5</sup> is Me; and q is 2.
In some forms of formula II and llb, R<sup>5</sup> is CF<sub>3</sub>; and what is
1.
In some forms of formula II and llb, R<sup>5</sup> is CF<sub>3</sub>; and what is
2.
In some forms of formula II and llb, R<sup>s</sup> is OMe; and what is
1.
In some forms of formula II and llb, R<sup>5</sup> is OMe; and what is
2.
In some forms of formula II and llb, R<sup>5</sup> is F and Me; and q is 2.
In some forms of formula II and llb, R<sup>5</sup> is F and CF<sub>3</sub>; and q is 2.
In some forms of formula II and llb, R<sup>5</sup> is F and OMe; and q is 2.
In some forms of formula II and llb, R<sup>s</sup> is CN; and q is 1.
In some forms of formula II and llb, R<sup>5</sup> is CN; and q is 2.
In some forms of formula II and llb, R<sup>5</sup> is F and CN; and q is 2.
In some forms of formula II and llb, at least one R<sup>5</sup> is -0, .2 alkyl.
In some forms of formula II and llb, at least one R<sup>5</sup> is ~ Ci-3 alkyl.
In some forms of formula II and llb, at least one R<sup>s</sup> is -C ,.<sub>4</sub> I rent.
In some forms of formula II and llb, at least one R<sup>5</sup> is -Ci-<sub>5</sub> I rent.
In some forms of formula II and llb, at least one R<sup>5</sup> is -C ,.<sub>6</sub> I rent.
In some forms of formula II and llb, at least one R<sup>5</sup> is -C<sub>2</sub>-6 alkyl.
In some forms of formula II and llb, at least one R<sup>s</sup> is -C<sub>3</sub>.<sub>8</sub> I rent.
In some forms of formula II and llb, at least one R<sup>s</sup> is -C<sub>4</sub>.<sub>and</sub> I rent.
In some forms of formula II and llb, at least one R<sup>s</sup> is -C<sub>2</sub>-5 alkyl.
In some forms of formula II and llb, at least one R<sup>5</sup> is -C<sub>3</sub>.<sub>5</sub> I rent.
Some forms of formula II include compounds of formula (He):
(R<sup>4</sup>)<sub>p</sub>
<img file="MX368248B_D0194.tif" />
Lie or salts, dermatologically acceptable salts, or prodrugs thereof.
In some modalities of the lie formula, ring C is S
In some embodiments of formula He, ring D is selected from the group consisting of where a carbon atom in the ring is attached to the carbonyl carbon.
In some lie formula modalities, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -0 -,. 3 haloalkyl, halide, -OR<sup>S</sup> and CN.
In some forms of formula He, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of -Ci.<sub>6</sub> unsubstituted alkyl, -C<sub>V</sub>3 haloalkyl, halide, -OR<sup>6</sup> and CN.
In some forms of the formula lie, R<sup>5th</sup> is a substituent attached to the para position of phenyl and is selected from the group consisting of -C<sub>2</sub>.<sub>6</sub> unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>6b</sup>)<sub>2</sub>, -C<sub>2</sub>.<sub>3 </sub>haloalkyl, iodide, -OR<sup>ea</sup> and CN.
In some forms of formula He, R<sup>5b</sup> is a substituent attached to the phenyl meta position and is selected from the group consisting of -Ci.g unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>)2 C<sub>2</sub>.<sub>3 </sub>haloalkyl, halide, -OR<sup>ea</sup> and CN.
In some forms of the formula lie, R<sup>5c</sup> is a substituent attached to the ortho position of phenyl and is selected from the group consisting of -Ci_6 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>eb</sup>) 2, -Cvs haloalkyl, F, Br, I, -OR<sup>day</sup> and CN.
In some forms of formula He, R<sup>5 d</sup> is a phenyl-linked substituent and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_e alkyl, CH2OH, -CH2N (R<sup>eb</sup>) 2, -Ci-3 haloalkyl, halide, -OR<sup>ea</sup> and CN; z is 2 to 5.
In some forms of the formula lie, R<sup>5e</sup> is a ring attached substituent and is selected from the group consisting of -C2.5 unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>) 2, -Ci.<sub>3</sub> haloalkyl, F, I, -OR<sup>6</sup> and CN; s is 1.
In some forms of formula He, R<sup>5f</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, CH2OH, -CH2N (R<sup>eb</sup>) 2, -Ci.<sub>3</sub> haloalkyl, F, Br, I, -OR® and CN; t is 1 or 2.
In some forms of formula He, R<sup>5f</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl, CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>6b</sup>)<sub>2</sub>, -Ci_<sub>3</sub> haloalkyl, F, Br, I, -OR<sup>6</sup> and CN; t is 0 to 2.
In some lie formula modalities, R®<sup>9</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C-ι.β unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -Cha haloalkyl, halide, -OR<sup>6</sup> and CN; u is 1 to 3.
In some forms of formula He, R<sup>5h</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -Ci-3 haloalkyl, halide, -OR<sup>6</sup> and CN; v is 1 or 2.
In some forms of formula He, R<sup>5h</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -Ci.e unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -Cvs haloalkyl, halide, -OR<sup>6</sup> and CN; v is 0 to 2.
In some forms of the formula lie, R<sup>5</sup>'is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of Η, H, -Ci and unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>) 2, -C-1.3 haloalkyl, halide, -OR<sup>6</sup> and CN; w is 1 to 4.
In some forms of the formula lie, R<sup>5</sup>'is a ring-attached substituent and is independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>6</sup> and CN; w is 0 to 4.
In some forms of formula He, each R<sup>6</sup> is independently selected from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl and -0 ^ 3 haloalkyl.
In some forms of formula He, each R<sup>6th</sup> is independently selected from the group consisting of -C<sub>2</sub>.<sub>and</sub> unsubstituted alkyl and -Ci.<sub>3</sub> haloalkyl.
In some forms of formula He, each R<sup>eb</sup> is independently selected from the group consisting of H and C ^ to unsubstituted alkyl.
In some embodiments of formula He, each U is independently N or C.
In some modalities of the lie formula, at least one U must be C.
In some modalities of the lie formula, Q is S or O.
In some modalities of the lie formula, at least one U must be N and at least one U must be C.
In some modalities of formula He, p is 0 to 3.
In some modalities of the lie formula, p is 1 to 3.
In some lie formula modalities, the D ring is
<img file="MX368248B_D0195.tif" />
R *<sup>b</sup>
<img file="MX368248B_D0196.tif" />
select from the group consisting of
<img file="MX368248B_D0197.tif" />
<img file="MX368248B_D0198.tif" />
(R<sup>to</sup>) w
<img file="MX368248B_D0199.tif" />
(R<sup>H</sup>) w
<img file="MX368248B_D0200.tif" />
where a carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of the formula He, t is 0.
In some modalities of the formula He, v is 0.
In some modalities of the lie formula, w is 0.
In some forms of formula He, R<sup>5th</sup>, R<sup>Sb</sup>, or R<sup>Sc</sup> is a
CN.
In some formula modalities
I have
R<sup>5b</sup> or R<sup>5c</sup> it is a halide.
In some formula modalities
I have
R<sup>5b</sup> or R<sup>Sc</sup> is a
In some formula modalities
I have
R<sup>5b</sup> is a Cl.
In some forms of lie formula,
R<sup>5b</sup> or R<sup>5c</sup> is a
I.
In some formula modalities
I have
R<sup>5c</sup> it's a CF<sub>3</sub>.
In some formula modalities
I have <sub>R</sub>5b
R<sup>5c</sup> is a
-C1-2 alkyl.
In some formula modalities
I have
RSb r5<sub>C</sub> is a
-Ci-3 alkyl.
In some forms of lie formula, <sub>R</sub>5b
CSR is a
-C1-4 alkyl.
In some formula modalities
I have <sub>R</sub>5b r<sup>5c</sup> is a
-Ci-5 alkyl.
In some forms of formula He, R<sup>5b</sup> or R<sup>SW</sup> is a
-Ci.e alkyl.
In some formula modalities
R<sup>5th</sup>, R<sup>5b</sup>, or
R<sup>5c</sup> is a
C<sub>2</sub>-6 alkyl.
In some
C<sub>3</sub>.<sub>6</sub> I rent.
In some
C<sub>4</sub>_e rent.
In some
C<sub>2</sub>.5 alkyl.
In some
C3-5
R<sup>5h</sup>,
R<sup>5h</sup>, I rent.
In some modalities modalities modalities modalities modalities or R<sup>5</sup>'is halide.
In some or R<sup>5i</sup> is F.
In some
R<sup>5h</sup>, or R<sup>5i</sup> is Cl.
In some
R<sup>5h</sup>, or R<sup>5i</sup> is Me.
In some
R<sup>5h</sup>, or R<sup>5i</sup> it's OH.
In some of of of of of formula formula formula formula formula
I have
I have
I have
I have
I have modalities modalities modalities modalities modalities
R<sup>5h</sup>, or R<sup>5i</sup> is OMe.
In some forms of of of of of formula formula formula formula formula formula formula
I have
I have
I have
I have
I have
R<sup>5th</sup>, R<sup>5b</sup>, or
R<sup>5th</sup>, R<sup>5b</sup>, or
R<sup>5th</sup>, R<sup>5b</sup>, or
R<sup>5th</sup>, R<sup>5b</sup>, at least to at
R<sup>5c</sup>
R<sup>5c</sup><sub>r5c</sub>
R<sup>50</sup> a is is is is a a an R<sup>5t</sup>, R<sup>5g</sup>, minus minus minus minus minus a one a one one
R<sup>5f</sup>, R<sup>59</sup>,
R<sup>5f</sup>, R<sup>59</sup>,
R<sup>5f</sup>, R<sup>59</sup>,
R<sup>5f</sup>, R<sup>59</sup>,
R<sup>5f</sup>, R<sup>Sg</sup>,
R<sup>5f</sup>, R<sup>Sg</sup>,
100
R<sup>Sh</sup>, or R<sup>5i</sup> is CF<sub>3</sub>.
In some forms of formula He, at least one R<sup>5f</sup>, R<sup>59</sup>, R<sup>5h</sup>, or R<sup>Yes</sup> it's CN.
In some modalities of the formula He, t is 1.
In some modalities of the formula He, t is 2.
In some modalities of formula He, t is 1 and R<sup>Sf</sup> is F.
In some modalities of the lie formula, t is 2 and both R<sup>5f</sup> They are f.
In some modalities of formula He, t is 1 and R<sup>5f</sup> is Me.
In some modalities of formula He, t is 2 and both R<sup>5f</sup> are Me.
In some modalities of formula He, t is 1 and R<sup>5</sup>'is CF<sub>3</sub>.
In some modalities of formula He, t is 2 and both R<sup>5f</sup> are CF<sub>3</sub>.
In some modalities of formula He, t is 1 and R<sup>5f</sup> is OMe.
In some modalities of the lie formula, t is 2 and both R<sup>Sf</sup> they are OMe.
In some modalities of formula He, t is 2 and an R<sup>5f</sup> is F and the other R<sup>5f</sup> is OMe.
In some modalities of the lie formula, t is 2 and an R<sup>5f</sup> is F and the other R<sup>Sf</sup> is CF<sub>3</sub>.
In some modalities of the lie formula, t is 2 and an R<sup>sf</sup> is F and the other R<sup>5f</sup> is OMe.
In some modalities of formula He, t is 1 and R<sup>5f</sup> it's CN.
In some modalities of the lie formula, t is 2 and both R<sup>5f</sup> are
101
CN.
In some modalities of formula He, t is 2 and an R<sup>5f</sup> is F and the other R<sup>5f</sup> it's CN.
In some lie formula modalities, at least one R<sup>sf</sup>, R<sup>59</sup>, 5 R<sup>5h</sup>, or R<sup>51</sup> is -Ci-<sub>2</sub> I rent.
In some forms of formula lio, at least one R<sup>Sf</sup>, R<sup>5g</sup>, R<sup>5h</sup>, or R<sup>5</sup>'is -C- |.<sub>3</sub> I rent.
In some lie formula modalities, at least one R<sup>5f</sup>, R<sup>5g</sup>, R<sup>Sh</sup>, or R<sup>51</sup> is -Ci-<sub>4</sub> I rent.
In some forms of formula He, at least one R<sup>5f</sup>, R<sup>5g</sup>,
R<sup>5h</sup>, or R<sup>51</sup> is -Cve alkyl.
In some forms of formula He, at least one R<sup>5f</sup>, R<sup>5g</sup>, R<sup>5h</sup>, or R<sup>5</sup>'is -Ci.e alkyl.
In some forms of formula He, at least one R<sup>5f</sup>, R<sup>5g</sup>, 15 R<sup>5h</sup>, or R<sup>5</sup>'is -C<sub>2</sub>.e rent.
In some forms of formula He, at least one R<sup>5f</sup>, R<sup>5g</sup>, R<sup>5h</sup>, or R<sup>5i</sup> is -C<sub>3</sub>.<sub>and</sub> I rent.
In some forms of formula He, at least one R<sup>5f</sup>, R<sup>5g</sup>, R<sup>5h</sup>, or R<sup>5</sup>'is -C<sub>4</sub>.<sub>6</sub> I rent.
In some lie formula modalities, at least one R<sup>5f</sup>, R<sup>5g</sup>,
R<sup>5h</sup>, or R<sup>5</sup>'is -C<sub>2</sub>.<sub>5</sub> I rent.
In some lie formula modalities, at least one R<sup>5f</sup>, R<sup>Sg</sup>, R<sup>5h</sup>, or R<sup>5</sup>'is -C<sub>3</sub>.<sub>5</sub> I rent.
In some forms of the lie formula, u is 1.
In some modalities of the formula He, u is 2.
102
In some modalities of formula He, u is 1 and R<sup>59</sup> is F.
In some modalities of the formula lie, u is 2 and both R<sup>59</sup> are
F.
In some modalities of formula He, u is 1 and R<sup>Sg</sup> is Me.
In some modalities of the formula lie, u is 2 and both R<sup>59</sup> are
I.
In some modalities of formula He, u is 1 and R<sup>59</sup> is CF<sub>3</sub>.
In some modalities of the formula lie, u is 2 and both R<sup>59</sup> are
CF<sub>3</sub>.
In some modalities of formula He, u is 1 and R<sup>59</sup> is OMe.
In some modalities of formula He, u is 2 and both R<sup>59</sup> are
OMe.
In some modalities of formula He, u is 2 and an R<sup>59</sup> is F and the other R<sup>59</sup> is OMe.
In some modalities of formula He, u is 2 and an R<sup>59</sup> is F and the other R<sup>59</sup> is CF<sub>3</sub>.
In some modalities of the lie formula, u is 2 and an R<sup>59</sup> is F and the other R<sup>5fl</sup> is OMe.
In some modalities of formula He, u is 1 and R<sup>59</sup> it's CN.
In some modalities of formula He, u is 2 and both R<sup>Sg</sup> they are CN.
In some modalities of formula He, u is 2 and an R<sup>Sg</sup> is F and the other R<sup>59</sup> it's CN.
In some modalities of the formula He, v is 1.
In some forms of the lie formula, v is 2.
103
In some modalities of formula He, v is 1 and R<sup>Sh</sup> is F.
In some modalities of formula He, v is 2 and both R<sup>5h</sup> are
F.
In some modalities of formula He, v is 1 and R<sup>5h</sup> is Me.
In some modalities of formula He, v is 2 and both R<sup>5h</sup> are
I.
In some modalities of formula He, v is 1 and R<sup>5h</sup> is CF<sub>3</sub>.
In some modalities of formula He, v is 2 and both R<sup>5h</sup> are
CF<sub>3</sub>.
In some modalities of formula He, v is 1 and R<sup>5h</sup> is OMe.
In some modalities of formula He, v is 2 and both R<sup>5h</sup> are
OMe.
In some modalities of the lie formula, v is 2 and an R<sup>5h</sup> is F and the other R<sup>5h</sup> is OMe.
In some modalities of formula He, v is 2 and an R<sup>5h</sup> is F and the other R<sup>5h</sup> is CF<sub>3</sub>.
In some modalities of formula He, v is 2 and an R<sup>5h</sup> is F and the other R<sup>5h</sup> is OMe.
In some modalities of formula He, v is 1 and R<sup>5h</sup> it's CN.
In some modalities of formula He, v is 2 and both R<sup>5h</sup> they are CN.
In some modalities of the lie formula, v is 2 and an R<sup>5h</sup> is F and the other R<sup>5h</sup> it's CN.
In some modalities of the formula He, w is 1.
In some modalities of the formula He, w is 2.
104
In some modalities of the lie formula, w is 1 and R<sup>5</sup>'is F.
In some forms of formula He, w is 2 and both R<sup>5i</sup> They are f.
In some modalities of the lie formula, w is 1 and R<sup>5</sup>'is Me.
In some modalities of the lie formula, w is 2 and both R<sup>S |</sup> are
I.
In some modalities of the lie formula, w is 1 and R<sup>5</sup>'is CF<sub>3</sub>.
In some modalities of the lie formula, w is 2 and both R<sup>S |</sup> are
CF<sub>3</sub>.
In some modalities of the lie formula, w is 1 and R<sup>S |</sup> is OMe.
In some modalities of the lie formula, w is 2 and both R<sup>5í</sup> they are OMe.
In some modalities of formula He, w is 2 and an R<sup>S |</sup> is F and the other R<sup>5</sup>'is OMe.
In some modalities of the lie formula, w is 2 and an R<sup>51</sup> is F and the other R<sup>51</sup> is CF<sub>3</sub>.
In some modalities of the lie formula, w is 2 and an R<sup>Yes</sup> is F and the other R<sup>5</sup>'is OMe.
In some modalities of the lie formula, w is 1 and R<sup>5</sup>'is CN.
In some modalities of the lie formula, w is 2 and both R<sup>5</sup>'are CN.
In some modalities of the lie formula, w is 2 and an R<sup>Yes</sup> is F and the other R<sup>51</sup> it's CN.
In some lie formula modalities, at least one R<sup>5f</sup>, R<sup>59</sup>, R<sup>5h</sup>, or R<sup>5i</sup> is -CH<sub>2</sub>Oh
105
In some forms of R<sup>5h</sup>, or R<sup>5i</sup> is -CH2N (R<sup>3b</sup>)2.
In some forms of R<sup>5h</sup>, or R<sup>5i</sup> is -CH<sub>2</sub>NH<sub>2</sub>.
In some forms of R<sup>5h</sup>, or R<sup>5i</sup> is -CH<sub>2</sub>NHMe.
In some forms of
R<sup>5h</sup>, or R<sup>5i</sup> is -CH<sub>2</sub>NMe<sub>2</sub>.
In some forms of R<sup>5h</sup>, or R<sup>5i</sup> is -CH<sub>2</sub>NHEt.
In some forms of
R<sup>5h</sup>, or R<sup>5i</sup> is -CH<sub>2</sub>N (Me) (Et)
In some lie formula modalities, at least one R<sup>5f</sup>, R<sup>59</sup>, formula lie, at least one R<sup>5f</sup>, R<sup>59</sup>, formula lie, at least one R<sup>5f</sup>, R<sup>59</sup>, formula He, at least one R<sup>5f</sup>, R<sup>59</sup>, formula lie, at least one R<sup>Sf</sup>, R<sup>59</sup>, formula He, at least one R<sup>5f</sup>, R<sup>59</sup>, formula lie, at least one R<sup>5f</sup>, R<sup>59</sup>,
R<sup>Sh</sup>, or R<sup>5i</sup> is -CH<sub>2</sub>NEt<sub>2</sub>.
Some forms of formula II include compounds of formula (lid):
<img file="MX368248B_D0201.tif" />
fight
<img file="MX368248B_D0202.tif" />
or salts, dermatologically acceptable salts, or prodrugs thereof.
In some modalities of the lid formula, ring C is
In some forms of lid formula, the D ring is
106 | I / J (<sup>r5c</sup>)> <1A select from the group consisting of <sup>(R8a) j</sup> (<sup>Ríb</sup>) k, (R ^ z'-i — CA <sup>(RSe)</sup>»^ ALA
7? / J ιζ / j <sup>0</sup> and n, where a carbon atom in the ring is attached to the carbonyl carbon.
In some forms of lid formula, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of H, -Ci_<sub>B</sub> unsubstituted alkyl, -Ci.3 haloalkyl, halide, -OR® and CN.
In some forms of lid formula, each R<sup>4</sup> is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl, -C-1.3 haloalkyl, halide, -OR<sup>and</sup> and CN.
In some forms of lid formula, R<sup>Sa</sup> is a ring attached substituent and is selected from the group consisting of -C2.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>) 2, -C ^ .a haloalkyl, halide, -OR®<sup>to </sup>and CN; j is 1.
In some forms of lid formula, R<sup>5b</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>ea</sup> and CN; k is 1 to 4.
In some forms of lid formula, R<sup>5b</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C ^ e unsubstituted alkyl,
107
CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>6b</sup>)<sub>2</sub>, -C1.3 haloalkyl, halide, -OR<sup>6th</sup> and CN; k is 0 to 4.
In some forms of lid formula, R<sup>5c</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C2.5 unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR® and CN; x is 1 to 3.
In some forms of lid formula, R<sup>Sd</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -C ^ e unsubstituted alkyl, CH2OH, -CH2N (R<sup>eb</sup>) 2, -C-i_<sub>3</sub> haloalkyl, halide, -OR<sup>6</sup> and CN; z is 1 or 2.
In some forms of lid formula, R<sup>5 d</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -Ci_6 unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR® and CN; z is 0 to 2.
In some forms of lid formula, R<sup>5e</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of Η, H, -C ^ e unsubstituted alkyl, -CH2OH, -CH2N (R®<sup>b</sup>) 2, Ύ_<sub>3</sub> haloalkyl, halide, -OR® and CN; s is 1 to 4.
In some forms of lid formula, R<sup>I know</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -Cve unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -Cvs haloalkyl, halide, -OR® and CN; s is 0 to 4.
In some embodiments of the lid formula, each R® is independently selected from the group consisting of H, -Ci.<sub>6</sub> alkyl no
108 substituted and -Ο<sub>ν3</sub> haloalkyl.
In some forms of lid formula, each R<sup>6th</sup> is independently selected from the group consisting of -C<sub>2</sub>.<sub>and</sub> unsubstituted alkyl and -Cj.<sub>3</sub> haloalkyl.
In some forms of lid formula, each R<sup>eb</sup> it is independently selected from the group consisting of H and -C1.3 unsubstituted alkyl.
<td>In some modalities</td><td>of formula</td><td>fight,</td><td>every</td><td>J</td><td>it is</td>
<td>independently N 0 C.</td><td></td><td></td><td></td><td></td><td></td>
<td colspan="2">In some forms of the lid formula,</td><td>less</td><td colspan="2">a J must</td><td>to be</td>
<td>N and at least one J must be C.</td><td></td><td></td><td></td><td></td><td></td>
<td>In some modalities</td><td>of formula</td><td>fight,</td><td>every</td><td>OR</td><td>it is</td>
independently N or C.
In some forms of lid formula, at least one U must be C.
In some modalities of the lid formula, p is 1 to 3.
In some modalities of the lid formula, p is 0 to 3.
In some forms of lid formula, the D ring is
<img file="MX368248B_D0203.tif" />
109
<img file="MX368248B_D0204.tif" />
where a carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of the lid formula, k is 0.
Some forms of formula II include compounds of formula (lie):
<img file="MX368248B_D0205.tif" />
Lie or salts, dermatologically acceptable salts, or prodrugs thereof.
In some modalities of the lie formula, ring C is
<img file="MX368248B_D0206.tif" />
where a carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of the lie formula, ring D is selected from the group consisting of
<img file="MX368248B_D0207.tif" />
<img file="MX368248B_D0208.tif" />
where a carbon atom in the ring is attached to the carbonyl carbon.
In some forms of formula He, each R<sup>4</sup> is a substituent attached to ring C and is independently selected
110 in each occurrence of the group consisting of H, -Ci.<sub>and</sub> unsubstituted alkyl, -Ci_3 haloalkyl, halide, -OR<sup>and</sup> and CN.
In some forms of formula He, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of -C ,. " unsubstituted alkyl, -Cva haloalkyl, halide, -OR<sup>and</sup> and CN.
In some forms of formula He, R<sup>Sa</sup> is a substituent attached to the para position of phenyl and is selected from the group consisting of H, -C ^ e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>)2 C<sub>b </sub>3 haloalkyl, F, Br, I, -OR® and CN.
In some forms of formula He, R<sup>5b</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -Ci, and unsubstituted alkyl, CH2OH, -CH2N (R®<sup>b</sup>) 2, -C- |.<sub>3</sub> haloalkyl, halide, -OR® and CN; k is 1 to 4.
In some forms of formula He, R<sup>5b</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -Ci.6 unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR® and CN; k is 0 to 4.
In some forms of formula He, R<sup>5c</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C2.5 unsubstituted alkyl, CH2OH, -CH2N (R®<sup>b</sup>) 2, -C1.3 haloalkyl, halide, -OR® and CN; x is 1 to 4.
In some forms of formula He, R<sup>5 d</sup> it is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of H, -C<sub>2</sub>.<sub>and</sub> unsubstituted alkyl,
111
CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>6b</sup>)<sub>2</sub>, <sup>-</sup>Ci_3 haloalkyl, halide, -OR<sup>ea</sup> and CN; z is 1 o
2.
In some forms of the formula lie, R<sup>5 d</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of -C2.e unsubstituted alkyl, CH2OH, -CH2N (R<sup>eb</sup>) 2, -Cvs haloalkyl, halide, -OR<sup>6th</sup> and CN; z is 0 to 2.
In some lie formula modalities, each R<sup>and</sup> it is independently selected from the group consisting of H, -C ^ e unsubstituted alkyl and -C ^ a haloalkyl.
In some lie formula modalities, each R<sup>ea</sup> is independently selected from the group consisting of -Ci_<sub>and</sub> unsubstituted alkyl and -C<sub>V3</sub> haloalkyl.
In some forms of formula He, each R<sup>eb</sup> is independently selected from the group consisting of H and C<sub>V3</sub> unsubstituted alkyl.
In some embodiments of formula He, each A is independently N or C.
In some modalities of the lie formula, at least one A must be C.
In some embodiments of formula He, each U is independently N or C.
In some modalities of the lie formula, at least one U must be N and at least one U must be C.
In some modalities of the formula He, p is 0 to 4.
112
In some modalities of the lie formula, p is 1 to 4.
In some modalities of the lie formula, ring C is selected from the group consisting of
<img file="MX368248B_D0209.tif" />
<img file="MX368248B_D0210.tif" />
<img file="MX368248B_D0211.tif" />
<img file="MX368248B_D0212.tif" />
In some modalities of formula He, select from the group consisting of
<img file="MX368248B_D0213.tif" />
ring D is
<img file="MX368248B_D0214.tif" />
<img file="MX368248B_D0215.tif" />
carbonyl carbon.
In some forms of formula He, R<sup>Sa</sup> it's an OMe.
In some forms of formula He, R<sup>5th</sup> it is a halide.
In some forms of formula He, R<sup>Sa</sup> is aF.
In some forms of formula He, R<sup>5th</sup> it's a me.
In some forms of the formula lie, R<sup>Sa</sup> it is an OH.
In some forms of the formula lie, R<sup>Sa</sup> is a CF
In some forms of formula He, R<sup>Sa</sup> is a CN.
In some forms of formula He, R<sup>5th</sup> is a -Ci_<sub>2</sub> I rent.
In some forms of the formula lie, R<sup>5th</sup> is a -Ci_<sub>3</sub> I rent.
113
In
In
In
In
In
In
In
In
In some some some some some some some some some modalities modalities modalities modalities modalities modalities formula formula formula formula formula formula formula formula formula formula modalities
Some modalities of formula (Hf):
He, R<sup>5th</sup>
He, R<sup>5th</sup>
He, R<sup>5th</sup>
I have
I have
I have
I have
He is is is a a
-Ci_<sub>4</sub> I rent.
-C1.5 alkyl.
-Ci_<sub>6</sub> I rent.
R<sup>5th</sup>
R<sup>5th</sup><sub>R</sub>5th
R<sup>5th</sup>
R<sup>5th</sup> is a
-C<sub>2</sub>-6 alkyl.
it is a —C3-6 alkyl.
It's a c<sub>4</sub>-6 alkyl.
it is a —C2-5 alkyl.
it is a —C3.5 alkyl.
lid and He, z is
0.
formula II include compounds of
<img file="MX368248B_D0216.tif" />
or dermatologically acceptable salts or prodrugs thereof.
In some embodiments of formula llf, ring C is where a carbonyl carbon atom is.
In some modalities, select from the group that
<img file="MX368248B_D0217.tif" />
in the ring is attached to the carbon of formula Hf, ring D consists of <sup>(R6a)</sup>J
<img file="MX368248B_D0218.tif" />
of be a
114 heteroaryl (R<sup>Sb</sup>)<sub>k</sub>, where a carbon atom in the ring is attached to the carbonyl carbon.
In some modalities of formula llf, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of H, -Ci.<sub>and</sub> unsubstituted alkyl, -C-i_<sub>3</sub> haloalkyl, halide, -OR<sup>and</sup> and CN.
In some modalities of formula llf, each R<sup>4</sup> it is a substituent attached to ring C and is independently selected at each occurrence from the group consisting of -Ci.<sub>and</sub> unsubstituted alkyl, -Ci_3 haloalkyl, halide, -OR<sup>6</sup> and CN.
In some modalities of formula llf, R<sup>Sa</sup> is a phenyl-linked substituent and is selected from the group consisting of H.-C ^ e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>eb</sup>)2 C<sub>13</sub> haloalkyl, halide, -OR<sup>6th</sup> and CN; j is 1 to 5.
In some modalities of formula llf, R<sup>5th</sup> is a phenyl-linked substituent and is selected from the group consisting of -C ^ e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>6b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>6th </sup>and CN; j is 0 to 5.
In some modalities of formula llf, R<sup>Sb</sup> is a ring-linked substituent and is independently selected at each occurrence from the group consisting of H, -Cve unsubstituted alkyl, CH2OH, -CH2N (R<sup>6b</sup>) 2, -Ci-<sub>3</sub> haloalkyl, halide, -OR<sup>6</sup> and CN; k is 1 to 4.
In some modalities of formula llf, R<sup>5b</sup> is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of -Ci_<sub>6</sub> unsubstituted alkyl,
115
CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>6b</sup>)<sub>2</sub>, -Ci.3 haloalkyl, halide, -OR<sup>6</sup> and CN; k is 0 to 4.
In some modalities of formula llf, each R<sup>6</sup> is independently selected from the group consisting of H, -0- ,.<sub>6</sub> unsubstituted alkyl and -C ,.<sub>3</sub> haloalkyl.
In some modalities of formula llf, each R<sup>6th</sup> is independently selected from the group consisting of -C<sub>2</sub>.<sub>6</sub> unsubstituted alkyl and -C ,.<sub>3</sub> haloalkyl.
In some modalities of formula llf, each R<sup>6b</sup> is independently selected from the group consisting of H and -Ci_<sub>3</sub> unsubstituted alkyl.
In some modalities of formula llf, each A is independently N or C.
In some modalities of formula llf, at least one A must be N and at least one A must be C.
In some modalities of the formula llf, Q is S or O.
In some modalities of the llf formula, p is 0 to 4.
In some modalities of formula llf, p is 1 to 4.
In some modalities of formula llf, ring C is
N selects from the group consisting of ° <sup>s</sup> , °
116
In some modalities of formula llf, ring D is
<img file="MX368248B_D0219.tif" />
ring binds carbonyl carbon.
In some modalities of the formula He and llf, k is 0.
In some forms of formula II, Ha, He, lid, He and llf, each R<sup>4</sup> is independently selected from the group consisting of F, CI, Me, OMe, OH, CF<sub>3</sub> and CN; and p is 0 to 2.
In some forms of formula II, lia, Hb, He, lid, He and llf, -Cvs haloalkyl is -CF<sub>3</sub>.
In some forms of formula II, lia, Hb, He, lid, He and llf, p is 0.
In some forms of formula II, lia, Hb, He, lid, He and llf, at least one R<sup>4</sup> it is a halide.
117
In some forms of formula II, lia,
Hb,
I have
Hd,
I have
Hf minus an R<sup>4</sup> is F.
In some forms of formula II, Ha,
Hb,
I have
Hd,
I have
Hf minus an R<sup>4</sup> is Cl.
to the
In some modalities less an R<sup>4</sup> is Me.
In some modalities less an R<sup>4</sup> it's OH.
In some modalities to that of formula II, Ha,
Hb,
I have
Hd,
Hf, of formula II, lia, lie, Hd, He of formula
He has,
Hb,
I have
Hd, and Hf, al lie
Hf minus an R<sup>4</sup> is OMe.
In some modalities less an R<sup>4</sup> is CF<sub>3</sub>.
In some modalities less an R<sup>4</sup> it's CN.
In some modalities es es es es de de de
0-3.
In
0-2.
In
2.
In
1.
In formula formula formula
He has,
Hb,
I have
Hd,
I have
Hf,
He has,
He has,
Hb,
Hb,
I have
I have
Hd,
Hd,
I have lie
Hf,
Hf, some some some some
R<sup>4</sup> is F; and p is 1.
In some modalities modalities modalities modalities modalities of of of of formula of formula formula formula formula formula lia,
Hb,
I have
Hd,
I have
Hf,
He has,
Hb,
I have,
I have
Hf,
He has,
Hb,
I have
Hd, lie
Hf, lia,
Hb,
I have
Hd, lie
Hf, lia,
Hb,
I have
Hd,
I have
Hf,
118
R<sup>4</sup> is F; and p is 2.
In some forms of formula II, Ha, He, lid, He and llf, R<sup>4 </sup>is OH; and p is 1.
In some forms of formula II, Ha, Hb, He, lid, He and llf, R<sup>4</sup> is OMe; and p is 1-2.
In some forms of formula II, lia, Hb, He, lid, He and llf, at least one R<sup>4</sup> is -Ο<sub>Ί</sub>.<sub>2</sub> I rent.
In some forms of formula II, Ha, Hb, He, lid, lie and llf, at least one R<sup>4</sup> is -C ^ s alkyl.
In some forms of formula II, Ha, Hb, He, lid, lie and llf, at least one R<sup>4</sup> is -C1.4 alkyl.
In some forms of formula II, Ha, Hb, He, lid, lie and llf, at least one R<sup>4</sup> is -C<sub>b5</sub> I rent.
In some forms of formula II, lia, Hb, He, lid, He and llf, at least one R<sup>4</sup> is -C ^ e alkyl.
In some forms of formula II, Ha, Hb, He, lid, He and llf, at least one R<sup>4</sup> is -C<sub>2</sub>.<sub>6</sub> I rent.
In some forms of formula II, Ha, Hb, lie, lid, lie and llf, at least one R<sup>4</sup> is -C<sub>3</sub>.<sub>and</sub> I rent.
In some forms of formula II, lia, Hb, He, lid, He and llf, at least one R<sup>4</sup> is -C<sub>4</sub>.<sub>and</sub> I rent.
In some forms of formula II, Ha, llb, lie, lid, lie and llf, at least one R<sup>4</sup> is -C<sub>2</sub>.<sub>5</sub> I rent.
In some forms of formula II, Ha, Hb, He, lid, He and llf, at least one R<sup>4</sup> is -C<sub>3</sub>.<sub>5</sub> I rent.
119
In some forms of formula lia,
I have,
I have
Hf, at least an R<sup>5th</sup> or R<sup>5b</sup> is -CH<sub>2</sub>Oh
In some formula modalities
He has,
Hd,
I have
Hf minus an R<sup>5th</sup> or R<sup>5b</sup> is -CH2N (R<sup>3b</sup>)2.
In some formula modalities
He has,
Hd,
I have
Hf minus an R<sup>5th</sup> or R<sup>5b</sup> is -CH<sub>2</sub>NH<sub>2</sub>.
In some formula modalities
He has,
I have
Hd, lie
Hf, at least an R<sup>5th</sup> or R<sup>5b</sup> is -CH<sub>2</sub>NHMe.
In some formula modalities
Ha, lie,
Hd, lie
Hf, at least an R<sup>5th</sup> or R<sup>5b</sup> is -CH<sub>2</sub>NMe<sub>2</sub>.
In some formula modalities
He has,
I have
Hd,
I have
Hf, at least an R<sup>5th</sup> or R<sup>5b</sup> is -CH<sub>2</sub>NHEt
In some formula modalities
He has,
I have
Hd,
I have
Hf, at least an R<sup>Sa</sup> or R<sup>Sb</sup> is -CH<sub>2</sub>N (Me) (Et).
In some forms of formula lia, lio,
Hd,
I have
Hf, at least an R<sup>5th</sup> or R<sup>5b</sup> is -CH<sub>2</sub>NEt<sub>2</sub>
In some modalities of formula Ha, He, lid and He, at least one R<sup>5C</sup> or R<sup>5 d</sup> is -CH<sub>2</sub>Oh
In some forms of formula Ha, lie,
Hd and He, at least an R<sup>5c</sup> or R<sup>5 d</sup> is -CH2N (R<sup>3b</sup>)2.
In some forms of formula Ha, lie,
Hd and He, at least an R<sup>5C</sup> or R<sup>5 d</sup> is -CH<sub>2</sub>NH<sub>2</sub>.
In some modalities of formula Ha, He, lid and He, at least one R<sup>5C</sup> or R<sup>5 d</sup> is -CH<sub>2</sub>NHMe.
In some forms of formula Ha, He,
Hd and He, at least
120 a R<sup>5c</sup> or R<sup>5 d</sup> is -CH<sub>2</sub>NMe<sub>2</sub>.
In some modalities of an R<sup>Sc</sup> or R<sup>sd</sup> is -CH<sub>2</sub>NHEt
In some modalities of an R<sup>5c</sup> or R<sup>5 d</sup> is -CH<sub>2</sub>N (Me) (Et).
In some modalities of an R<sup>5c</sup> or R<sup>5 d</sup> is -CH<sub>2</sub>NEt<sub>2</sub>.
In some forms of R<sup>I know</sup> is -CH<sub>2</sub>Oh
In some forms of R<sup>5e</sup> is -CH2N (R<sup>3b</sup>)2.
In some forms of R<sup>I know</sup> is -CH<sub>2</sub>NH<sub>2</sub>.
In some forms of R<sup>I know</sup> is -CH<sub>2</sub>NHMe.
In some forms of R<sup>5e</sup> is -CH<sub>2</sub>NMe<sub>2</sub>.
In some forms of R<sup>5e</sup> is -CH<sub>2</sub>NHEt
In some forms of R<sup>5e</sup> is -CH<sub>2</sub>N (Me) (Et).
In some forms of
R<sup>5e</sup> is -CH<sub>2</sub>NEt<sub>2</sub>.
formula Ha, He, lid and He, at least formula Ha, He, lid and He, at least formula Ha, He, lid and He, at least formula Ha, He and lid, at least one formula Ha, He and lid, at least one formula lia, He and lid, at least one formula lia, lie and lid, at least one formula Ha, He and lid, at least one formula lia, lie and lid, at least one formula Ha, He and lid, at least one formula Ha, lie and lid, at least one
In some modalities of formula II, Ha, Hb, He, lid, He and Hf,
R<sup>and</sup> is -Ο<sub>ν2</sub> I rent.
121
In some forms of formula II, Ha, llb, He, lid, lie and llf, R<sup>6</sup> is -C1.3 alkyl.
In some forms of formula II, Ha, Hb, lie, lid, lie and llf, R<sup>and</sup> is -0, .4 alkyl.
In some forms of formula II, Ha, llb, He, lid, lie and llf, R<sup>6</sup> is -Cn-s alkyl.
In some forms of formula II, lia, Hb, He, lid, lie and llf, R® is -0, .6 alkyl.
In some forms of formula II, lia, Hb, lie, lid, lie and llf, R<sup>6</sup> is -0<sub>2</sub>-β alkyl.
In some forms of formula II, lia, llb, He, lid, He and llf, R<sup>6</sup> is -C<sub>3</sub>.<sub>6</sub> I rent.
In some forms of formula II, lia, llb, He, lid, He and llf, R<sup>6</sup> is -C<sub>4</sub>.e rent.
In some forms of formula II, Ha, Hb, He, lid, He, and llf, R® is —C<sub>2</sub>-5 alkyl.
In some forms of formula II, Ha, Hb, He, lid, He and llf, R® is -C<sub>3</sub>.<sub>5</sub> I rent.
In some modalities of formula lia, lid and llf, at least one R<sup>5th</sup> it is halide.
In some modalities of the lid formula, He and llf, at least one R<sup>5b</sup> it is halide.
In some modalities of formula lia, lid and He, at least one R<sup>5c</sup> it is halide.
In some forms of formula lia, He, lid and He, at least
122 a R<sup>5 d</sup> it is halide.
In some modalities of formula lia and lid, at least one R<sup>5e </sup>it is halide.
In some forms of formula Ha, lid and llf, at least one R<sup>5th</sup> is F.
In some modalities of formula lia, lid, He and llf, at least one R<sup>5b</sup> is F.
In some modalities of formula Ha, lid and He, at least one R<sup>5</sup>° is F.
In some modalities of formula Ha, He, lid and He, at least one R<sup>5 d</sup> is F.
In some modalities of formula Ha, He and lid, at least one R<sup>5e</sup> is F.
In some modalities of formula lia and lid, at least one R<sup>Sa</sup> or R<sup>5e</sup> is Cl.
In some modalities of the lid formula, He and llf, at least one R<sup>5b</sup> is Cl.
In some modalities of formula lia, lid and lie, at least one R<sup>5C</sup> is Cl.
In some modalities of formula lia, He, lid, He and llf, at least one R<sup>5 d</sup> is Cl.
In some modalities of formula lia and llf, at least one R<sup>5th </sup>is Me.
In some modalities of formula lia, lid, He and llf, at least one R<sup>5b</sup> is Me.
123
In some forms of formula lia, at least one R<sup>5c</sup> is Me.
In some modalities of formula lia, lie and llf, at least one R<sup>5 d</sup> is Me.
In some modalities of formula Ha and lid, at least one R<sup>5e </sup>is Me.
In some forms of formula lia, at least one R<sup>5th</sup> it's OH.
In some forms of R<sup>5b</sup> it's OH.
In some forms of R<sup>5c</sup> it's OH.
In some forms of it is OH.
In some forms of R<sup>5e</sup> it's OH.
In some forms of it is OMe.
In some forms of R<sup>5C</sup> or R<sup>5 d</sup> is OMe.
In some forms of R<sup>5e</sup> is OMe.
In some forms of
R<sup>5th</sup> is CF<sub>3</sub>.
formula lia, He and llf, at least one formula lia, lid and He, at least one formula lia and lid, at least one R<sup>Sd</sup> formula Ha, He and lid, at least one formula He and llf, at least one R<sup>5b</sup> formula lia, lid and He, at least one formula lia, He and lid, at least one formula Ha, lid and llf, at least one
In some modalities of formula lia, lid, He and llf, at least one R<sup>5b</sup> is CF<sub>3</sub>.
124
In some modalities of formula lia, lid and lie, at least one
R<sup>5c</sup> is CF<sub>3</sub>.
In some modalities of formula lia, lid and lie, at least one R<sup>5 d</sup> is CF<sub>3</sub>.
In some
R<sup>5e</sup> is CF<sub>3</sub>.
In some
R<sup>5th</sup> it's CN.
In some an R<sup>5b</sup> it's CN.
In some
R<sup>5c</sup> it's CN.
In some an R<sup>5 d</sup> it's CN.
In some
R<sup>5e</sup> it's CN.
In some is is is is
-Ci_2 alkyl.
In some
-C<sub>V3</sub> I rent.
In some
-C -,. 4 alkyl.
In some ~ Ci_5 I rent.
modalities modalities modalities modalities modalities modalities modalities modalities modalities of formula Ha, formula Ha, de de de de de de de de
I have and lid, at least one lid and llf, at least one formula formula formula formula formula formula formula formula formula
He has,
He has,
He has,
He has,
He has
Lid, He and llf, at least lid
I have
I have and lie, at least one lid and lie, at least llf, llf, llf,
Hf, lid, at least one at least at least minus minus one a one <sub>R</sub>5th
R<sup>5th</sup><sub>R</sub>5th <sub>R</sub>5th
In some forms of formula lia and
llf, at least one <sub>R</sub>5th
125 is -C<sub>16</sub> I rent.
In some modalities of formula lia, lid, lie and llf, at least one R<sup>5th</sup>, R<sup>5b</sup>, R<sup>5c</sup>, R<sup>5 d</sup>, or R<sup>5e</sup> is -C<sub>2</sub>.<sub>and</sub> I rent.
In some modalities of formula lia, lid, He and llf, at least one R<sup>5th</sup>, R<sup>5b</sup>, R<sup>5c</sup>, R<sup>5 d</sup>, or R<sup>5e</sup> is -C<sub>3</sub>.<sub>and</sub> I rent.
In some modalities of formula lia, lid, He and llf, at least one R<sup>5th</sup>, R<sup>5b</sup>, R<sup>5C</sup>, R<sup>5 d</sup>, or R<sup>5e</sup> is -C<sub>4</sub>.<sub>and</sub> I rent.
In some modalities of formula Ha, lid, He and llf, at least one R<sup>Sa</sup>, R<sup>Sb</sup>, R<sup>sc</sup>, R<sup>5 d</sup>, or R<sup>5</sup>® is -C<sub>2</sub>.<sub>5</sub> I rent.
In some modalities of formula Ha, lid, He and llf, at least one R<sup>5th</sup>, R<sup>5b</sup>, R<sup>5C</sup>, R<sup>5 d</sup>, or R<sup>5</sup>® is -C<sub>3</sub>.<sub>5</sub> I rent.
In some modalities of an R<sup>5b</sup> is -Ci.3 alkyl.
In some modalities of an R<sup>5b</sup> is -C1.4 alkyl.
In some modalities of an R<sup>5b</sup> is -C<sub>15</sub> I rent.
formula lia, lid, He and llf, at least formula lia, lid, He and llf, at least formula lia, lid, He and llf, at least
In some modalities of formula la, lid, He and llf, at least one R<sup>5b</sup> is -Ci.<sub>and</sub> I rent.
In some forms of formula Ha, at least one R<sup>Sc</sup> is -Ci_alkyl.
In some forms of formula Ha, at least one R<sup>sc</sup> is -C<sub>v</sub><sub>4</sub> I rent.
In some forms of formula Ha, at least one R<sup>Sc</sup> is -C ,.
<sub>5</sub> I rent.
126
In some forms of formula lia, at least one R<sup>Sc</sup> is -Ci_ e alkyl.
<td></td><td>In some modalities</td><td>from</td><td>formula</td><td>He has,</td><td>lie</td><td>Y</td><td>fight,</td><td>to the</td><td>less</td><td>a</td>
<td>R<sup>5 d</sup></td><td>is -C1.3 alkyl.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some modalities</td><td>from</td><td>formula</td><td>lia,</td><td>lie</td><td>Y</td><td>Hd,</td><td>to the</td><td>less</td><td>a</td>
<td>R<sup>5 d</sup></td><td>is -C1.4 alkyl.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some modalities</td><td>from</td><td>formula</td><td>He has,</td><td>I have</td><td>Y</td><td>Hd,</td><td>to the</td><td>less</td><td>a</td>
<td>R<sup>5 d</sup></td><td>is -C<sub>15</sub> I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some modalities</td><td>from</td><td>formula</td><td>lia,</td><td>lie</td><td>Y</td><td>fight,</td><td>to the</td><td>less</td><td>a</td>
R<sup>5 d</sup> is -Cve alkyl.
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lia</td><td>Y</td><td>Hd,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>5e</sup></td>
<td>is -C</td><td>V3 alkyl.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lia</td><td>Y</td><td>Hd,</td><td>to the</td><td>less</td><td>a</td><td><sub>R5e</sub></td>
<td>is -C</td><td>1.4 alkyl.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lia</td><td>Y</td><td>Hd,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>5e</sup></td>
<td>is -C</td><td>vs alkyl.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lia</td><td>Y</td><td>Hd,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>5e</sup></td>
is -Cve alkyl.
In some modalities of formula lia, lid, and llf, j is 1 and R<sup>5th</sup> is F.
In some modalities of formula lia, lid and llf, j is 2 and both R<sup>5th</sup> They are f.
In some modalities of formula lia and llf, j is 1 and R<sup>5th</sup> is Me.
In some modalities of formula lia and llf, j is 2 and both R<sup>5th</sup> are Me.
127
CF<sub>3</sub>.
In some formula modalities
Ha, lid and llf, j is 1 and
R<sup>5th</sup> it is
In some formula modalities
Ha, lid and llf, j is 2 and both
R<sup>5th</sup> are CF<sub>3</sub>.
In some formula modalities
Ha and llf, j is 2 and a
R<sup>5th</sup> it is
F and the other R<sup>5th</sup> it is
I.
In some formula modalities
Ha, lid llf, j is an R<sup>5th</sup> is F and the other R<sup>5th</sup> is CF<sub>3</sub>.
In some formula modalities
Ha, lid llf, j es
R<sup>5th</sup> it is
CN.
some
R<sup>5th</sup> they are CN.
In some it is F and the other R<sup>sa</sup>
In some modalities modalities is CN.
formula modalities formula
He has,
Ha, lid lid formula
He has,
Hd,
Hf, j
Hf, j
He is is both a
R<sup>5th</sup> llf, is
R<sup>5b</sup> is F.
In some formula modalities
He has,
Hd,
I have
Hf, it's both R<sup>5b</sup> They are f.
In some
R<sup>5b</sup> is Me.
In some modalities modalities both R<sup>5b</sup> are Me.
In some modalities
R<sup>5b</sup> is CF<sub>3</sub>.
of of of formula formula formula
He has,
He has,
Hd,
Hd,
Ha, lid,
I have
I have lie
Hf, llf, llf, is is is
In some modalities of formula lia, lid, lie and
llf, k
is and
128 both R<sup>5b</sup> are CF<sub>3</sub>.
In some modalities of the formula lia, lid, He and llf, k is 2 and an R<sup>5b</sup> is F and the other R<sup>5b</sup> is Me.
In some modalities of formula lia, lid, lie and llf, k is 2 and an R<sup>5b</sup> is F and the other R<sup>5b</sup> is CF<sub>3</sub>.
In some modalities of the formula Ha, lid, He and llf, k is 1 and R<sup>5b</sup> it's CN.
In some modalities of formula Ha, lid, He and llf, k is 2 and both R<sup>5b</sup> they are CN.
In some modalities of the formula lia, lid, He and llf, k is 2 and an R<sup>5b</sup> is F and the other R<sup>5t></sup> it's CN.
In some modalities of formula Ha, lid and He, x is 1 and R<sup>5c </sup>is F.
In some modalities of formula Ha, lid and lie, x is 2 and both R<sup>5c</sup> They are f.
In some modalities of formula Ha, x is 1 and R<sup>5c</sup> is Me.
In some modalities of formula Ha, x is 2 and both R<sup>5c</sup> are Me.
In some modalities of formula Ha, lid and He, x is 1 and R<sup>5c </sup>is CF<sub>3</sub>.
In some modalities of formula lia, lid and He, x is 2 and both R<sup>5c</sup> are CF<sub>3</sub>.
In some modalities of formula Ha, lid and He, x is 1 and R<sup>Sc </sup>is OMe.
In some modalities of the formula lia, lid, and He, x is 2 and
129 both R<sup>Sc</sup> they are OMe.
In some modalities of formula Ha, x is 2 and an R<sup>5c</sup> is F and the other R<sup>Sc</sup> is Me.
In some modalities of formula lia, lid and lie, x is 2 and an R<sup>5c</sup> is F and the other R<sup>5c</sup> is CF<sub>3</sub>.
In some modalities of formula Ha, lid, and He, x is 2 and an R<sup>5c</sup> is F and the other R<sup>5c</sup> is OMe.
In some modalities of formula Ha, lid and He, x is 1 and R<sup>5C </sup>it's CN.
In some modalities of formula Ha, lid and lie, x is 2 and both R<sup>5c</sup> they are CN.
In some modalities of formula Ha, lid, and He, x is 2 and an R<sup>5C</sup> is F and the other R<sup>5c</sup> it's CN.
In some modalities of formula Ha, lie, lid and lie, z is 1 and R<sup>5 d</sup> is F.
In some modalities of formula lia, He, lid, and He, z is 2 and both R<sup>5 d</sup> They are f.
In some modalities of formula Ha, He, and Hf, z is 1 and R<sup>5 d</sup> is Me.
In some modalities of formula Ha, He and Hf, z is 2 and both R<sup>5 d</sup> are Me.
In some modalities of formula lia, He, lid, and He, z is 1 and R<sup>5 d</sup> is CF<sub>3</sub>.
In some modalities of formula lia, He, lid, and lie, z is 2 and both R<sup>5 d</sup> are CF<sub>3</sub>
130 you
In some modalities of formula Ha, lid and lie, z is 1 and R<sup>5 d </sup>is OMe.
In some modalities of formula lia, lid and He, z is 2 and both R<sup>5 d</sup> they are OMe.
In some modalities of formula Ha and He, z is 2 and an R<sup>sd</sup> is F and the other R<sup>5 d</sup> is Me.
In some modalities of formula Ha, lie, lid, and He, z is 2 and an R<sup>5 d</sup> is F and the other R<sup>5 d</sup> is CF<sub>3</sub>.
In some modalities of formula Ha, lid, and He, z is 2 and an R<sup>5 d</sup> is F and the other R<sup>5 d</sup> is OMe.
In some modalities of formula lia, lie, lid and lie, z is 1 and R<sup>5 d</sup> it's CN.
In some modalities of formula Ha, He, lid, and He, z is 2 and both R<sup>5 d</sup> they are CN.
In some modalities of formula lia, lie, lid and He, z is 2 and an R<sup>5 d</sup> is F and the other R<sup>5 d</sup> it's CN.
In some modalities of formula lia and lid, ses 0.
In some modalities of formula Ha and lid, ses 1.
In some modalities of formula lia and lid, ses 2.
In some modalities of formula Ha, He and lid, s is 1 and R<sup>5e</sup> is F.
In some modalities of formula lia, He and lid, s is 2 and both R<sup>5e</sup> They are f.
In some modalities of formula lia and lid, s is 1 and R<sup>5e</sup> is Me.
131
In some modalities of formula lia and lid, s is 2 and both R<sup>5e</sup> are Me.
In some modalities of the formula lia, He and lid, s is 1 and R<sup>5e </sup>is CF<sub>3</sub>.
In some modalities of formula lia, He and lid, s is 2 and both R<sup>5e</sup> are CF<sub>3</sub>.
In some modalities of the formula lia, He and lid, s is 1 and R<sup>5e </sup>is OMe.
In some modalities of formula lia, He and lid, s is 2 and 10 both R<sup>5e</sup> they are OMe.
In some modalities of formula Ha and lid, s is 2 and an R<sup>I know</sup> is F and the other R<sup>5e</sup> is Me.
In some modalities of the formula Ha, He, and lid, s is 2 and an R<sup>5e</sup> is F and the other R<sup>5e</sup> is CF<sub>3</sub>.
In some forms of formula lia, He and lid, s is 2 and a
R<sup>5e</sup> is F and the other R<sup>5e</sup> is OMe.
In some modalities of formula lia, lie and lid, s is 1 and R<sup>5e </sup>it's CN.
In some modalities of formula Ha, He and lid, s is 2 and 20 both R<sup>I know</sup> they are CN.
In some modalities of the formula Ha, He, and lid, s is 2 and an R<sup>5e</sup> is F and the other R<sup>5e</sup> it's CN.
Some embodiments of the present disclosure include compounds of formula (III):
132
III or salts, dermatologically acceptable salts or prodrugs thereof.
In some forms of formula III, each R<sup>7</sup> is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of Cva unsubstituted alkyl, -CH2OH, -CH2N (R<sup>9a</sup>)2 C<sub>V</sub>3 haloalkyl, halide, -OR® and CN.
In some forms of formula III, each R<sup>8</sup> is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of H, -CM unsubstituted alkyl, -CH2OH, -CH2N (R<sup>8a</sup>) 2, -C1.3 haloalkyl, halide, -OR® and CN.
In some forms of formula III, each R<sup>8</sup> is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of Cve unsubstituted alkyl, -CH2OH, -CH2N (R<sup>9a</sup>) 2, -Ci_<sub>3</sub> haloalkyl, halide, -OR® and CN.
In some embodiments of formula III, each R® is independently selected from the group consisting of H, -C<sub>V</sub>e unsubstituted alkyl and -C1.3 haloalkyl.
In some Formula III modalities, each R®<sup>to</sup> is selected
133 regardless of the group consisting of H and -0, .3 unsubstituted alkyl.
In some forms of formula III, each q is 1 to 5.
In some forms of formula III, each R<sup>7</sup> is independently selected from the group consisting of F, Cl, Me, OMe, OH,
CF<sub>3</sub> and CN.
In some forms of formula III, at least one R<sup>7</sup> it is halide.
In some formula modalities
III, minus one is
In some formula modalities
III, at least one
R<sup>7</sup> it is
Cl.
In some formula modalities at least one
R<sup>7</sup> it is
I.
In some formula modalities at least one
R<sup>7</sup> it is
Oh
In some forms of formula III, at least one R<sup>7</sup> it is
OMe.
In some formula modalities at least one R<sup>7</sup> is CF<sub>3</sub>.
In some formula modalities
III, at least one R<sup>7</sup> it's CN.
In some formula modalities
III is
In some formula modalities
III is
3.
In some forms of formula it is
2.
In some formula modalities
III is
2.
In some forms of formula it is
1.
In some formula modalities
III is
R<sup>7</sup> is F.
In some modalities of formula III, q is 2 and both R<sup>7</sup> are
In some modalities of formula III, q is 1 and R<sup>7</sup> is Me.
134
In some modalities of formula III, q is 2 and both R<sup>7</sup> are
I.
In some modalities of formula III, q is 1 and R<sup>7</sup> is CF<sub>3</sub>.
In some modalities of formula III, q is 2 and both R<sup>7</sup> are
CF<sub>3</sub>.
In some modalities of formula III, q is 1 and R<sup>7</sup> is OMe.
In some modalities of formula III, q is 2 and both R<sup>7</sup> they are OMe.
In some modalities of formula III, q is 2 and an R<sup>7</sup> is F and the other R<sup>7</sup> is Me.
In some modalities of formula III, q is 2 and an R<sup>7</sup> is F and the other R<sup>7</sup> is CF<sub>3</sub>.
In some modalities of formula III, q is 2 and an R<sup>7</sup> is F and the other R<sup>7</sup> is OMe.
In some modalities of formula III, q is 1 and R<sup>7</sup> it's CN.
In some modalities of formula III, q is 2 and both R<sup>7</sup> they are CN.
In some modalities of formula III, q is 2 and an R<sup>7</sup> is F and the other R<sup>7</sup> it's CN.
In some forms of formula III, at least one R<sup>7</sup> is -C ^<sub>2 </sub>I rent.
In some forms of formula III, at least one R<sup>7</sup> is -C1.3 alkyl.
In some forms of formula III, at least one R<sup>7</sup> it's alkyl.
135
In some forms of the alkyl formula.
For rent.
For rent.
For rent.
For rent.
For rent.
For rent.
In some some some some some some formula modalities formula modalities formula modalities formula modalities formula modalities formula modalities some modalities select independently
Me, OMe, OH, CF<sub>3</sub> and CN.
In halide.
In
In
In
In
In from
OMe.
some modalities some some some of
III, at least one R<sup>7</sup> is -C1.5
III,
III,
III,
III, at least one R<sup>7</sup> is -C- |.<sub>6</sub> at least a is ~ C2-6 al al al formula III, minus minus minus a a a
R<sup>7</sup> is —C3-6 is —C4-6
R<sup>7</sup> is —C2.5
R<sup>7</sup> is —C3.5 at least one
R<sup>8</sup> is group consisting of H, formula III, at least one modalities of formula modalities of formula modalities of formula some modalities of formula
III,
III,
III,
III, al al al al
Cl, minus minus minus a one a one
R<sup>8</sup> it is
R<sup>8</sup>
R<sup>8</sup>
R<sup>8</sup>
R<sup>8</sup> is is is is
F.
Cl.
I.
Oh
some modalities of formula III, at least one R<sup>8</sup> it is
136
In some forms of formula III, at least one R<sup>8</sup> is CF<sub>3</sub>.
In some forms of formula III, at least one R<sup>8</sup> it's CN.
In some modalities of formula III, p is 0 to 4.
In some modalities of formula III, p is 0 to 3.
In some modalities of formula III, p is 0 to 2.
In some forms of formula III, p is 1 to 4.
In some forms of formula III, p is 1 to 3.
In some embodiments of formula III, p is 1 or 2.
In some forms of formula III, p is 2.
In some embodiments of formula III, p is 1.
In some forms of formula III, p is 0.
In some modalities of formula III, p is 1 and R<sup>8</sup> is F.
In some modalities of formula III, p is 2 and both R<sup>8</sup> are
F.
I.
CF<sub>3</sub>
In some modalities of formula III, p is 1 and R<sup>8</sup> is Me.
In some modalities of formula III, p is 2 and both R<sup>8</sup> are
In some modalities of formula III, p is 1 and R<sup>8</sup> is CF<sub>3</sub>.
In some modalities of formula III, p is 2 and both R<sup>8</sup> are
In some modalities of formula III, p is 1 and R<sup>8</sup> is OMe.
In some modalities of formula III, p is 2 and both R<sup>8</sup> are
OMe.
In some embodiments of formula III, p is 2 and an R<sup>8</sup> is F and the other R<sup>8</sup> is Me.
137
In some embodiments of formula III, p is 2 and an R<sup>8</sup> is F and the other R® is CF<sub>3</sub>.
In some embodiments of formula III, p is 2 and an R<sup>8</sup> is F and the other R® is OMe.
In some embodiments of formula III, p is 1 and R® is CN.
In some embodiments of formula III, p is 2 and both R® are CN.
In some embodiments of formula III, p is 2 and one R® is F and the other R<sup>8</sup> it's CN.
In some forms of formula III, at least one R<sup>8</sup> is -C ^<sub>2 </sub>I rent.
In some forms of formula III, at least one R<sup>8</sup> is -C1.3 alkyl.
In some forms of formula III, at least one R<sup>8</sup> is -8, .4 alkyl.
In some forms of formula III, at least one R<sup>8</sup> is -C ,.<sub>5 </sub>I rent.
In some embodiments of formula III, at least one R® is -Ci_<sub>and </sub>I rent.
In some embodiments of formula III, at least one R® is -C<sub>2</sub>.6 alkyl.
In some embodiments of formula III, at least one R® is -C<sub>3</sub>.<sub>6 </sub>I rent.
In some embodiments of formula III, at least one R® is -C<sub>4</sub>.<sub>and </sub>I rent.
138
In some formula modalities at least one R<sup>8</sup> is -C<sub>2</sub>.<sub>5</sub> I rent.
In some formula modalities at least one R<sup>8</sup> is -C<sub>3</sub>.<sub>5</sub> I rent.
In
In
In
In
In
In
In
In
In
In
In is is is is is some some some some some some some some some some some
-CH<sub>2</sub>Oh
In some
-CH<sub>2</sub>N (R<sup>9a</sup>)<sub>2</sub>.
In some
-CH<sub>2</sub>NH<sub>2</sub>.
In some
-CH<sub>2</sub>NHMe
In some
-CH<sub>2</sub>NMe<sub>2</sub>.
In some modalities modalities modalities modalities modalities modalities modalities modalities formula formula formula formula formula formula formula formula formula formula modalities modalities modalities modalities modalities modalities modalities
III,
III,
III,
III,
III,
III,
III,
III,
III,
III, of of of of of of formula formula formula formula formula formula
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
R<sup>9</sup>
III,
III,
III,
III,
III,
III, is is is is is is is is is is al al al al al
-Ci-2
-Ci_3
-Ci-4
-Ci-5
-C1-6 alkyl.
I rent.
I rent.
I rent.
I rent.
-C<sub>2</sub>-e —C3-6 —C4.6 —C<sub>2</sub>-5 —C3.5 minus minus minus minus minus alkyl.
I rent.
I rent.
I rent.
I rent.
a one a one one
R<sup>7</sup>
R<sup>7</sup>
R<sup>7</sup>
R<sup>7</sup>
R<sup>7</sup>
R<sup>7</sup> and / oy / oy / oy / oy / oy / o
R<sup>8</sup>
R<sup>8</sup>
R<sup>8</sup>
R<sup>8</sup>
R<sup>8</sup>
R<sup>8</sup>
139 is -CH<sub>2</sub>NHEt.
In some forms of formula III, at least one R<sup>7</sup> and / or R<sup>8 </sup>is -CH<sub>2</sub>N (Me) (Et).
In some forms of formula III, at least one R<sup>7</sup> and / or R<sup>8 </sup>is -CH<sub>2</sub>NEt<sub>2</sub>.
Some forms of formula III include compounds of formula (Illa):
(R<sup>12</sup>)<sub>what</sub>
<img file="MX368248B_D0220.tif" />
Illa or salts, dermatologically acceptable or prodrugs thereof.
In some forms of the Illa formula, R<sup>10</sup> is a substituent attached to the ortho position of phenyl and is selected from the group consisting of H, -C ^ e unsubstituted alkyl, -0 ^ 3 haloalkyl, halide, -OR<sup>13</sup> and CN.
In some forms of the Illa formula, R<sup>11</sup> is a substituent attached to the ortho position of phenyl and is selected from the group consisting of unsubstituted -Ci.e alkyl, -CH2OH, CH2N (R<sup>13b</sup>) 2, "Cj-3 haloalkyl, halide, -OR<sup>13</sup> and CN.
In some forms of the Illa formula, each R<sup>12</sup> is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of H,
140
-Cve unsubstituted alkyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>N (R<sup>13b</sup>)<sub>2</sub>, -C ^ s haloalkyl, halide, -OR<sup>13</sup> and CN.
In some forms of the Illa formula, each R<sup>12</sup> is a substituent attached to the fenllo ring and is independently selected at each occurrence from the group consisting of Ci-e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>13b</sup>) 2, -C1.3 haloalkyl, halide, -OR<sup>13</sup> and CN.
In some forms of the Illa formula, each R<sup>13</sup> is independently selected from the group consisting of -Ci_<sub>and </sub>unsubstituted alkyl and -0, .3 haloalkyl.
In some forms of the Illa formula, each R<sup>13b</sup> is independently selected from the group consisting of H and -Cva unsubstituted alkyl.
In some forms of the Illa formula, q is 0 to 5.
In some forms of the Illa formula, q is 1 to 5.
In some Illa formula modalities, at least one R<sup>12</sup> is selected from the group consisting of H, F, Cl, Me, OMe, CF<sub>3</sub> and CN.
In some forms of the Illa formula, q is 0.
In some Illa formula modalities, at least one R<sup>12</sup> it is a halide.
In some Illa formula modalities, at least one R<sup>12</sup> is F.
In some Illa formula modalities, at least one R<sup>12</sup> is Cl.
In some Illa formula modalities, at least one R<sup>12</sup> is Me.
In some Illa formula modalities, at least one R<sup>12</sup> it is
141
Oh
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>12</sup></td><td>it is</td>
<td>OMe.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>12</sup></td><td>it is</td>
<td>cf<sub>3</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>12</sup></td><td>it is</td>
<td>CN.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td colspan="5">some modalities of formula Illa, q</td><td>it is</td><td>1 and R<sup>12</sup></td><td>it is</td><td>F.</td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa,</td><td>what</td><td>is 2 and</td><td colspan="2">both of them</td><td>R<sup>12</sup></td>
They are f.
In some forms of the Illa formula, q is 1 and R<sup>12</sup> is Me.
In some forms of the Illa formula, q is 2 and both R<sup>12 </sup>are Me.
In some forms of the Illa formula, q is 1 and R<sup>12</sup> is CF<sub>3</sub>.
In some forms of the Illa formula, q is 2 and both R<sup>12 </sup>are CF<sub>3</sub>.
In some forms of the Illa formula, q is 1 and R<sup>12</sup> is OMe.
In some forms of the Illa formula, q is 2 and both R<sup>12 </sup>they are OMe.
In some forms of the Illa formula, q is 2 and an R<sup>12</sup> is F and the other R<sup>12</sup> is Me.
In some forms of the Illa formula, q is 2 and an R<sup>12</sup> is F and the other R<sup>12</sup> is CF<sub>3</sub>.
In some forms of the Illa formula, q is 2 and an R<sup>12</sup> is F and the other R<sup>12</sup> is OMe.
142
In some forms of the Illa formula, q is 1 and R<sup>12</sup> it's CN.
In some forms of the Illa formula, q is 2 and both R<sup>12 </sup>they are CN.
In some forms of the Illa formula, q is 2 and an R<sup>12</sup> is F and the other R<sup>12</sup> it's CN.
In some forms of the Illa formula, q is 1 and R<sup>12</sup> is F or CI.
In some Illa formula modalities, at least one R<sup>12</sup> is C<sub>12</sub> I rent.
In some Illa formula modalities, at least one R<sup>12</sup> it is Ci-3 alkyl.
In some Illa formula modalities, at least one R<sup>12</sup> it is Ci-4 alkyl.
In some Illa formula modalities, at least one R<sup>12</sup> is Ci_5 alkyl.
In some Illa formula modalities, at least one R<sup>12</sup> is Cve alkyl.
In some Illa formula modalities, at least one R<sup>12</sup> is C<sub>2</sub>-e rent.
In some Illa formula modalities, at least one R<sup>12</sup> is C<sub>3</sub>.e rent.
In some Illa formula modalities, at least one R<sup>12</sup> is C<sub>4</sub>.6 alkyl.
In some Illa formula modalities, at least one R<sup>12</sup> is C<sub>2</sub>-5 alkyl.
In some Illa formula modalities, at least one R<sup>12</sup> is 143
C<sub>3</sub>.<sub>5</sub> I rent.
Some embodiments of formula III include compounds of formula (lllb):
<img file="MX368248B_D0221.tif" />
lllb or dermatologically acceptable salts or prodrugs thereof.
In some forms of the lllb formula, R<sup>14</sup> is selected from the group consisting of -Ci.<sub>and</sub> unsubstituted alkyl and -Ci.<sub>3</sub> haloalkyl.
In some forms of the lllb formula, R<sup>15</sup> is selected from the group consisting of -Cve unsubstituted alkyl and -C<sub>13</sub> haloalkyl.
In some forms of the lllb formula, each R<sup>16</sup> it is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of Ci.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>17b</sup>) 2, -C ^<sub>3</sub> haloalkyl, halide, -OR<sup>17</sup> and CN.
In some forms of the lllb formula, each R<sup>17</sup> is independently selected from the group consisting of -Ci_<sub>6 </sub>unsubstituted alkyl and -Ci_<sub>3</sub> haloalkyl.
In some forms of the lllb formula, each R<sup>17b</sup> is independently selected from the group consisting of H and C<sub>V</sub>3 unsubstituted alkyl.
In some modalities of the lllb formula, each q is 0 to 5.
144
In some modalities of formula lllb, at least one R<sup>16</sup> is selected from the group consisting of H, F, Cl, Me, OMe, CF<sub>3</sub> and CN.
In some modalities of the lllb formula, q is 0.
In some modalities of formula lllb, at least one R<sup>16</sup> it's OH.
In some modalities of formula lllb, at least one R<sup>16</sup> is OMe.
In some modalities of formula lllb, q is 1 and R<sup>16</sup> is F.
In some modalities of formula lllb, q is 2 and both R<sup>16 </sup>They are f.
In some modalities of formula lllb, q is 1 and R<sup>16</sup> is Me.
In some modalities of formula lllb, q is 2 and both R<sup>16 </sup>are Me.
In some modalities of formula lllb, q is 1 and R<sup>16</sup> is CF<sub>3</sub>.
In some modalities of formula lllb, q is 2 and both R<sup>16 </sup>are CF<sub>3</sub>.
In some modalities of formula lllb, q is 1 and R<sup>1 B</sup> is OMe.
In some modalities of formula lllb, q is 2 and both R<sup>18 </sup>they are OMe.
In some modalities of formula lllb, q is 2 and an R<sup>18</sup> is F and the other R<sup>16</sup> is Me.
In some modalities of formula lllb, q is 2 and an R<sup>16</sup> is F and the other R<sup>1</sup>® is CF<sub>3</sub>.
In some modalities of formula lllb, q is 2 and an R<sup>16</sup> is F and the other R<sup>16</sup> is OMe.
145
In some forms of formula 11Ib, q is 1 and R<sup>16</sup> it's CN.
In some modalities of formula lllb, q is 2 and both R<sup>16 </sup>they are CN.
In some modalities of formula lllb, q is 2 and an R<sup>1</sup>® is F and the other R<sup>1</sup>® is CN.
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>16</sup></td><td>it is -</td>
<td>CH<sub>2</sub>Oh</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>16</sup></td><td>it is -</td>
<td colspan="2">CH<sub>2</sub>N (R<sup>17b</sup>)<sub>2</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb,</td><td>to the</td><td>less</td><td>a</td><td>R<sup>18</sup></td><td>it is -</td>
CH<sub>2</sub>NH<sub>2</sub>.
<td></td><td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb al</td><td>minus one</td><td>R<sup>1</sup>®</td><td>it is -</td>
<td>ch<sub>2</sub></td><td colspan="2">NHMe</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb al</td><td>minus one</td><td>R<sup>18</sup></td><td>it is -</td>
<td>ch<sub>2</sub></td><td colspan="2">NMe<sub>2</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb al</td><td>minus one</td><td>R<sup>1</sup>®</td><td>it is -</td>
<td>ch<sub>2</sub></td><td colspan="2">NHEt.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb al</td><td>minus one</td><td>R<sup>1</sup>®</td><td>it is -</td>
<td colspan="3">CH<sub>2</sub>N (Me) (Et)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb al</td><td>minus one</td><td>R16</td><td>it is -</td>
<td>ch<sub>2</sub></td><td>NEt<sub>2</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In</td><td>some</td><td colspan="3">formula modalities</td><td>lllb, R<sup>17</sup></td><td colspan="2">is -Cj.2 alkyl</td><td></td>
<td></td><td>In</td><td>some</td><td colspan="3">formula modalities</td><td>lllb, R<sup>17</sup></td><td colspan="2">is -Cvs alkyl</td><td></td>
<td></td><td>In</td><td>some</td><td colspan="3">formula modalities</td><td>lllb, R<sup>17</sup></td><td colspan="2">is -Ci-4 alkyl</td><td> -</td>
<td></td><td>In</td><td>some</td><td colspan="3">formula modalities</td><td>lllb, R<sup>17</sup></td><td colspan="2">is -Cvs alkyl</td><td></td>
146
In some forms of the lllb formula,
R<sup>17</sup> it is
-Ci-6 alkyl.
In some forms of the lllb formula,
R<sup>17</sup> it is
-C<sub>2</sub>-6 alkyl.
In some forms of the lllb formula,
R<sup>17</sup> is —C3.6 alkyl.
In some forms of the lllb formula,
R<sup>17</sup> is —C4.6 alkyl.
In some forms of the lllb formula,
R<sup>17</sup> is —C2-5 alkyl.
In some forms of the lllb formula,
R<sup>17</sup> is —C3.5 alkyl.
Some forms of formula III include compounds of formula (lile):
<img file="MX368248B_D0222.tif" />
lile or dermatologically acceptable salts or prodrugs thereof.
In some modalities of lile formula, the E ring is <sub>R</sub>«B
<img file="MX368248B_D0223.tif" />
In some forms of formula lile, R<sup>10</sup> is a substituent attached to the ortho position of the phenyl ring and is selected from the group consisting of H, -Ci_<sub>6</sub> unsubstituted alkyl, -C1.3 haloalkyl, halide, -OR<sup>13</sup> and CN.
147
In some forms of formula lile, R<sup>11</sup> is a substituent attached to the ortho position of the phenyl ring and is selected from the group consisting of -Ci.6 unsubstituted alkyl, -CH2OH, CH2N (R<sup>13b</sup>) 2, -Ci.<sub>3</sub> haloalkyl, halide, -OR<sup>13</sup> and CN.
In some forms of formula Ule, R<sup>12a</sup> is a substituent attached to the para position of the phenyl ring and is selected at each occurrence from the group consisting of -C2.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>13b</sup>)2 C<sub>2</sub>.<sub>3</sub> haloalkyl, Cl, I, -OEt and CN.
In some forms of formula Ule, R<sup>12b</sup> is a substituent attached to the meta position of the phenyl ring and is selected at each occurrence from the group consisting of -C2.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>13b</sup>)2 C<sub>V3</sub> haloalkyl, iodide and OR<sup>13a</sup>.
In some forms of formula lile, R<sup>12c</sup> is a substituent attached to the ortho position of the phenyl ring and is selected at each occurrence from the group consisting of -C2.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>13b</sup>) 2, -Ci_<sub>3</sub> haloalkyl, F, I, -OR<sup>13a</sup> and CN.
In some forms of formula lile, R<sup>12d</sup> is a ring-attached substituent and are independently selected at each occurrence from the group consisting of -Ci_e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>13b</sup>)2 C<sub>13</sub> haloalkyl, F, Br, I, -OR<sup>13</sup> and CN; k is 2 to 5.
In some modalities of the Ule formula, each R<sup>13</sup> I know
148 select regardless of the group consisting of -C<sub>b6</sub> unsubstituted alkyl and -C-.<sub>3</sub> haloalkyl.
In some forms of the Ule formula, each
R<sup>13a</sup> is independently selected from the group consisting of -C<sub>2</sub>.<sub>6</sub> unsubstituted alkyl and -Ci_<sub>3</sub> haloalkyl.
In some modalities of lile formula, each
R<sup>13b</sup> is independently selected from the group consisting of
H y-Ci. 3 unsubstituted alkyl.
In some formula modalities
Ule, minus a
R<sup>12d</sup> is C<sub>2</sub>_6 alkyl.
In some formula modalities
Ule, minus a
R<sup>12d</sup> is C<sub>2</sub>_5 alkyl.
In some forms of lile formula, minus one <sub>Rl2d</sub> is C<sub>2</sub>-4 alkyl.
In some formula modalities
Ule, at least one
R<sup>12d</sup> is C<sub>3</sub>.<sub>and</sub> I rent.
In some forms of lile formula, at least one
R<sup>12d</sup> is C<sub>4</sub>.e rent.
In some forms of formula lile, and / or
R<sup>13a</sup> is -C<sub>2</sub>_6 alkyl.
In some modalities of lile formula, <sub>R</sub>12a <sub>R</sub>i2b <sub>r12C</sub> I
R<sup>13a</sup> is -C<sub>2</sub>.5 alkyl.
In some modalities of lile formula, <sub>R</sub>l2a <sub>R</sub>l<sub>2</sub>b <sub>r12c</sub> I
R<sup>13a</sup> is -C<sub>2</sub>.<sub>4</sub> I rent.
In some modalities of lile formula, <sub>R</sub>12a <sub>R</sub>l<sub>2</sub>b
R<sup>12c</sup> I
149
R<sup>13a</sup> is -C<sub>3</sub>-6 alkyl.
In some forms of formula lile, R<sup>12a</sup>, R<sup>12b</sup>, R<sup>12c</sup>, and / or R<sup>13a</sup> is -C4.6 alkyl.
In some modalities of lile formula, at least one R<sup>12d</sup> is 5 Me.
In some modalities of lile formula, at least one R<sup>12d</sup> is CF<sub>3</sub>.
In some forms of formula lile, R<sup>13a</sup> is Me.
In some forms of formula lile, R<sup>12b</sup>, R<sup>12c</sup>, and / or R<sup>13a</sup> is 10 CF<sub>3</sub>.
In some modalities of lile formula, at least one R<sup>12d</sup> is F.
In some forms of formula lile, R<sup>12c</sup> is F.
In some forms of formula lile, R<sup>12a</sup> is Cl.
In some modalities of lile formula, at least one R<sup>12d</sup> it is
CN.
In some modalities of lile formula, at least one R<sup>12d</sup> is CH<sub>2</sub>Oh
In some modalities of lile formula, at least one R<sup>12d</sup> is CH2N (R<sup>13b</sup>)2.
In some modalities of lile formula, at least one R<sup>12d</sup> is CH<sub>2</sub>NH<sub>2</sub>.
In some modalities of lile formula, at least one R<sup>12d</sup> is CH<sub>2</sub>NHMe
In some modalities of lile formula, at least one R<sup>12d</sup> is 25 CH<sub>2</sub>NMe<sub>2</sub>.
150
In some modalities of lile formula, at least one R<sup>12d</sup> is CH<sub>2</sub>NHEt.
In some modalities of lile formula, at least one R<sup>12d</sup> is CH<sub>2</sub>N (Me) (Et).
In some forms of formula lile, R<sup>12a</sup>, R<sup>12c</sup>, or R<sup>12c</sup> it's CN.
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lile,</td><td>p12a Ri2b</td><td> 0</td><td>R<sup>12c</sup></td><td>it is</td>
<td>CH<sub>2</sub>Oh</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lile,</td><td>p12a Rl2b</td><td> 0</td><td><sub>r12</sub>C</td><td>it is</td>
<td colspan="2">CH<sub>2</sub>N (R<sup>13b</sup>)<sub>2</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lile,</td><td>p12a p12b</td><td> 0</td><td>r<sup>12c</sup></td><td>it is</td>
CH<sub>2</sub>NH<sub>2</sub>
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lile, R<sup>12a</sup>, R<sup>12b</sup>,</td><td>or</td><td>R<sup>12c</sup></td><td>it is</td>
<td>CH</td><td><sub>2</sub>NHMe</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lile, R<sup>12a</sup>, R<sup>12b</sup>,</td><td>or</td><td>R<sup>12c</sup></td><td>it is</td>
<td>CH</td><td><sub>2</sub>NMe<sub>2</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lile, R<sup>12a</sup>, R<sup>12b</sup>,</td><td>or</td><td>R<sup>12c</sup></td><td>it is</td>
<td>CH</td><td><sub>2</sub>NHEt.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>lile, R<sup>12a</sup>, R<sup>12b</sup>,</td><td>or</td><td>R<sup>12c</sup></td><td>it is</td>
CH<sub>2</sub>N (Me) (Et).
In some forms of formula Illa and lile, R<sup>11</sup> is -CH<sub>2</sub>NEt<sub>2</sub>.
In some forms of formula Illa and lile, R<sup>10</sup> is selected from the group consisting of H, F, Cl, Me, OMe, CF<sub>3</sub> and CN.
In some forms of formula Illa and lile, R<sup>11</sup> is selected from the group consisting of F, Cl, Me, OMe, CF<sub>3</sub> and CN.
151
In some forms of formula Illa and lile, R<sup>10</sup> it's H; and R<sup>11 </sup>is F.
In some forms of formula Illa and lile, R<sup>10</sup> it's H; and R<sup>11 </sup>is Cl.
In some forms of formula Illa and lile, R<sup>10</sup> it's H; and R<sup>11 </sup>is Me.
In some forms of formula Illa and lile, R<sup>10</sup> it's H; and R<sup>11 </sup>is OMe.
In some forms of formula Illa and lile, R<sup>10</sup> it's H; and R<sup>11 </sup>is CF<sub>3</sub>.
In some forms of formula Illa and lile, R<sup>10</sup> it's H; and R<sup>11 </sup>it's CN.
In some forms of formula Illa and lile, R<sup>10</sup> is F; and R<sup>11 </sup>is F.
In some forms of formula Illa and lile, R<sup>10</sup> is F; and R<sup>11 </sup>is Cl.
In some forms of formula Illa and lile, R<sup>10</sup> is F; and R<sup>11 </sup>is Me.
In some forms of formula Illa and lile, R<sup>10</sup> is F; and R<sup>11 </sup>is OMe.
In some forms of formula Illa and lile, R<sup>10</sup> is F; and R<sup>11 </sup>is CF<sub>3</sub>.
In some forms of formula Illa and lile, R<sup>10</sup> is F; and R<sup>11 </sup>it's CN.
In some forms of formula Illa and lile, R<sup>10</sup> is -C<sub>12</sub>
152 I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
In some I rent.
modalities modalities modalities modalities modalities modalities modalities modalities modalities modalities modalities formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and formula Illa and lile, R<sup>10</sup> is -0 ^ 3 lile, R<sup>10</sup> is -0<sub>ν4</sub> lile, R<sup>10</sup> is -C ^ s lile, R<sup>10</sup> is -Ο ,.<sub>β</sub>
Ule, R<sup>10</sup> is -C<sub>2</sub>.<sub>6</sub>
Ule, R<sup>10</sup> is -C<sub>3</sub>.<sub>6</sub>
Ule, R<sup>10</sup> is -C4.e lile, R<sup>10</sup> is -C2.<sub>5 </sub>lile, R<sup>10</sup> is -C3.5 lile, R<sup>11</sup> is -Cu2 lile, R<sup>11</sup> is -0 ^ 3 lile, R<sup>11</sup> is -0<sub>ν4</sub>
153
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In
In
In
In
In
In some some some some some some formula Illa and lile, R<sup>11</sup> is -C1.5 formula Illa and lile, R<sup>11</sup> is -Ci.<sub>6</sub> formula Illa and lile, R<sup>11</sup> is -C<sub>2</sub>.e formula Illa and lile, R<sup>11</sup> is -C<sub>3</sub>.<sub>6</sub> formula Illa and lile, R<sup>11</sup> is -C<sub>4</sub>.<sub>and</sub> formula Illa and Ule, R<sup>11</sup> is -C2-5 formula Illa and lile, R<sup>11</sup> is -C<sub>3</sub>.<sub>5</sub> formula modalities formula modalities formula modalities formula modalities formula modalities formula modalities
In some modalities
CH<sub>2</sub>N (R<sup>13b</sup>)<sub>2</sub>.
In some modalities
CH2NH2.
In some modalities
Illa and lile, which is 1 a
Illa and lile, which is 1 a
Illa, q is 1 or 2.
Illa
Illa
Illa
3.
lile, lile, lile, q is 2.
R<sup>11</sup> is -CH<sub>2</sub>Oh
of formula Illa y lile, R<sup>11</sup> is a formula Illa and lile, R<sup>11</sup> is a formula Illa and lile, R<sup>11</sup> is a
154
<td>CH<sub>2</sub>NHMe</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa</td><td>Y</td><td>lile,</td><td>R<sup>11</sup></td><td>it is</td><td>a</td>
<td>CH<sub>2</sub>NMe<sub>2</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa</td><td>Y</td><td>lile,</td><td>R<sup>11</sup></td><td>it is</td><td>a</td>
<td>CH<sub>2</sub>NHEt.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa</td><td>Y</td><td>lile,</td><td>R<sup>11</sup></td><td>it is</td><td>a</td>
<td>CH<sub>2</sub>N (Me) (Et).</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa</td><td>Y</td><td>lile,</td><td>R<sup>11</sup></td><td>it is</td><td>a</td>
CH<sub>2</sub>NEt<sub>2</sub>.
In some forms of formula Illa and lile, R<sup>13</sup> is a -Ci_<sub>2</sub> I rent.
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa</td><td>Y</td><td>lile,</td><td>R<sup>13</sup></td><td>is -Ci.<sub>3</sub></td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa</td><td>Y</td><td>lile,</td><td>R<sup>13</sup></td><td>is -Ci.<sub>4</sub></td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>Illa</td><td>Y</td><td>lile,</td><td>R<sup>13</sup></td><td>is -Ci.s</td>
I rent.
In some forms of formula Illa and lile, R<sup>13</sup> it is a -C ^ e alkyl.
In some forms of formula Illa and lile, R<sup>13</sup> It's a c<sub>2</sub>.<sub>and </sub>I rent.
In some forms of formula Illa and lile, R<sup>13</sup> It's a c<sub>3</sub>.<sub>and </sub>I rent.
In some forms of formula Illa and lile, R<sup>13</sup> It's a c<sub>4</sub>.<sub>and </sub>I rent.
155
In some forms of formula Illa and lile, R<sup>13</sup> It's a c<sub>2</sub>.5 alkyl.
In some forms of formula Illa and lile, R<sup>13</sup> It's a c<sub>3</sub>.<sub>s </sub>I rent.
Some embodiments of formula III include compounds of formula (llld):
<img file="MX368248B_D0224.tif" />
llld or dermatologically acceptable salts or prodrugs thereof.
In some modalities of formula llld, R<sup>14</sup> is selected from the group consisting of -Ci.<sub>6</sub> unsubstituted alkyl and -0 ^ 3 haloalkyl.
In some modalities of formula llld, R<sup>1S</sup> is selected from the group consisting of -8, .5 unsubstituted alkyl, and -C ,.<sub>3</sub> haloalkyl.
In some modalities of formula llld, each R<sup>16</sup> is a substituent attached to phenyl ring and is independently selected at each occurrence from the group consisting of -Ci.e unsubstituted alkyl, -CH2OH, -CH2N (R<sup>17b</sup>) 2, -8, .3 haloalkyl, halide, -OR<sup>17a</sup> and CN.
In some modalities of formula llld, each R<sup>17a</sup> is independently selected from the group consisting of —C<sub>3</sub>.<sub>and </sub>unsubstituted alkyl and -C ,.<sub>3</sub> haloalkyl.
156
In some modalities of formula llld, each R<sup>17b </sup>independently selected from the group consisting of H and -C unsubstituted alkyl.
In some modalities of formula llld, q is 1 to 5.
In some modalities of formula llld, R<sup>17a</sup> is -C<sub>3</sub>.<sub>6</sub> I rent.
In some modalities of formula llld, R<sup>17a</sup> is -C<sub>4</sub>.<sub>6</sub> I rent.
In some modalities of formula llld, R<sup>17a</sup> is -C<sub>3</sub>.<sub>5</sub> I rent.
In some forms of CH<sub>2</sub>Oh
In some forms of CH<sub>2</sub>N (R<sup>17b</sup>)<sub>2</sub>.
In some forms of CH<sub>2</sub>NH<sub>2</sub>.
In some forms of CH<sub>2</sub>NHMe.
In some forms of CH<sub>2</sub>NMe<sub>2</sub>.
In some forms of CH<sub>2</sub>NHEt
In some forms of CH<sub>2</sub>N (Me) (Et).
In some forms of CH<sub>2</sub>NEt<sub>2</sub>.
In some modalities of formula llld, at least one R<sup>16</sup> is llld formula, at least one R<sup>16</sup> is llld formula, at least one R<sup>16</sup> is llld formula, at least one R<sup>16</sup> is llld formula, at least one R<sup>16</sup> is llld formula, at least one R<sup>16</sup> is llld formula, at least one R<sup>16</sup> is llld formula, at least one R<sup>1S</sup> it is formula Illa, lllb, lile and llld, -Ci.<sub>3</sub> haloalkyl is -CF<sub>3</sub>.
157
In some forms of formula lllb and Ilid, R<sup>14</sup> is me
In some forms of formula lllb and Ilid, R<sup>14</sup> is Et.
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -C<sub>12</sub></td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>1 lid.</td><td>R<sup>14</sup></td><td>is -C -,. 3</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -C<sub>V</sub>4</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -C1.5</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -Cve</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is - C<sub>2</sub>-and</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -C<sub>3</sub>-and</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -C<sub>4</sub>.6</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -C2.5</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is —C3.5</td>
<td>I rent.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -Ci.<sub>2</sub></td>
<td colspan="2">haloalkyl.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>lllb</td><td>Y</td><td>llld,</td><td>R<sup>14</sup></td><td>is -C1.3</td>
158 haloalkyl.
In some modalities of formula lllb and llld, R<sup>14</sup> is -C<sub>2</sub>.<sub>3 </sub>haloalkyl.
In some modalities of formula lllb and llld, R<sup>14</sup> is CF<sub>3</sub>.
In some modalities of formula lllb and llld, R<sup>15</sup> is me
In some modalities of formula lllb and llld, R<sup>15</sup> is Et.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some types of alkyl.
In some modalities of formula lllb and llld, R<sup>15</sup> is -C<sub>1</sub>.<sub>2</sub> formula lllb and llld, R<sup>15</sup> is -Ci_<sub>3</sub> formula lllb and llld, R<sup>15</sup> is -C1.4 formula lllb and llld, R<sup>15</sup> is -Ci.s formula lllb and llld, R<sup>15</sup> is -Ci_<sub>6</sub> formula lllb and llld, R<sup>15</sup> is -C<sub>2</sub>.<sub>6</sub> formula lllb and llld, R<sup>15</sup> is -C<sub>3</sub>.<sub>6</sub> formula lllb and llld, R<sup>15</sup> is -C<sub>4</sub>.<sub>and</sub> formula lllb and llld, R<sup>15</sup> is -C<sub>2</sub>.<sub>5</sub> formula lllb and llld, R<sup>15</sup> is -C<sub>3</sub>.<sub>5</sub>
159 I rent.
In some haloalkyl.
In some haloalkyl.
In some haloalkyl.
modalities of modalities of modalities of formula lllb and formula lllb and formula lllb and llld, R<sup>15</sup> is -Cva llld, R<sup>15</sup> is -Ci.3 llld, R<sup>15</sup> is -C<sub>2</sub>.<sub>3</sub>
In some modalities of formula lllb and llld, R<sup>15</sup> is CF<sub>3</sub>.
In some modalities of formula lllb and llld, at least one R<sup>18 </sup>it is a halide.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is F.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is Cl.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is Me.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is CF<sub>3</sub>.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>it's CN.
In some modalities of formula lllb and llld, q is 1 to 4.
In some modalities of formula lllb and llld, q is 1 to 3.
In some modalities of formula lllb and llld, q is 1 or 2.
In some modalities of formula lllb and llld, q is 2.
In some modalities of formula lllb llld, it is
1.
160
In some modalities of formula lllb and 11Id, q is 1 and R<sup>18</sup> is F or Cl.
In some modalities of formula lllb and IIId, at least one R<sup>16 </sup>is ~ Ci-2 alkyl.
In some modalities of formula lllb and IIId, at least one R<sup>16 </sup>is -Cvj alkyl.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -Ci_<sub>4</sub> I rent.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -Ci-<sub>5</sub> I rent.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -Ci-6 alkyl.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -C<sub>2</sub>-e rent.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -C<sub>3</sub>.<sub>and</sub> I rent.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -C<sub>4</sub>.<sub>and</sub> I rent.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -C<sub>2</sub>_5 alkyl.
In some modalities of formula lllb and llld, at least one R<sup>16 </sup>is -C<sub>3</sub>_5 alkyl.
Some embodiments of the present disclosure include compounds of formula (IV):
161
<img file="MX368248B_D0225.tif" />
Acceptable or salts, dermatologically prodrugs thereof.
In some formula modalities
IV, ring F is
<img file="MX368248B_D0226.tif" />
In some formula modalities
IV, ring G is selected from the group consisting of <sup>Rl9a</sup><sub>R</sub>19b
<img file="MX368248B_D0227.tif" />
<img file="MX368248B_D0228.tif" />
(R<sup>19c</sup>) k
<img file="MX368248B_D0229.tif" />
and heteroaryl (R<sup>19d</sup>)<sub>z</sub> 5-6 membered where a carbon atom in the ring binds to the carbonyl carbon.
In some forms of formula IV, each R<sup>18</sup> is a substituent attached to ring F and is independently selected at each occurrence from the group consisting of H, -C1.3 haloalkyl, halide, -OR<sup>20</sup> and CN.
In some forms of formula IV, each R<sup>18</sup> is a substituent attached to ring F and is independently selected at each occurrence from the group consisting of -Cj.3 haloalkyl, halide, -OR<sup>20</sup> and CN.
162
In some forms of formula IV, R<sup>19th</sup> is a substituent attached to the para position of phenyl and is selected from the group consisting of H, -C2.e unsubstituted alkyl, -CH2OH, CH2N (R<sup>21</sup>)2 C<sub>V</sub>3 haloalkyl, F, Br, I, -OR<sup>20</sup> and CN.
In some forms of formula IV, R<sup>19b</sup> is a substituent attached to the meta or ortho position of phenyl and is selected from the group consisting of H, -C2.e unsubstituted alkyl, CH2OH, -CH2N (R<sup>21</sup>) 2, -Cva haloalkyl, halide, -OR<sup>20</sup> and CN.
In some forms of formula IV, R<sup>19c</sup> is a phenyl-linked substituent and is independently selected at each occurrence from the group consisting of H, -CH2OH, -CH2N (R<sup>21</sup>) 2i Ci-3 haloalkyl, halide, -OR<sup>20</sup> and CN; k is 2 to 5.
In some forms of formula IV, R<sup>19c</sup> is a phenyl-linked substituent and is independently selected at each occurrence from the group consisting of -CH2OH, -CH2N (R<sup>21</sup>) 2, -Ci. <sub>3</sub> haloalkyl, halide, -OR<sup>20</sup> and CN; k is 0 to 5.
In some forms of formula IV, R<sup>19d</sup> is a substituent attached to the heteroaryl ring and is independently selected at each occurrence from the group consisting of H, -CH2OH, -CH2N (R<sup>21</sup>) 2i ”Ci_<sub>3</sub> haloalkyl, halide, -OR<sup>20</sup> and CN; z is 0 to 4.
In some forms of formula IV, R<sup>19d</sup> it is a substituent attached to the heteroaryl ring and is independently selected at each occurrence from the group consisting of CH2OH, -CH2N (R<sup>21</sup>) 2i -Cvs haloalkyl, halide, -OR<sup>20</sup> and CN; z is 1 a
163
In some forms of formula IV, each R<sup>20</sup> I know regardless of the group consisting of H, -C<sub>36</sub> substituted and -C ,.<sub>3</sub> haloalkyl.
In some forms of formula IV, each R<sup>21</sup> I know independently of the group consisting of H and -Ci.<sub>3</sub> select alkyl does not select unsubstituted alkyl.
In
In
In
In
In some some some some formula modalities formula modalities formula modalities formula modalities
IV,
IV,
IV,
IV, is is is to 13.
to 13.
0.
r is 1 a
5.
some modalities of formula IV, (R<sup>1</sup>%
<img file="MX368248B_D0230.tif" />
<img file="MX368248B_D0231.tif" />
In some modalities of formula IV, select from the group consisting of:
<img file="MX368248B_D0232.tif" />
is selected from the group consisting of:
<img file="MX368248B_D0233.tif" />
is selected from the group consisting of
H
Cl, Me, OMe,
CF<sub>3</sub> Y
CN.
In some formula modalities
IV, at least one R<sup>19c</sup> or R<sup>19d</sup>
164 it is halide.
In some formula modalities
IV, at least one
R<sup>19c</sup>
R<sup>19d</sup> it is
In some formula modalities
IV, at least one
R<sup>19c</sup>
R<sup>19d</sup> is is is is is is
Cl.
In
I.
In
Oh
In
OMe.
In
CF<sub>3</sub>.
In
CN.
In some some some some some some modalities modalities modalities formula formula formula formula formula modalities
IV,
IV,
IV,
IV,
IV, al al al at least minus minus minus minus one one one one one
R<sup>19c</sup>
R<sup>19c</sup>
R<sup>19c</sup>
R<sup>19c</sup>
R<sup>19c</sup>
R<sup>19d</sup>
R<sup>19d</sup>
R<sup>19d</sup>
R<sup>19d</sup>
R<sup>19d</sup> modalities of formula IV, R<sup>19b</sup> is selected from the group consisting of H, F, Cl, Me, OMe, CF<sub>3</sub> and CN.
In
In
In
In
In
In
In
In some some some some some some some some modalities modalities modalities modalities modalities modalities modalities formula formula formula formula formula formula formula formula
IV, R<sup>19th</sup>
IV,
IV,
IV,
IV,
IV,
IV,
IV,
R<sup>19b</sup> it is
H.
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup><sub>R</sub>1<sup>0b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup> is is is is is is is halide.
Cl.
I.
Oh
OMe.
CF<sub>3</sub>.
165
In some forms of formula IV, R<sup>19th</sup> or R<sup>19b</sup> it's CN.
In some forms of formula IV, z is 1.
In some forms of formula IV, z is 2.
In some modalities of formula IV, z is 2 and both R<sup>19d</sup> They are f.
In some modalities of formula IV, z is 2 and both R<sup>19d</sup> are Me.
In some modalities of formula IV, z is 2 and both R<sup>19d</sup> are CF<sub>3</sub>.
In some modalities of formula IV, z is 2 and both R<sup>19d</sup> they are OMe.
In some forms of formula IV, z is 2 and an R<sup>19d</sup> is F and the other R<sup>19d</sup> is Me.
In some forms of formula IV, z is 2 and an R<sup>19d</sup> is F and the other R<sup>1Sd</sup> is CF<sub>3</sub>.
In some forms of formula IV, z is 2 and an R<sup>19d</sup> is F and the other R<sup>19d</sup> is OMe.
In some modalities of formula IV, z is 2 and both R<sup>19d</sup> they are CN.
In some forms of formula IV, z is 2 and an R<sup>19d</sup> is F and the other R<sup>19d</sup> it's CN.
In some forms of formula IV, z is 2 and an R<sup>19d</sup> is F and the other R<sup>19d</sup> is Cl.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -Ci-2 alkyl.
166
In some forms of formula IV, at least one
R<sup>19c</sup> or R<sup>19d</sup> is -C1.3 alkyl.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -Ci-4 alkyl.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -Ci_5 alkyl.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -Ci_e alkyl.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -C<sub>2</sub>-e rent.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -C<sub>3</sub>.<sub>and</sub> I rent.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is —C<sub>4</sub>.e rent.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -C<sub>2</sub>-5 alkyl.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -C<sub>3</sub>_<sub>5</sub> I rent.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -CH<sub>2</sub>Oh
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -CH2N (R<sup>13b</sup>)2.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d </sup>is -CH<sub>2</sub>NH<sub>2</sub>.
In some forms of formula IV, at least one R<sup>19c</sup> or R<sup>19d</sup>
167 it is
-CH<sub>2</sub>NHMe.
In some formula modalities
IV, at least one
R<sup>19c</sup> it is
-CH<sub>2</sub>NMe<sub>2</sub>.
In some formula modalities
IV, at least one
R<sup>19c</sup> is is is
-CH<sub>2</sub>NHEt
In some formula modalities
-CH<sub>2</sub>N (Me) (Et).
In some formula modalities
-CH<sub>2</sub>NEt<sub>2</sub>.
For rent.
For rent.
For rent.
For rent.
For rent.
For rent.
For rent.
For rent.
IV, at
IV, at least at least one
R<sup>19c</sup>
R<sup>19c</sup> some some some some some some some some modalities modalities modalities modalities modalities modalities modalities of of of of of of of formula formula formula formula formula formula formula formula formula
IV,
IV,
IV,
IV,
IV,
IV,
IV,
IV,
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19th</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup>
R<sup>19b</sup> is is is is is is is is
R<sup>19d</sup>
R<sup>19d</sup>
R<sup>19d</sup>
R<sup>19d </sup>• Ci-2 • Ci_3 Ci_4
Ci-5
Ci-e • C<sub>2</sub>-e • C3-6 C4.6
168
In some forms of formula IV, R<sup>19th</sup> or R<sup>19b</sup> is -C<sub>2</sub>.<sub>5 </sub>I rent.
In some forms of formula IV, R<sup>10a</sup> or R<sup>19b</sup> is -C<sub>3</sub>.<sub>5 </sub>I rent.
<td rowspan="2">In In</td><td colspan="4">some modalities of formula IV,</td><td colspan="5">R<sup>19th</sup> 0 R<sup>19b</sup> is -CH<sub>2</sub>Oh</td>
<td>some</td><td>modalities</td><td>from</td><td>formula</td><td>iv,</td><td>R<sup>19th</sup></td><td>OR</td><td>Rlflb</td><td>it is -</td>
<td colspan="2">CH<sub>2</sub>N (R<sup>13b</sup>)<sub>2</sub>.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td colspan="4">some modalities of formula IV,</td><td>R<sup>19th</sup></td><td>or R<sup>19b</sup></td><td>it is</td><td>-CH</td><td><sub>2</sub>NH<sub>2</sub>.</td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>IV,</td><td><sub>R</sub>19th</td><td> 0</td><td>R<sup>19b</sup></td><td>it is -</td>
CH<sub>2</sub>NHMe.
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>IV,</td><td>R<sup>19th</sup></td><td> 0</td><td>R<sup>19b</sup></td><td>it is -</td>
<td>CH<sub>2</sub>NMe<sub>2</sub></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>IV,</td><td>R<sup>19th</sup></td><td> 0</td><td>R<sup>10b</sup></td><td>it is -</td>
<td>CH<sub>2</sub>NHEt.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>IV,</td><td>R<sup>19th</sup></td><td>or</td><td>R<sup>19b</sup></td><td>it is -</td>
<td colspan="2">CH<sub>2</sub>N (Me) (Et).</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>some</td><td>modalities</td><td>from</td><td>formula</td><td>IV,</td><td>R<sup>19th</sup></td><td>or</td><td>R<sup>19b</sup></td><td>it is -</td>
CH<sub>2</sub>NEt<sub>2</sub>.
<img file="MX368248B_D0234.tif" />
169
<img file="MX368248B_D0235.tif" />
Γ / Ο<sup>5</sup> ν, ν, ν ν, ν and N; where the carbonyl carbon of formula IV can bond with any unsubstituted carbon in ring G.
In some forms of formula IV,
<img file="MX368248B_D0236.tif" />
is selected from the group consisting of:
<img file="MX368248B_D0237.tif" />
of the group consisting of:
170
<img file="MX368248B_D0238.tif" />
In some forms of formula IV, -C- |.<sub>3</sub> haloalkyl is CF<sub>3</sub>.
Illustrative compounds of formulas I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, He, lid, lie, llf, III, Illa, lllb, lile, llld and IV se shown in table 1.
Table 1
<td> ' ¢0¼¾ ‘</td><td></td>
<td>Oh</td><td>Oh</td>
<td> cS ° <sup>1</sup></td><td>OMe</td>
<td>7 < Ό '^^ ψ ^ ΟΜβ ° OMe</td><td> ¢6¼°</td>
171
<img file="MX368248B_D0239.tif" />
172
<td> 23</td><td>OMe cXrS ^</td><td> 24</td><td>s Λ rr</td>
<td> 25</td><td></td><td> 26</td><td></td>
<td> 27</td><td>0 r ^ N</td><td> 28</td><td>CXrSr<sup>0</sup></td>
<td> 29</td><td></td><td> 30</td><td>QF,</td>
<td> 31</td><td> ¢0¼°</td><td> 32</td><td>ccAV?</td>
<td> 33</td><td>F ccfeV<sup>3</sup></td><td> 34</td><td></td>
<td> 35</td><td>0 OMe w</td><td> 36</td><td>OMe C<sub>s</sub>X ^ ia ^</td>
173
<td> 37</td><td></td><td> 38</td><td></td>
<td> 39</td><td>CrrSfe<sup>1</sup></td><td> 40</td><td>O r ^ N CCñr</td>
<td> 41</td><td></td><td> 42</td><td>cXrHrí</td>
<td> 43</td><td>φφγώ</td><td> 44</td><td></td>
<td> 45</td><td>CCrW?</td><td> 46</td><td>F CoSfe<sup>3</sup></td>
<td> 47</td><td>Ccfer<sup>0</sup>'</td><td> 48</td><td>CoSfe</td>
<td> 49</td><td>OMe CoSfe<sup>1</sup></td><td> 50</td><td> 00¼^</td>
174
<td> 51</td><td> ¢0¼<sup>0</sup></td><td> 52</td><td>tx / U s</td>
<td> 53</td><td></td><td> 54</td><td>cxU °</td>
<td> 55</td><td> 00¼¾</td><td> 56</td><td>CCóC</td>
<td> 57</td><td>or Z ^<sup>CF</sup>' ϊ ΓΤ USA ϊ</td><td> 58</td><td> 00<sup>1</sup>¼</td>
<td> 59</td><td> 0¼¾</td><td> 60</td><td>/F ! Γϊ Υχ / ^ Α / 'Χ / ΧΖ Cu í</td>
<td> 61</td><td>υπΛ ^ τ UUUU OR OMe</td><td> 62</td><td>OMe QyL ^ Ú</td>
<td> 63</td><td>/ OMe ϊ ΠΓ or</td><td> 64</td><td>ϊ ΓΊ (I ^ r <sup>N </sup>CCC ^ <sup>0</sup></td>
<td> 65</td><td>ϊ u CU 4</td><td> 66</td><td>Ϊ Cu J</td>
175
<img file="MX368248B_D0240.tif" />
176
<td> 81</td><td>F<sub>x</sub>Fx F</td><td>toYr?</td><td> 82</td><td>Fx, Fx, TO</td><td>CF<sub>S</sub>í fl χΟχΧ ^ χΑχ ^ χ ^ Α ^ χ<sup>1 </sup>lAJ I</td>
<td> 83</td><td>F Fx ^ Fx F ^</td><td>_ ^ x ^ / CF, aA / AJ x χΥχ! 0 0</td><td> 84</td><td>FF \ Fx ^ F ^</td><td>: χΛγ9</td>
<td> 85</td><td>Fx</td><td>F<sup>F</sup> ϊ ΓΊ <XJ Y</td><td> 86</td><td>F</td><td>X ^ x xF ϊ ΓΎ .Xj i</td>
<td> 87</td><td>Fx ^ Fx ^ F ^</td><td>01Λύ9</td><td> 88</td><td>Fx, Fx, F<sup>x</sup></td><td>OMe Ϊ MY ÍXJ Y</td>
<td> 89</td><td>F Fx ^^</td><td>or YA 'ooAY</td><td> 90</td><td>Fx ^ Fx ^</td><td>ϊ ΓΊ YY ^ T <sup>N </sup>X xY A o or</td>
<td> 91</td><td>Fx ^ Fx</td><td>μΟχ ^ ΐ ^ χΧ), OxT Y CT</td><td> 92</td><td></td><td>Ϊ Χ ° Χχ<sup>χ</sup>% Χ \<sub>χ</sub>ΧχΧ% χ<sup>)</sup>OxJ Y<sup>x</sup>or</td>
<td> 93</td><td>F F\ Fx F</td><td><sup>0</sup> rYi χθΧχ ^ Υχ ^ χ ^ ΧχΑχΧ χΧΤ Y OR</td><td> 94</td><td>F<sub>x </sub>Fx F ^</td><td>í ^ vYY ^ k<sub>or</sub>A> <sup>0 CF</sup>3</td>
177
<td> 95</td><td>Fv, F ''</td><td>cf<sub>3</sub>f í 1Ί 1XX Y OR</td><td> 96</td><td>F Fx ^ F ^</td><td><sub>n</sub> ^^<sup>CFa </sup>^^ AA ^ CX .X7 X</td>
<td> 97</td><td>F ^ F ^ F</td><td>coA9</td><td> 98</td><td>Fx F'</td><td>F · = Ϊ 1Ί XX7 X ''or</td>
<td> 99</td><td>FF \ F ^</td><td>aA ^ AJ .XX Y</td><td> 100</td><td>F<sub>x</sub>Fx</td><td>/ SxqVx ^ <<sub>0</sub>A> O ° Me</td>
<td> 101</td><td>F<sub>x </sub>F<sup>x</sup></td><td>OMe aaX</td><td> 102</td><td>F<sup>F</sup>\ z F ^ F ^ '</td><td>^ x / OMe í ΓΎ<sup>S</sup>\ X '^ SxA' ^ '' \ xA% A XX Y ~ or</td>
<td> 103</td><td>TO U. LL 11-</td><td>ϊ A TA » \ ALA or</td><td> 104</td><td>F F<sub>x </sub>Fx ^ F</td><td>| O Α \ ζ ^^ Χ \ ζ ^ \ α% /<sup>ν </sup>cxt t</td>
<td> 105</td><td>F<sub>x </sub>F<sup>x</sup></td><td>^ J ^ í<sup>1</sup>1XX X 0</td><td> 106</td><td>Fx Fx ^</td><td>! Γ1 z ^<sup>s</sup>'xx% XXxxaXaA lXX T</td>
<td> 107</td><td>Α7 \ UU IL</td><td>xXA</td><td> 108</td><td>Fx Fx F'</td><td> <?<sup>F</sup>3 wJX ^ Ó XXX Y</td>
178
<td> 109</td><td>f F<sub>x</sub>V</td><td>„X'X * '· XjY s</td><td> 110</td><td>Fx Fx F</td><td>boW?</td>
<td> 111</td><td>F<sub>x</sub>Fx F<sup>x</sup></td><td></td><td> 112</td><td>F Fx ^ Fx F ^ '</td><td>! fY XY Y</td>
<td> 113</td><td>FF<sub>x </sub>Fx F ^</td><td>. «ΓχΑ ^ γΡ 0 OMe</td><td> 114</td><td>F> F> F'</td><td>OMe ! Γ1<sub>χ</sub> / Οχζ ^ Α ^ / Χ / Χ / XXY Y</td>
<td> 115</td><td>F</td><td>^ x / 0Me χΥΥ</td><td> 116</td><td>FF ^ Fx F</td><td>Ϊ Al YY ^ y<sup>n</sup>\ Yk AO</td>
<td> 117</td><td>Fx F<sub>x</sub>F<sup>x</sup></td><td>j | z<sup>0</sup>\ z \ Y \ z \ Yv<sup>N </sup><XT Y s</td><td> 118</td><td>FF<sub>x </sub>F ^ F ^</td><td>ϊ o \ JL JO</td>
<td> 119</td><td>F Fx ^ F \ F</td><td>ϊ ΓΊ / ΟχΖ ^ ΥΥ ^ χΛΥ, χτ Y S</td><td> 120</td><td colspan="2">cc '.2 OMe</td>
<td> 121</td><td colspan="2">X 'ñ OMe</td><td> 122</td><td colspan="2">o5S ° OMe</td>
179
<td> 123</td><td>OMe 0 aynV OMe</td><td> 124</td><td><sub>or</sub>Y<sub>n</sub>¿ OMe</td>
<td> 125</td><td>OMe O | < OMe</td><td> 126</td><td>OMe 0 OMe</td>
<td> 127</td><td>OMe oy-T<sup>0 </sup>OMe</td><td> 128</td><td>/ OM® OMe O OMe</td>
<td> 129</td><td>OMe</td><td> 130</td><td>¢ ^ ¼ ° OMe</td>
<td> 131</td><td>OMe 0 i ^ N q / li<sup>0</sup>OMe</td><td> 132</td><td>.....> í 0 OH</td>
<td> 133</td><td>: .ti: r</td><td> 134</td><td>/ CF<sub>S</sub>oh or ii / OvVVvV CXX I ^ oh</td>
180
<td> 135</td><td>(• e ...... 1 ' 0 OH</td><td> 136</td><td>Pi·</td>
<td> 137</td><td>OH O Γ If CXX Y O OH</td><td> 138</td><td>ax 'h</td>
<td> 139</td><td>OMe OH 0 Y | l yyyj 0 OH</td><td> 140</td><td>.OMe OH O | Y Oy ^ U Oh</td>
<td> 141</td><td>oyy<sup>1</sup></td><td> 142</td><td>oSS °</td>
<td> 143</td><td> '¿''.<sup>:3</sup></td><td> 144</td><td>oYY? O OMe</td>
<td> 145</td><td>or ~; i</td><td> 146</td><td>/ CF<sub>3 </sub>OMe O Oyyy O OMe</td>
<td> 147</td><td>what? 0 OMe</td><td> 148</td><td>. »Ii</td>
181
<td> 149</td><td>OMe O [¡| (XX Y O OMe</td><td> 150</td><td>OMe O AXl Or5ÓAíV ΑΆ ». <sup>0</sup> °·</td>
<td> 151</td><td>OMe OMe 0 Ab] oXX</td><td> 152</td><td>^ OMe OMe O jp (¿I <sup>J</sup>O OMe</td>
<td> 153</td><td>OMe 0 AA. XX<sup>or</sup></td><td> 154</td><td>r ϊ O COXA</td>
<td> 155</td><td>oáXX</td><td> 156</td><td>FOR OMe</td>
<td> 157</td><td>αχΥ OMe</td><td> 158</td><td>ϊ 1Ϊ (XX and 0 OMe OMe</td>
<td> 159</td><td>oXX? OMe</td><td> 160</td><td>F cccHa O OMe OMe</td>
<td> 161</td><td>oXY OMe</td><td> 162</td><td>rVT ^ ArV k A \ A \ © OMe 0 OMe OMe</td>
182
<img file="MX368248B_D0241.tif" />
183
<td> 175</td><td>OMe 00¼<sup>0</sup>Oh</td><td> 176</td><td>/ OMe or. I fT Oh</td>
<td> 177</td><td>Opkk Oh</td><td> 178</td><td>? Π 0/77 Oh</td>
<td> 179</td><td>or. 1 Π Oh</td><td> 180</td><td>/ vUUX) C<sub>0</sub>) and ^ í ^ Oh</td>
<td> 181</td><td>Tokk O OH</td><td> 182</td><td>cf<sub>3</sub>! ΓΊ QXXh °</td>
<td> 183</td><td>QXXh °</td><td> 184</td><td>cckk? 0 OH</td>
<td> 185</td><td>F or. I Λ ÓOOí ^ 0 OH</td><td> 186</td><td>ϊ ΠΓ CXXÍ 0 OH</td>
<td> 187</td><td>O OH</td><td> 188</td><td>OMe í or ΛγζΟ / 77 (XaT Oh</td>
184
<td> 189</td><td>/ OMe ϊ ΓΎ CXXT Ο OH</td><td> 190</td><td>// J C / Ccs O OH</td>
<td> 191</td><td>l O</td><td> 192</td><td>CU I O OH</td>
<td> 193</td><td>ϊ Π CU í 0 OH</td><td> 194</td><td>How?</td>
<td> 195</td><td>.Y</td><td> 196</td><td> /<sup>CF</sup>3 OH O | II OAA<sup>1</sup></td>
<td> 197</td><td>ii '. °</td><td> 198</td><td>(¿'I</td>
<td> 199</td><td> /<sup>F </sup>OH O Γ || AC</td><td> 200</td><td>tVA <<sub>OR</sub>> UO OMe</td>
<td> 201</td><td>OMe cU</td><td> 202</td><td>.OMe OH O [II CáHr<sup>5</sup></td>
<td> 203</td><td>OH 0 A | AC</td><td> 204</td><td></td>
185
<img file="MX368248B_D0242.tif" />
186
<td> 221</td><td>XX) CXX ^ Y ^</td><td> 222</td><td>I jO <ΌυΊΑ</td>
<td> 223</td><td> ° <sup>CF</sup>’</td><td> 224</td><td><? F<sub>S </sub>AUÓ XXXi</td>
<td> 225</td><td><sub>Λ</sub> ^^ CFs v ^ JUCT 'ΛϊΧ ϊ</td><td> 226</td><td>fi ^ Xji, Δ ^ 'Τ ^ Χ ^ ΤΤ Λ-V ° <sup>F</sup></td>
<td> 227</td><td>F<sub>F</sub> Garlic<sup>0</sup></td><td> 228</td><td><sup>0</sup> r Y<sub>F</sub>y ^ A ^<sub>Y</sub>M or ·<sup>1</sup>^' · <sup>0</sup></td>
<td> 229</td><td>fa ^ Xji VA ° <sup>OMe</sup></td><td> 230</td><td>OMe F jó<sup>Λ</sup>οΑ> <sup>0</sup></td>
<td> 231</td><td>. ^. OMe F ^ O ^ JCjU<sup>F</sup>XXjr</td><td> 232</td><td><sup>0</sup>Vo <sup>0</sup></td>
<td> 233</td><td>ΑχΛΧ<sup>1</sup></td><td> 234</td><td>FA / ^ / O fVTt ^ V ^ vV <sup>0</sup></td>
<td> 235</td><td><sup>0</sup> XY Λ ^ ύΥ ^ Α \ A> 0</td><td> 236</td><td>XX</td>
187
<td> 237</td><td>cf<sub>3</sub></td><td> 238</td><td> ^\/<sup>CF</sup>3 <oo θ</td>
<td> 239</td><td></td><td> 240</td><td>í ^ yUjjó</td>
<td> 241</td><td>i<sub>1</sub>and ^<sub>T</sub>OR'</td><td> 242</td><td>or OMe</td>
<td> 243</td><td>OMe</td><td> 244</td><td>/ OMe f 0 0 [II u °</td>
<td> 245</td><td></td><td> 246</td><td></td>
<td> 247</td><td>sy ..... and</td><td> 248</td><td>yyy)</td>
<td> 249</td><td>H</td><td> 250</td><td>CF<sub>3 </sub>z ^ jcjÓ H</td>
188
<td> 251</td><td>/ CF<sub>3</sub>H</td><td> 252</td><td>H</td>
<td> 253</td><td>αζΑτθ H</td><td> 254</td><td>/F<sup>0</sup> \ II CX ^^^ X ^ H</td>
<td> 255</td><td>OR Ν-ΧΧ ° <sup>OM</sup>® H</td><td> 256</td><td>OMe OR H</td>
<td> 257</td><td>0Me Ol ° H</td><td> 258</td><td>X jQ \ A ^ ° H</td>
<td> 259</td><td>CXXX ^ XX ^ H</td><td> 260</td><td>H</td>
<td> 261</td><td>^ JCuO CXj ^ ° H</td><td> 262</td><td>\ -ΛΧ ° <sup>cf</sup>> H</td>
<td> 263</td><td>CCrS ^ H</td><td> 264</td><td> /<sup>CF</sup>3 I jCT <) jr H</td>
189
<img file="MX368248B_D0243.tif" />
190
<td> 279</td><td>CCrSr ^</td><td> 280</td><td>ií <X<sup>F</sup></td>
<td> 281</td><td><sup>0 0Me</sup></td><td> 282</td><td>OMe z ^^ cuó vLJ °</td>
<td> 283</td><td>.OMe CX ^ '^ °</td><td> 284</td><td>coSv</td>
<td> 285</td><td>? OR CXX ^ X · ^</td><td> 286</td><td>Z ^ zVUO ζΧΧ '^' θ</td>
<td> 287</td><td>CÍJ</td><td> 288</td><td>o / vP<sup>0 CF</sup>3</td>
<td> 289</td><td>cf<sub>3</sub>i Λ</td><td> 290</td><td> ^\<<sup>CFí</sup></td>
<td> 291</td><td>i ΧΊ coHV</td><td> 292</td><td>F I ÍJ oxnr ^</td>
<td> 293</td><td>ζΧΧ ^ Χι ^</td><td> 294</td><td>mW?<sup>0 0Me</sup></td>
191
<td> 295</td><td>OMe OR</td><td> 296</td><td> /<sup>0Me</sup>I £ ϊ φΊΓ</td>
<td> 297</td><td> 00¼<sup>0</sup></td><td> 298</td><td>or O n ^ OoVA ^<sup>n</sup></td>
<td> 299</td><td> ° ¢0¼¼</td><td> 300</td><td>I jO , N ^ z% O \ / \ zSz</td>
<td> 301</td><td> 0--¼ <sup>0 CF</sup>></td><td> 302</td><td>cc / A</td>
<td> 303</td><td>CÍX ^ X »^</td><td> 304</td><td>OO ^ Ail</td>
<td> 305</td><td>coA</td><td> 306</td><td>íZ'O</td>
<td> 307</td><td>, ¼Aj or OMe</td><td> 308</td><td>OMe z ^ A ^ JU</td>
<td> 309</td><td>. ^. OMe cxx °</td><td> 310</td><td>fTT ^ r <sup>N1</sup></td>
192
<td> 311</td><td>? or</td><td> 312</td><td>. Ι ^ Χ)</td>
<td> 313</td><td>^? iO</td><td> 314</td><td>ΟΛ ^ ?? HN— ° <sup>cf</sup>3</td>
<td> 315</td><td>cf<sub>3</sub>C ^ v / J</td><td> 316</td><td>ΟΛύ<sup>0</sup>'</td>
<td> 317</td><td>0Λύ9</td><td> 318</td><td>OR/·-/<sup>3</sup>HN ^ °</td>
<td> 319</td><td>QyVyQ Η<sub>Ν</sub>^ O OMe</td><td> 320</td><td>OMe ΟΛγώ</td>
<td> 321</td><td>, ° Me > -and ..... s</td><td> 322</td><td></td>
<td> 323</td><td>QrS °</td><td> 324</td><td>QA / í HN— °</td>
<td> 325</td><td>0Λύ °</td><td> 326</td><td>HN — NO CF<sub>3</sub></td>
193
<td> 327</td><td>ΟΆυΧ- ·<sup>5</sup>HNN 0</td><td> 328</td><td>/ CF<sub>3</sub>/ ¾¾. or Γ if hVn O</td>
<td> 329</td><td>HN 0 F</td><td> 330</td><td>F HN<sup>N</sup> °</td>
<td> 331</td><td>qa-Y HN<sup>N 0</sup></td><td> 332</td><td>QAAQ<sub>HN</sub>—NO OMe</td>
<td> 333</td><td>OMe HN<sup>N</sup> 0</td><td> 334</td><td>.OMe QAY<sup>1</sup>hn<sup>n 0</sup></td>
<td> 335</td><td>QyVyO HN<sup>N</sup> 0</td><td> 336</td><td>QAY<sup>1</sup>HN — NO</td>
<td> 337</td><td>QA-Y hn<sup>n 0</sup></td><td> 338</td><td>OA-Y HN<sup>N</sup> °</td>
<td> 339</td><td>cxYY</td><td> 340</td><td>OR Coya</td>
<td> 341</td><td>CO- '<sup>1</sup></td><td> 342</td><td>oYY?</td>
194
<td> 343</td><td></td><td colspan="2"></td>
<td> 345</td><td> ¢0¼<sup>0</sup></td><td> 346</td><td> ¢0¼<sup>0</sup></td>
<td> 347</td><td></td><td> 348</td><td></td>
<td> 349</td><td></td><td> 350</td><td></td>
<td> 351</td><td>: ÍXrSr °</td><td> 352</td><td><sup>0</sup></td>
<td> 353</td><td>0 r ^ N</td><td> 354</td><td></td>
<td> 355</td><td></td><td> 356</td><td>ico '......> °</td>
<td> 357</td><td>Xcferr<sup>0</sup></td><td> 358</td><td>coffe</td>
195
<img file="MX368248B_D0244.tif" />
196
<td> 375</td><td>I £></td><td> 376</td><td><sup>0</sup> Y ¢ 0½ ^</td>
<td> 377</td><td>i Λ</td><td> 378</td><td>XX) fA ^ A ^ °</td>
<td> 379</td><td>i XX</td><td> 380</td><td>x XX F<sup>Z</sup>b '<sup>J</sup>k ^<sup>)</sup> °</td>
<td> 381</td><td>? AF oAJ °</td><td> 382</td><td><sup>0</sup> ϊ ^ Χι XXAV-</td>
<td> 383</td><td>x jCj ΥΎ 1 T </td><td> 384</td><td>IX) \ ° TjYi <sup>s </sup>/ \ Α> <sup>0</sup></td>
<td> 385</td><td>I JD ^ ργγχ / χΖ'ν ΛΛγ o</td><td> 386</td><td>or τ ^ Ί</td>
<td> 387</td><td>JK XX j<sup>N </sup>e, ο ^ ν<sup>Λχ</sup>-<sup>/</sup>ν ^<sup>> </sup>fXX ^ X ^ í ^</td><td> 388</td><td>coW?</td>
<td> 389</td><td>ΟθΛγλ</td><td> 390</td><td>ccYX</td>
197
<td>391 3Í<sub>or</sub><sup>! i |</sup>¿</td><td><sup>0</sup> ? ^ Ίι ίχΑΥ ^</td>
<td>s JL jO 393 3 <</td><td> ¢0¼<sup>0</sup></td>
<td> 395 <sup>3Í</sup></td><td>cXrHfe<sup>1</sup></td>
<td>O / S 397 $ 3 ugly</td><td>:, 5CoWfe</td>
<td>"Ϊ́ ^ ΟΟ ^ ΊΤθ '"</td><td>.γγ ^ γΟτ '</td>
<td> 401 4(</td><td>γθλγ.</td>
<td>~ ¡^ OcAV ^ ·</td><td>(fex / V ^</td>
<td></td><td>fexAV<sup>0</sup></td>
198
<td> 407</td><td></td><td> 408</td><td> ¢0¼^</td>
<td> 409</td><td></td><td> 410</td><td>cXrH<sup>0</sup></td>
<td> 411</td><td> ¢0¼°</td><td> 412</td><td><sup>0</sup>CCrr</td>
<td> 413</td><td></td><td> 414</td><td></td>
<td> 415</td><td>cxrhr<sup>0</sup></td><td> 416</td><td>ΐΟ<sup>Λ</sup>¡~</td>
<td> 417</td><td>Co '....... °</td><td> 418</td><td>ΜβΟ</td>
<td> 419</td><td>° Ι ^ Ί MeO. JL _ζ->. JL Xj ^ ¿ <sup>F</sup>Meo</td><td> 420</td><td>? MeO '<sup>/</sup>^<sup>Xi</sup>^</td>
<td> 421</td><td>• Ογ ^ Α ^ γ-Ο ° “·</td><td> 422</td><td>II <sup>CF</sup>' Meo</td>
199
<td> 423</td><td>XX ϊ Meo</td><td> 424</td><td>"ΙΥηΥ Meo</td>
<td> 425</td><td>or XX XX Y Meo</td><td> 426</td><td>^ XJJ XX Y Meo</td>
<td> 427</td><td>J -</td><td> 428</td><td>1 O. And | OMe 33X 0 Meo</td>
<td> 429</td><td>/ JUjXT ” ΜθΟ<sup>/ Αχί</sup>Υ</td><td> 430</td><td>O Γ H Me °.<sub>x</sub>/ í<sub>S! 5</sub>/3<sub>v</sub>//3/<sub>/</sub>N MeoYA ^</td>
<td> 431</td><td><sup>0</sup> <Ί MeO. / ^. 33 / \ / 3. J Yv r <sup>N</sup>JL / 3 or Meo</td><td> 432</td><td>ϊ Y1 γγ '^ Υ'<sup>Ν </sup>/A./3 or Meo</td>
<td> 433</td><td>° X<sup>N</sup>X Meo<sub>N</sub>// JX /// 3<sub>!5!></sub>X MeO ^^^</td><td> 434</td><td>/ N ^ o Y n MeO / Z ^ s ^ / X ^ / Z / Xs / l MeoY ^^</td>
<td> 435</td><td>3Λύ9</td><td> 436</td><td>(C ^<sup>0 0</sup> J ^ JL Uií ^</td>
<td> 437</td><td>X ^ o <sup>0 </sup>or \ zA% s / 3 / ^ / X ^ / 3 XX Y</td><td> 438</td><td>/ \ / * K <oo in XX Y</td>
200
<img file="MX368248B_D0245.tif" />
201
<img file="MX368248B_D0246.tif" />
202
<td> 471</td><td>I o <XAV-</td><td> 472</td><td>I J3 \ A> o</td>
<td> 473</td><td><sup>0</sup> Ά</td><td> 474</td><td>JLñ</td>
<td> 475</td><td>cc ££ H</td><td> 476</td><td>I £ 1 <or H</td>
<td> 477</td><td>i ££ £; H</td><td> 478</td><td>, N. Ϊ oy H</td>
<td> 479</td><td>O Π<sub>N</sub><sup>0</sup>H</td><td> 480</td><td>_x ^ jO (Yji <sup>N</sup>H</td>
<td> 481</td><td>I JO (Tji <sup>s</sup>H</td><td> 482</td><td>I jo <<sup>n</sup>YYyi ° H</td>
<td> 483</td><td>° Τ ^ 'Ίΐ H</td><td> 484</td><td>XXJ ζΧ ^ ι ^ ι ^ H</td>
<td> 485</td><td>co ££</td><td> 486</td><td>I £ 1</td>
203
<td> 487</td><td>CXjCu</td><td> 488</td><td>ϊ A</td>
<td> 489</td><td><sup>0</sup> / ¼</td><td> 490</td><td>Λ Λ Afj ^ T <sup>N </sup>GO> °</td>
<td> 491</td><td>ccU</td><td> 492</td><td>I> o \ A> <sup>0</sup></td>
<td> 493</td><td>x jO</td><td> 494</td><td>i Λ</td>
<td> 495</td><td>° vA> ° <sup>F </sup>H</td><td> 496</td><td>i XI ° H</td>
<td> 497</td><td>/F , Π vV ° H</td><td> 498</td><td>CCfCíX H</td>
<td> 499</td><td>I £ 1 IVOn * vA> o H</td><td> 500</td><td>_uuucr <Cij ^ H</td>
<td> 501</td><td>1 jO -¼] ¼ vV <sup>0 1</sup>H</td><td> 502</td><td>uun<sup>n</sup>, 'or H</td>
204
<img file="MX368248B_D0247.tif" />
205
<td> 517</td><td>.Ν. ° ι íl * \ OL λ ο Ν—<sup>OR</sup>Η</td><td> 518</td><td>ΟΛϋ?</td>
<td> 519</td><td>ΗΝ — ® <sup>0</sup></td><td> 520</td><td>ΟΛίΑ</td>
<td> 521</td><td><~ Ύ I 7 ίΧΑ ^ · hW θ</td><td> 522</td><td></td>
<td> 523</td><td>γύι ^ Ο 7Τ7Τ</td><td> 524</td><td>OJCx> 0 ΗΝ-® O</td>
<td> 525</td><td>OXJ) W1 ΗΝ — ® <sup>0</sup></td><td> 526</td><td>/ = ¾. ο 0θΎ °</td>
<td> 527</td><td> ^<sup>Ν</sup>χ / === ^ 0 / Ν 0Αύ °</td><td> 528</td><td>Οτ ^ ΊΤ ^ ΗΝΝ or 1</td>
<td> 529</td><td>ΗΝ—<sup>Ν 0</sup></td><td> 530</td><td>ΟΛ-Ρ ' ΗΝ—<sup>Ν 0</sup></td>
<td> 531</td><td>Qyt ^ O ην-<sup>ν</sup> 0</td><td> 532</td><td>QyC ^ íX) ΗΝ—<sup>Ν</sup> °</td>
206
<td> 533</td><td>οχχαο χΥΑτ<sup>Ν</sup>ην-ν <sup>0</sup></td><td> 534</td><td>ΟΧΧ ηΧΧ ΗΝ—<sup>Ν 0</sup></td>
<td> 535</td><td>ΓΑΧΧΧ MAX ”ην-<sup>ν 0</sup></td><td> 536</td><td>.Ν. ° <sup>Ν</sup> Ίι ΟΛΑ ΗΝ—<sup>Ν 0</sup></td>
<td> 537</td><td>ΟΛΑ ΗΝ—<sup>Ν 0</sup></td><td> 538</td><td>οΧ9</td>
<td> 539</td><td>οΧΟ '·</td><td> 540</td><td>/F Ο Γ || /<sup>Ν</sup>ν ^ \ Α <Α / ο</td>
<td> 541</td><td>(ΥατΡ ΧΧ Or cf<sub>3</sub></td><td> 542</td><td></td>
<td> 543</td><td><sup>0</sup> ΑΧ<sup>0</sup></td><td> 544</td><td>XX</td>
<td> 545</td><td>ν ^ αΧΧ 0</td><td> 546</td><td>aaCT</td>
<td> 547</td><td>(XaíV<sup>1</sup>0 OMe</td><td> 548</td><td><sup>0</sup> ΑΧ / Ν. JL JL Λ γ όμθ</td>
207
<td> 549</td><td></td><td> 550</td><td>.N. Ϊ or UJ</td>
<td> 551</td><td><sup>0</sup>F<sup>N</sup></td><td> 552</td><td>/ vVvM (j¡</td>
<td> 553</td><td><sub>N</sub>or</td><td> 554</td><td>.1 ^ 1} u!</td>
<td> 555</td><td><sup>0</sup> TO</td><td> 556</td><td>JK ? jT j</td>
<td> 557</td><td>cAV?</td><td> 558</td><td>I Λ Vs or</td>
<td> 559</td><td><ύ ^ ύΡ</td><td> 560</td><td>oV9</td>
<td> 561</td><td>/ ^ VdCk VS 0</td><td> 562</td><td>VS OR OMe</td>
<td> 563</td><td></td><td> 564</td><td><sup>0</sup> V ^ ll Vs or</td>
208 ** 'i
<td> 565</td><td>I Ώ Vs or</td><td> 566</td><td><sup>0 N</sup>V VS 0</td>
<td> 567</td><td>? _rj VS 0</td><td> 568</td><td>ccW</td>
<td> 569</td><td>CoW?</td><td> 570</td><td>oVV</td>
<td> 571</td><td>r ° yV ^ T 0 OMe</td><td> 572</td><td>aW? Oh</td>
<td> 573</td><td>CcAVxl</td><td> 574</td><td></td>
<td> 575</td><td>XcVr?</td><td> 576</td><td>XoHr?</td>
<td> 577</td><td></td><td> 578</td><td>XiWL</td>
<td> 579</td><td>τχ / ηΧ</td><td> 580</td><td><sub>Oh</sub>v<sub>r</sub>9 HO O ^^</td>
209
<td> 581</td><td>λΥύ? ηο<sup>χ</sup>ό<sup>/ χ</sup>^</td><td> 582</td><td>HO</td>
<td> 583</td><td>XCrAr?</td><td> 584</td><td>ΧοΆΧ</td>
<td> 585</td><td>χσΥΥ</td><td> 586</td><td>F</td>
<td> 587</td><td>OR \ Av '\ A / \ zU 4 T j JT</td><td> 588</td><td>3X<sup>J</sup>...... Λ</td>
<td> 589</td><td>^ XJTX.</td><td> 590</td><td>F</td>
<td> 591</td><td></td><td> 592</td><td><sup>0</sup> ϊ ** '*' '! OCjXi</td>
<td> 593</td><td>CoSV</td><td> 594</td><td></td>
<td> 595</td><td><sup>0</sup> T<sup>1</sup>*** '! Χ / ΙχΥ 0 OMe</td><td> 596</td><td>CCrSX</td>
210
<td> 597</td><td></td><td> 598</td><td>οχ ..... Ζ</td>
<td> 599</td><td><sub>:</sub>χ · ...... Λ '</td><td> 600</td><td> ¢(¼¼</td>
<td> 601</td><td></td><td> 602</td><td>cxA9 O OH</td>
<td> 603</td><td>¢ 0¼¼ I</td><td> 604</td><td><sup>0</sup>Oah</td>
<td> 605</td><td>CoAtt</td><td> 606</td><td>OR or CF3</td>
<td> 607</td><td>° Τ *** ''! o ^ ykx-γΛ ^ οΑΖ ° OMe</td><td> 608</td><td>i jO CCaY<sup>0</sup> Oh</td>
<td> 609</td><td>αΑ I</td><td> 610</td><td><sup>0</sup>Aha</td>
<td> 611</td><td><sup>0</sup><sup>F</sup> OΑζ θ F</td><td> 612</td><td> & <sub>/</sub>o ^ Y '<sup>z</sup>%<sub>r</sub>TO<sub>s</sub>/ '\ ^ nAJ <sup>0 CF</sup>’</td>
211
<td> 613</td><td>° Π</td><td> 614</td><td>χΑΑ</td>
<td> 615</td><td></td><td> 616</td><td>ο Ν<sup>,#!</sup>Υ Η</td>
<td> 617</td><td>Η</td><td> 618</td><td>ο ϊ<sup>8</sup>^ CXX ο X Η</td>
<td> 619</td><td>° Ϊ ^ Υΐ ° <sup>οΜβ</sup>Η</td><td> 620</td><td>? η OCj'AiX Η</td>
<td> 621</td><td>coHX η I</td><td> 622</td><td>° Ϊ ^ Ί <XjAít Η</td>
<td> 623</td><td>Ο Ν ^ | \ Ά> ° <sup>F</sup>Η</td><td> 624</td><td><sup>0 ,</sup>¡<sup>l <88r</sup>'' l νΑ> 0 ¿F<sub>3</sub>Η</td>
<td> 625</td><td><sup>0</sup>\ ΆΑ <sup>0 0Μβ</sup>Η</td><td> 626</td><td>1 jO ΖΎγ ^ τγ Ν- ^ · 'OH</td>
<td> 627</td><td><ΥΑ Η |</td><td> 628</td><td><sup>0</sup> ϊ<sup>8</sup>^ CCAit</td>
212
<td> 629</td><td><sup>0</sup>Wh</td><td> 630</td><td></td>
<td> 631</td><td>co'-Λ</td><td> 632</td><td>ccML</td>
<td> 633</td><td>I</td><td> 634</td><td>a? ..... r °</td>
<td> 635</td><td>COÁrí</td><td> 636</td><td>° ϊ<sup><#</sup>^ 1ΐ ° X</td>
<td> 637</td><td><sup>0</sup>\ -XxjiA <sup>Ο θΜβ</sup></td><td> 638</td><td></td>
<td> 639</td><td>ccAA I</td><td> 640</td><td>V ..... r °</td>
<td> 641</td><td><V ..... ή '</td><td> 642</td><td>Q / A? |)<sub>N</sub>A 0 cf<sub>3</sub></td>
<td> 643</td><td>QAY 0 OMe</td><td> 644</td><td>οχΎ</td>
213
<td> 645</td><td></td><td> 646</td><td>QAV? hVn 0 <sup>1</sup></td>
<td> 647</td><td>QAv?<sub>h</sub>Vn or F</td><td> 648</td><td>TO<sub>HN</sub>—N 0 CF<sub>3</sub></td>
<td> 649</td><td>or <sup>ν <</sup>Άι QtSV 0 OMe</td><td> 650</td><td></td>
<td> 651</td><td></td><td> 652</td><td><? ...... or<sup>1</sup></td>
<td> 653</td><td><sup>0</sup> Ή V-0 0 F</td><td> 654</td><td></td>
<td> 655</td><td>or V-0 0 OMe</td><td> 656</td><td>oM Oh</td>
<td> 657</td><td>N I</td><td> 658</td><td><sub>(</sub>/,OR</td>
<td> 659</td><td><sup>0 Ν</sup>Π VS 0 F</td><td> 660</td><td> 0 <sup>N</sup>TO aA2</td>
214
<td> 661</td><td><sup>0</sup> OR VS 0 OMe</td><td> 662</td><td>oAX Oh</td>
<td> 663</td><td>TO?, I</td><td> 664</td><td>OR (jAi</td>
<td> 665</td><td><sup>0</sup>Uai</td><td> 666</td><td><sup>0</sup>L ^ J or cf<sub>3</sub></td>
<td> 667</td><td><sup>0</sup>O OMe</td><td> 668</td><td>cAX</td>
<td> 669</td><td>oAA I</td><td> 670</td><td><sup>0</sup> Τ ^ Ίι C ^ -<sup>n</sup> ° li</td>
<td> 671</td><td>C ^<sub>N</sub> ° <sup>F</sup></td><td> 672</td><td>C ^<sup>N 0 CF</sup>3</td>
<td> 673</td><td><sup>0</sup> n ^ 'Ai t ^ N 0 OMe</td><td> 674</td><td>cAV.</td>
<td> 675</td><td>cA9<sub>F</sub>,</td><td> 676</td><td><sub>or</sub>!.<sub>r</sub>9</td>
215
<td> 677</td><td> ° <sup>Ν</sup>^ ΊΙ CFTT</td><td> 678</td><td>c<sup>l</sup>..... Λ</td>
<td> 679</td><td>or<sup>1</sup>.....>2</td><td> 680</td><td>oY ?.</td>
<td> 681</td><td> 1</td><td> 682</td><td>ό 'ύ9</td>
<td> 683</td><td>0 '....... r?</td><td> 684</td><td>F Ο <sup>Ν <ί!? Χ</sup>]1 x ^ J or cf<sub>3</sub></td>
<td> 685</td><td>or '....... 2</td><td> 686</td><td> 6’......¿</td>
<td> 687</td><td>OM. 1</td><td> 688</td><td><sup>0</sup>ΡχζΧ ^ Χ / ΧΧ ^^ Χ ^^ YZ YY</td>
<td> 689</td><td>Oops</td><td> 690</td><td><sup>0</sup>Ρχ-Χ ^ χΥχ / '^^ X ^ J 0 <sup>CF</sup>3</td>
<td> 691</td><td>O 'ί ^' Ίΐ or OMe</td><td> 692</td><td>'oYY</td>
216
<td> 693</td><td>I</td><td> 694</td><td>ώ<sup>1</sup>...... fi></td>
<td> 695</td><td>σ '.....</td><td> 696</td><td>δ * ...... Λ '</td>
<td> 697</td><td>ο ~ -Λ</td><td> 698</td><td></td>
<td> 699</td><td>όΜ. 1</td><td> 700</td><td>w</td>
<td> 701</td><td> 6¼°</td><td> 702</td><td>CF<sub>3</sub> 0 or cf<sub>3</sub></td>
<td> 703</td><td>0 OMe</td><td> 704</td><td>δ '.....</td>
<td> 705</td><td>δΗζ. 1</td><td> 706</td><td>δ '...... δ'</td>
<td> 707</td><td>ΟΜβ 0 Ν ^^ ΪΙ</td><td> 708</td><td>OMe 0 άΜ</td>
217
<td> 709</td><td></td><td> 710</td><td>δ * .....</td>
<td> 711</td><td>cM .. 1</td><td> 712</td><td>ucCO C ^><sup>n</sup> °</td>
<td> 713</td><td>F ϊ ΓΊ 0</td><td> 714</td><td>υ ^ νΟ ^ ÍX<sup>N 0</sup></td>
<td> 715</td><td>«X? O CX><sup>N</sup> °</td><td> 716</td><td><sub>rt</sub><sup>F</sup>3<sup>C</sup>\ ^ <\ -sA-XPO C ^ n °</td>
<td> 717</td><td>MeO. ϊ ΤΊ or</td><td> 718</td><td>C ^<sup>n</sup> °</td>
<td> 719</td><td>i Π rAV ^ Xi ^<sup>N 0</sup></td><td> 720</td><td></td>
<td> 721</td><td>CCrSr?</td><td> 722</td><td></td>
<td> 723</td><td>or L Jl J 0 OMe 0</td><td> 724</td><td><sup>0</sup></td>
218
<td> 725</td><td> 0</td><td> 726</td><td>ccAV?</td>
<td> 727</td><td>° Π OCo ^ OR</td><td> 728</td><td>CCrSfe</td>
<td> 729</td><td></td><td> 730</td><td> ¢0¼^</td>
<td> 731</td><td>I> o Cur 0</td><td> 732</td><td>IX) ^ cr</td>
<td> 733</td><td> ° <sup>N <í #</sup>^ l</td><td> 734</td><td>or OCjíí</td>
<td> 735</td><td> ° <sup>N <íí?> X</sup>I</td><td> 736</td><td> ° <sup>N <!!!? X</sup>ii L ^ zA ^ JO OMe</td>
<td> 737</td><td><sup>;</sup> 'Λ</td><td> 738</td><td></td>
<td> 739</td><td><sup>0</sup> Π OD ^ i</td><td> 740</td><td>/ -v-vVjQ OR <sup>F</sup></td>
219
<td> 741</td><td><sup>0</sup></td><td> 742</td><td></td>
<td> 743</td><td></td><td> 744</td><td>coYfe</td>
<td> 745</td><td>coY °</td><td> 746</td><td>QjVyO</td>
<td> 747</td><td>coYX</td><td> 748</td><td>CcYrX</td>
<td> 749</td><td>coYX</td><td> 750</td><td></td>
<td> 751</td><td>ccYfe.</td><td> 752</td><td>coSX</td>
<td> 753</td><td><χΛύ9</td><td> 754</td><td>CCjh</td>
<td> 755</td><td><sup>0</sup> τ * Χι or cf<sub>3</sub></td><td> 756</td><td>° O OMe</td>
220
<td> 757</td><td>ο</td><td> 758</td><td>OQir</td>
<td> 759</td><td>χαΟ <Xj °</td><td> 760</td><td><Xjíj</td>
<td> 761</td><td>1 XI OjT<sup>F</sup></td><td> 762</td><td>j<sup>z</sup>¡</td>
<td> 763</td><td>ο Αχ xJ ^ J or cf<sub>3</sub></td><td> 764</td><td>X ^ JL ^ JO OMe</td>
<td> 765</td><td>1 13 cqaí <sup>0</sup></td><td> 766</td><td>IX) CCji <sup>s</sup></td>
<td> 767</td><td>goose<sup>1</sup></td><td> 768</td><td>XoA?</td>
<td> 769</td><td>.CO<sup>1</sup>.....TO'</td><td> 770</td><td>ήΟσΑ F <sup>W</sup></td>
<td> 771</td><td>CCrA?</td><td> 772</td><td>coA?</td>
221
<td> 773</td><td></td><td> 774</td><td></td>
<td> 775</td><td>«Μ Η</td><td> 776</td><td><oW? Η</td>
<td> 777</td><td>z ^ JL-JO CX / j Íí</td><td> 778</td><td>ιο'-ί?</td>
<td> 779</td><td>QAV?</td><td> 780</td><td>Η<sub>Ν</sub>Ν O CI</td>
<td> 781</td><td>αΜ</td><td> 782</td><td>αΜ</td>
<td> 783</td><td></td><td> 784</td><td>yw?</td>
<td> 785</td><td>οΜ</td><td> 786</td><td>.and ..... Λ<sup>1</sup></td>
<td> 787</td><td>V-Λ '</td><td> 788</td><td>and ..... Λ</td>
222
<td> 789</td><td>δ'-Λ<sup>1</sup></td><td> 790</td><td>OM</td>
<td> 791</td><td><sup>0</sup>or Cl</td><td> 792</td><td><sup>0</sup>L, Az ° <sup>ci</sup></td>
<td> 793</td><td>CCrSX</td><td> 794</td><td> ¢0½<sup>0</sup></td>
<td> 795</td><td><sub>c</sub>> and Z</td><td> 796</td><td> ¢0¼°</td>
<td> 797</td><td>CC ^ yjr</td><td> 798</td><td>CCrSA</td>
<td> 799</td><td> ¢0¼°^</td><td> 800</td><td>CoSr<sup>0</sup></td>
<td> 801</td><td><sup>0</sup> Χ<sup>ί</sup>*<sup>Χ</sup>| Γ What ϊ</td><td> 802</td><td>0 <Y<sup>OMe</sup>QjJtyv</td>
<td> 803</td><td>q / ^ a</td><td> 804</td><td>πχΧι. or</td>
223
<td> 805</td><td></td><td> 806</td><td>9007 HN—<sup>J 0</sup></td>
<td> 807</td><td>Q / k?</td><td> 808</td><td>✓Cl</td>
<td> 809</td><td>/And so</td><td> 810</td><td>✓x ✓Br Br — Z \ °</td>
<td> 811</td><td>ζχΧΑθ \ / X <sup>0</sup></td><td> 812</td><td><sup>0</sup> Γ'Λ II / k /<sup>NH</sup>HN-J O</td>
<td> 813</td><td>✓x ^ ✓ »/ UAxXX V-NH O</td><td> 814</td><td>I J3 </ II <sup>H</sup>V-NH 0</td>
<td> 815</td><td>/ Cl i xj Cl ^^^</td><td> 816</td><td>✓UCx / 0 Νχ ^ 0</td>
<td> 817</td><td>θΧγΟ</td><td> 818</td><td></td>
<td> 819</td><td>I jO k ^<sup>N 0</sup></td><td> 820</td><td>ix ^ -NO Br</td>
224
<img file="MX368248B_D0248.tif" />
225
<img file="MX368248B_D0249.tif" />
226
<td> 853</td><td>χ JL / -<sup>Br</sup>VS 0 NC</td><td> 854</td><td>Br. NC? iT ^ S \ -S 0</td>
<td> 855</td><td><sup>Br</sup>X i) 3 Vs or</td><td> 856</td><td>i jy ~ \ -S 0</td>
<td> 857</td><td>Br go $ Br— Vs or</td><td> 858</td><td>π Γν_ U Jl / —Br y — s 0 Br</td>
<td> 859</td><td>9 rv_ X _ JL / —Br - ii<sup>s</sup></td><td> 860</td><td>? rv XX / —Br Br</td>
<td> 861</td><td>1 jS ___ Ζ® * γ ^ Αχ ^ \ χ ^<sub>δ</sub>SW</td><td> 862</td><td>érA °</td>
<td> 863</td><td>I> o Vs or</td><td> 864</td><td>1 x></td>
<td> 865</td><td><sup>0</sup> TO\ II Ls</td><td> 866</td><td>d to rC<sup>Cl</sup>- * cr</td>
227
<td> 867</td><td>1 cxv</td><td> 868</td><td>Cl CL / ci 9 Γλ \ 11 II / —ci c'Yíj <sup>s</sup>And so Cl</td>
<td> 869</td><td>Cl<sup>0</sup>II / s \<sub>s</sub>u 0</td><td> 870</td><td>ϊ rv 1 JL · z ~~ ci Af — ll ^<sup>8 </sup>VS 0</td>
<td> 871</td><td>ci<sup>0</sup>ii> L · /<sup>8 ci</sup>-YY ^ ii \ Wci 0 Cl</td><td> 872</td><td>? ΓΎ X II y — ci And so Cl</td>
<td> 873</td><td>I £) Vo o</td><td> 874</td><td>(/TO</td>
<td> 875</td><td>Vo o</td><td> 876</td><td><yVyOL</td>
<td> 877</td><td>oM</td><td> 878</td><td>✓OMe I £ 1 Z<sup>!5</sup>Y ^<sup>Xs</sup>-<sup>/ X</sup>A ^<sup>txZ</sup>^ OMe Vo 0</td>
<td> 879</td><td>✓OMe xf /</td><td> 880</td><td>VVyQ ~</td>
<td> 881</td><td><sup>0</sup>II what</td><td> 882</td><td>V-0 0</td>
228
<img file="MX368248B_D0250.tif" />
229
<td> 897</td><td>Cl</td><td> 898</td><td></td>
<td> 899</td><td></td><td> 900</td><td>^ OMe CXC OMe</td>
<td> 901</td><td>.OMe</td><td> 902</td><td>.OMe ιϊΓΓ OCjí</td>
<td> 903</td><td></td><td> 904</td><td>c?</td>
<td> 905</td><td>OMe</td><td colspan="2"></td>
The compounds provided herein can be prepared using methods known and understood by those of ordinary skill in the art. For example, synthetic methods such as those described in PCT / US2011 / 048086 and PCT / US2014 / 017794 can be used and both applications are incorporated herein by reference in their entirety.
The skilled artisan will recognize that some structures described herein may be resonance forms or tautomers of compounds that can be represented.
230 entirely by other chemical structures, even when kinetically, the technician recognizes that such structures are only a very small portion of a sample of such or such compounds. Such compounds are clearly contemplated within the scope of this disclosure, although such forms of resonance or tautomers are not represented herein.
The compounds provided herein can encompass various stereochemical forms. The compounds also encompass diastereomers as well as topical isomers, for example, mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods, which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or shown by a structure without specifying stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.
As used in the glove, "alkyl" means a straight or branched chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, secbutyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl. Alkyl groups can be either unsubstituted or substituted with
231 one or more substituents. Alkyl groups can be saturated or unsaturated (eg, containing -C = C- or -C = C- subunits), in one or more positions. Typically, the alkyl groups will comprise 1 to 9 carbon atoms (eg, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).
As used herein, "carbocyclyl" means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls can include multiple fused rings. Carbocyclyls can have any degree of saturation as long as at least one ring in the ring system is not aromatic. Carbocyclyl groups can be either unsubstituted or substituted with one or more substituents. Typically, carbocyclyl groups will comprise 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.
As used herein, "lower alkyl" means a subset of alkyl having 1 to 3 carbon atoms, which is linear or branched. Examples of lower alkyls include methyl, ethyl, n-propyl, and isopropyl. Similarly, radicals using the term "minor" refer to radicals having 1 to about 3 carbons in the alkyl portion of the radical.
As used herein, "aryl" means an aromatic ring system that contains a single ring (eg, phenyl) or multiple fused rings (eg, naphthyl or anthryl) with only carbon atoms present in the ring skeleton . The
232 Aryl groups can be either unsubstituted or substituted with one or more substituents. In some embodiments, aryl is phenyl.
As used herein, "arylalkyl" means an aryl-alkyl- group, in which the aryl and alkyl portions are as previously described. In some embodiments, the arylalkyl groups contain a portion of C ^ alkyl. Exemplary arylalkyl groups include benzyl and 2-phenethyl.
As used herein, the term "heteroaryl" means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9 or 10 ring atoms; having 6, 10 or 14 pi electrons shared in a cyclic arrangement; wherein at least one ring in the system is aromatic and at least one ring in the system contains one or more heteroatoms selected independently from the group consisting of N, O, and S. Heteroaryl groups can be either substituted or unsubstituted with one or more substituents. Examples of heteroaryl include, thienllo, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, benzyloyl, pyridazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl, triazinyl. cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido [2,3-djpyrimidinyl, pyrrolo [2,3bjpiridinyl, quinazolinyl, quinolinyl, thieno [2,3-c] pyridinyl, pyrazolo [3,4-b] pyridinyl, pyrazolo [3,4-c] pyridinyl, pyrazolo [4,3cjpyridine, pyrazolo [4,3-] pyridi n yl, tetrazolyl, chroman, 2.3233 μ ¿μ dihydrobenzo [b] [1.4] dioxin, benzo [d] [1.3] dioxol, 2,3dihydrobenzofuran, 2,3-dihydrobenzo [b] [1,4 ] oxatiine and others.
> As used herein, "heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl portions are as previously described. In some embodiments, heteroarylalkyl groups contain a C- | moiety.<sub>4</sub> I rent. Exemplary heteroarylalkyl groups include pyridylmethyl.
As used herein, "acyl" means a group H-CO- or alkyl-CO-, carbocyclyl-CO-, aryl-CO-, heteroaryl-CO-, or heterocyclylCO-, wherein the alkyl group, carbocyclyl, aryl or heterocyclyl is as described herein. In some embodiments, acyls contain a lower alkyl. Exemplary alkyl acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, t-butylacetyl, butanoyl, and palmitoyl.
As used herein, "alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein. Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.
As used herein, "alkoxy" means an alkylO- group, in which the alkyl group is as described herein. Exemplary alkoxy groups include difluoromethoxy, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, tbutoxy, pentoxy, hexoxy, and heptoxy thereof and also linear or branched positional isomers thereof.
As used herein, the terms "halo", "halide" or
2. 3. 4 "Halogen" are used interchangeably and means a chlorine, bromine, fluoro or iodine atom radical. In some embodiments, a halo is a chlorine, bromine, or fluoro. For example, a halo can be fluoro.
As used herein, "haloalkyl" means a hydrocarbon substituent, which is a linear or branched or cyclic alkyl, alkenyl or alkynyl substituted with one or more chlorine, bromine, fluoro or iodine atoms. In some embodiments, a haloalkyl is a fluoroalkyl, where one or more hydrogen atoms have been replaced by fluoro. In some embodiments, the haloalkyls are from 1 to about 3 carbons in length (eg, 1 to about 2 carbons in length or 1 carbon in length). The term "haloalkylene" means a dirradical variant of haloalkyl and such dirradicals may act as spacers between radicals, other atoms, or between one ring and another functional group.
As used herein, "heterocyclyl" means a non-aromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls can include multiple fused rings. Heterocyclyls can be substituted or unsubstituted with one or more substituents. In some modalities, heterocycles have 5-7 members. In six-membered monocyclic heterocycles, the heteroatom (s) is selected from one to three of O, N or S and where when the heterocycle is five-membered, it may have one or two
235 heteroatoms selected from O, N or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxethanil, tietanyl, 1,4,2-dithiazolyl, dihyd-ropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolenyl id nor it, tetrahydofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, ti azo I idini I or, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imdazolidinyl, thiomorpholinyl and others.
The term "substituted" refers to portions that have substituents that replace a hydrogen at one or more non-hydrogen atoms in the molecule. It will be understood that "substitution" or "substituted with" includes the implicit as long as such substitution is in accordance with the allowed valence of the substituted atom and the substituent and that the substitution results in a stable compound, for example, it does not undergo transformation spontaneously, such such as by rearrangement, cycling, elimination, etc. Substituents may include, for example, - (Cj.g alkyl) optionally substituted with one or more hydroxyl, -NH<sub>2</sub>, -NH (Ci.<sub>3 </sub>alkyl) and -N (Ci_<sub>3</sub> I rent)<sub>2</sub>; - (C ^ g haloalkyl); a halide; a hydroxyl; a carbonyl [such as -C (O) OR and -C (O) R]; a thiocarbonyl [such as -C (S) OR, -C (O) SR and -C (S) RJ; - (C ^ g alkoxy) optionally substituted with one or more halide, hydroxyl, -NH<sub>2</sub>, -NH (Ci_<sub>3</sub> alkium) and -Ν (0ν<sub>3</sub> I rent)<sub>2</sub>; -OPO (OH)<sub>2</sub>; a phosphonate [such as -PO (OH)<sub>2</sub> and PO (OR ')<sub>2</sub>]; -OPO (OR ') R ”; -NRR '; -C (O) NRR '; -C (NR) NR'R ”; C (NR ') R; a cyano; a nitro; an azido; -SH; -MR; -BEAR<sub>2</sub>(OR); a sulfonate [such as -SO<sub>2</sub>(OH) and -SO<sub>2</sub>(OR)]; -SW<sub>2</sub>NR'R ”; And so<sub>2</sub>R; at
236 which each occurrence of R, R 'and R ”are independently selected from H; - (C ^ g alkyl); C<sub>and</sub>.io aryl optionally substituted with from 1-3R '"; 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from N, O and S and optionally with from 1-3 R '"; C<sub>3</sub>.<sub>7</sub> carbocyclyl optionally substituted with from 1-3 R '"; and 3-8 membered heterocyclyl having 1-4 heteroatoms independently selected from N, O and S and optionally substituted with from 1-3 R '"; where each R 'is independently selected from - (C<sub>V</sub>6 alkyl), - (Cve haloalkyl), a halide (eg F), a hydroxyl, -C (O) OR, C (O) R, - (Ci-<sub>6</sub> alkoxy), -NRR ', -C (O) NRR' and a cyano, in which each occurrence of R and R 'is independently selected from H and - (Ci_6 alkyl). In some embodiments, the substituent is selected from - (Ο<sub>ν6</sub> alkyl), - (Ο, .β haloalkyl), a halide (eg F), a hydroxyl, -C (O) OR, -C (O) R, - (Ci-<sub>6</sub> alkoxy), -NRR ', C (O) NRR' and a cyano, in which each occurrence of R and R 'is independently selected from H and - (Ci_<sub>6</sub> I rent).
As used herein, when two groups are indicated as "bonded" or "bonded" to form a "ring", it is understood that a bond is formed between the two groups and may involve the replacement of one hydrogen atom with one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled technician will recognize that such rings can and are easily formed by routine chemical reactions. In some embodiments, such rings have 3-7 members, per
237 example, 5 or 6 members.
"Solvate" refers to the compound formed by the interaction of a solvent and a compound as provided herein or a salt thereof. Suitable solvates are pharmaceutically or dermatologically acceptable solvates including hydrates.
Methods of use v / o treatment
The compounds and compositions provided herein can be used in methods to treat, protect and / or improve the condition and / or aesthetic appearance of the skin. For example, the compounds and compositions provided herein can be used in methods to alter the aesthetic appearance of skin associated with or affected by, or to treat or prevent, skin lines and / or wrinkles caused, for example, due to cellular senescence, environmental damage or dermatoheliosis. The description also relates to methods for stimulating skin cell turnover, increasing cell or tissue regeneration, promoting fibroblast proliferation, and synthesizing elastin, collagen, proteoglycans, and / or new connective tissue, thereby reducing or improving the appearance of wrinkles, restoring elasticity, resilience and / or flexibility to the skin. Such methods include administering to a subject in need thereof an effective amount of a compound according to formula I, ia, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, lie , lid, He, Hf, III, Illa, lllb, lile, Hld, and / or IV, or a dermatologically acceptable salt thereof.
238
The compounds and compositions provided herein can be useful in improving the aesthetic appearance of the skin. Such enhancements may include, but are not limited to, all visible and tactilely perceptible external manifestations as well as any other macro or micro effects due to aging or skin damage. Such manifestations and effects can be induced or caused by intrinsic and / or extrinsic factors, for example, chronological aging, environmental damage, weather, sun exposure (UV), smoking, drugs, alcohol consumption, hourly decompensation, night work, changes in the circadian rhythm, pregnancy, menopause, genetic factors, nutritional factors and / or deficiencies, dehydration, tension, allergies (for example, to plants, animals, medicines and other substances), exposure to industrial and / or household chemicals, interior heating and cooling, various disorders and diseases, such as arteriosclerosis, diabetes, heart disease, liver disease and obesity, thinning of the outer layer of the skin, decreases in the number of cells that they contain pigment, increases in the size of pigment-containing cells, changes in connective tissue and a reduction in the strength and elasticity of the skin.
The aesthetic appearance of the skin can be improved, for example, by improving the appearance of the skin associated with or affected by one or more wrinkles, dry skin, sensitive skin; wrinkles and sagging; acne; Vitiligo (skin condition in which there is a
239 loss of brown (pigment) from areas of the skin); expression lines, lean skin, thinning of the dermis, degradation of collagen fibers, sagging skin, thinned skin and skin exposed to ultraviolet radiation in some modalities, a compound or composition can improve the aesthetic appearance of the skin by reducing the appearance of expression lines on the skin; create a more youthful appearance of the skin; decrease bags and / or rings around the eyes; increase or restore the elasticity, resilience and / or flexibility of the skin; increase the apparent thickness, elasticity, flexibility, radiance, brightness and fatness of the skin; improve the fineness of the skin texture; improve the appearance of wrinkles, expression lines, dry, flaky, aged and / or photodamaged skin; treat or prevent photodamaged skin; reduce the signs of skin aging; reduce the occurrence of hyperplgmentation; treat or prevent hyperpigmentation; treating or preventing the deposition of pigment on the skin (for example, that caused by UV exposure); reduce the appearance of skin discolorations; and whiten, lighten and / or bleach the skin.
The compounds and compositions provided herein can also be used in methods of treating or preventing a skin condition or disorder. For example, a compound or composition can improve the aesthetic appearance of the skin by promoting the proliferation and / or mobility of skin keratinocytes and / or dermis fibroblasts; improve epidermal cell repair activity; increase fibroblast proliferation,
240 keratinocyte proliferation and / or collagen expression; reduce collagenase activity; treating or preventing a wound healing disorder; increase the thickness of the epidermis; and inhibit melanin production.
In one embodiment, the present disclosure provides a method of improving the aesthetic condition and appearance of the skin. The method comprising administering a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, l¡, II, lia, llb, He, lid, He , Hf, III, Illa, Hlb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of the skin associated with or affected by skin aging. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, Η, II, lia, llb, He, Hd, He, llf, III, Illa, Hlb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of the skin associated with or affected by environmental damage to the skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, li, II, lia, llb, He, Hd, He, Hf, III, Illa, Hlb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of skin associated with or affected by one or more of wrinkles, dry skin, sensitive skin, and dermatological symptoms caused by non-homeostatic regulation.
241 effective healthy skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, lie, lid, He, Hf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of the skin associated with or affected by, or treating or preventing, a skin condition / disorder (eg, a skin condition / disorder accompanied by a loss of skin elasticity). The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, Hf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of improving the barrier function and viability of the skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, lie, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of skin associated with or affected by wrinkles, sagging, and / or a loss of skin elasticity. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Η, II, Ha, llb, He, lid, He, Hf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present description provides a
242 method of altering the aesthetic appearance of the skin associated with or affected by, or treating or preventing, acne. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, li, II, lia, llb, He, lid, He, llf, III, Illa, lllb, lile, Hld, and / or IV. In some modalities, acne can be selected from one or more simple acne, comedonic acne, papulopustular acne, papulocomedonic acne, nodulocystic acne, conglobata acne, keloid acne on the neck, recurrent military acne, necrotic acne, neonatal acne, occupational acne , acne rosacea, senile acne, solar acne, or medication related acne.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of the skin associated with or affected by impaired viscoelasticity of the skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, li, II, Ha, llb, He, lid, He, llf, III, Illa, lllb, lile, Hld, and / or IV.
In one embodiment, the description refers to the use of a compound according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, li, II, Ha, llb, He, lid, lie, llf, III, Illa, lllb, lile, Hld, and / or IV to alter the aesthetic appearance of the skin associated with or affected by one or more wrinkles and / or fine lines, lean skin, a lack of elasticity, and / or o of skin tone, thinning of the dermis, degradation of collagen fibers, sagging skin, thinned skin and internal skin breakdown following radiation exposure
243 ultraviolet.
In one embodiment, the present disclosure provides a method of decreasing the appearance of fine lines and / or wrinkles on the skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, II, II, lia, llb, lie, lid, lie, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of creating a more youthful appearance of the skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of decreasing the appearance of bags and / or rings around the eyes. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, Hd, He, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of reducing the appearance of hyperpigmentation. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, II, II, Ha, llb, He, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of increasing or restoring elasticity, resilience, and / or
244 skin flexibility. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, He, lid, lie, llf, III, Illa, lllb, lile, IIId, and / or IV.
In one embodiment, the present disclosure provides a method of improving or increasing one or more of the thickness, elasticity, flexibility, radiance, shine, and plumpness of the skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, Hd, He, llf, III, Illa, lllb, lile, Hld, and / or IV.
In one embodiment, the present disclosure provides a method of improving the fineness of skin texture. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, Hb, He, Hd, He, llf, III, Illa, lllb, lile, Hld, and / or IV.
In one embodiment, the present disclosure provides a method of improving the appearance of wrinkled, fine, dry, flaky, aged, or photodamaged skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, Hb, He, Hd, lie, Hf, III, Illa, lllb, Hlc, Hld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of skin associated with or affected by skin discolorations. The method comprises administering to a subject an effective amount of a compound of
245 according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, lie, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of bleaching, lightening and / or bleaching of the skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of skin associated with or affected by, or treating or preventing, hyperpigmentation. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, H, II, Ha, llb, He, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of altering the aesthetic appearance of skin associated with or affected by, or treating or preventing, photodamaged skin. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, lio, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of treating or preventing pigment deposition on the skin caused by UV exposure. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Η, II, Ha, llb, lie, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV.
246
In one embodiment, the present disclosure provides a method of treating or preventing vitiligo (a skin condition in which there is a loss of brown (pigment) from areas of the skin). The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, II, II, lia, llb, He, lid, lie, llf, III, Illa, lllb, Ule, llld, and / or IV.
In one embodiment, the present disclosure provides a method of treating or preventing a wound healing disorder in a mammal. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, II, II, lia, llb, He, lid, lie, llf, III, Illa, lllb, lile, llld, and / or IV. For example, a compound or composition provided herein can be used as a medicine to prevent and / or treat an ulcer in a mammal.
In one embodiment, the present disclosure provides a method of promoting skin keratinocyte proliferation and / or mobility and / or dermis fibroblasts (eg, to increase skin regeneration). The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, II, II, lia, llb, lie, lid, lie, llf, III, Illa, lllb, Ule, llld, and / or IV.
In one embodiment, the present disclosure provides a method of enhancing epidermal cell repair activity, eg, in a human. The method comprises administering to a subject an effective amount of a compound of
247 according to formula I, la, Ib, le, Id, le, If, lg, Ih, li, II, Ha, llb, He, Hd, He, Hf, III, Illa, Hlb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of increasing fibroblast proliferation, keratinocyte proliferation, and / or collagen expression. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, Η, II, lia, llb, He, Hd, He, Hf, III, Illa, Hlb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of reducing collagenase activity. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, li, II, Ha, llb, He, Hd, lie, Hf, III, Illa, Hlb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of increasing or improving the thickness of the epidermis. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, li, II, Ha, llb, He, Hd, He, Hf, III, Illa, Hlb, lile, llld, and / or IV.
In one embodiment, the present disclosure provides a method of inhibiting melanin production. The method comprises administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, lg, Ih, li, II, lia, llb, He, lid, He, Hf, III, Illa, Hlb, lile, llld, and / or IV.
The various effects on the skin (eg skin conditions / disorders) described above can be
248 caused by or associated with various internal and external influences.
In some modalities, the skin condition / disorder is caused by or associated with aging.
In some modalities, the skin condition / disorder is caused by or associated with environmental factors.
In some modalities, the skin condition / disorder is caused by or associated with genetic factors.
In some modalities, the skin condition / disorder is caused by or associated with nutritional factors and / or deficiencies.
In some embodiments, the skin condition / disorder is caused by or associated with blood vessel diseases such as arteriosclerosis.
In some modalities, the skin condition / disorder is caused by or associated with dehydration.
In some modalities, the skin condition / disorder is caused by or associated with diabetes.
In some modalities, the skin condition / disorder is caused by or associated with heart disease.
In some modalities, the skin condition / disorder is caused by or associated with liver disease.
In some modalities, the skin condition / disorder is caused by or associated with obesity.
In some modalities, the skin condition / disorder is caused by or associated with tension.
249
In some embodiments, the skin condition / disorder is caused by or associated with allergies to plants and other substances.
In some modalities, the skin condition / disorder is caused by or associated with the weather.
In some modalities, the skin condition / disorder is caused by or associated with clothing.
In some modalities, the skin condition / disorder is caused by or associated with exposure to household and industrial chemicals.
In some embodiments, the skin condition / disorder is caused by or associated with interior heating / cooling.
In some modalities, the skin condition / disorder is caused by or associated with sunlight (UV exposure).
In some embodiments, the skin condition / disorder is caused by or associated with a medication (eg, adverse reaction).
In some modalities, the skin condition / disorder related to thinning of the outer layer of the skin (epidermis).
In some modalities, the skin condition / disorder is related to a decrease in the number of pigment-containing cells (melanocytes).
In some modalities, the skin condition / disorder is related to an increase in the size of pigment-containing cells (melanocytes).
250
In some modalities, the skin condition / disorder is related to enlarged pigmented spots (called age spots, liver spots, or lentigines).
In some modalities, the skin condition / disorder is related to a change in the connective tissue.
In some modalities, the skin condition / disorder is related to a reduction in the strength and elasticity of the skin (elastosis).
In some modalities, the skin condition / disorder is related to the blood vessels in the dermis that become more fragile.
In some embodiments, the skin condition / disorder is related to a reduction in sebum production (eg, a reduction in sebum production from the sebaceous glands).
In some modalities, the skin condition / disorder is related to a thinning of the subcutaneous fat layer.
In some modalities, the skin condition / disorder is related to a reduction in sweat production by the sweat glands.
In some embodiments, the skin condition / disorder is related to growth such as skin marks and / or warts.
The term "subject" as used herein, means a human or a non-human mammal, eg, a dog, a cat,
251 a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, for example a chicken, as well as any other vertebrate or invertebrate. In some modalities, a subject is a human.
The term "mammal" is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mouse, rat, cow, sheep, pig, goat and non-human primate, but also includes many other species.
The phrase "effective amount" is used to mean a "therapeutically effective amount" or "cosmetically effective amount" that depends on the intended use of the compound or composition to which it refers. An effective amount as used herein means an amount of a compound or composition sufficient to achieve a desirable result in response to one or more skin conditions / disorders, but low enough to avoid serious side effects. The effective amount of the compound or composition will vary with the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated / prevented, the duration of treatment, the nature of other treatments, the compound or product / specific composition employed, the particular carrier used and similar factors. "Effective amount is also intended to include one or more compounds of formulas I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, Hb, He, lid, lie, llf, III, Illa , IHb, lile, IIId, and / or IV, or a dermatologically acceptable salt thereof, in combination with one or more agents
252 different having a purported cosmetic or dermopharmaceutical effect. The compound combination can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 2755, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered Manage only as a simple agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds.
"Treating", "treating" or "treating", as used herein means reversing, alleviating (eg, reducing or eliminating) one or more symptoms of, inhibiting the progress of and / or delaying, either partially or completely , a skin disease or disorder including, for example, the skin conditions / disorders described herein.
The term "skin condition / disorder" includes, but is not limited to, one or more of skin aging, skin exposed to excessive sunlight (eg photoaged or photodamaged skin), age spots, unwanted wrinkles , expression lines, clefts, lumps, large pores (for example, associated with attached structures, such as sweat gland ducts, sebaceous glands, or hair follicles), skin roughness or roughness, loss of skin elasticity (eg, loss of activation of functional skin elastin) sagging (including swelling in the eye and jaw area), loss of firmness
253 of the skin, loss of tightness of the skin, loss of skin recoil from deformation, discoloration (including (black) circles around the eyes), spotting, sallow color, hyperpigmentation, such as age spots, freckles, blemishes, stressed skin, rough skin, dry skin, celulltis, irritated skin, scars, sagging lips, acne, keratosis, abnormal differentiation, hyperkeratinization, elastosis, decomposition of collagen and other histological changes in the stratum corneum, dermis, epidermis, the vascular system of the skin (eg, telangiectasia or spider vessels) and underlying tissues, especially those close to the skin.
The term "wound" as used herein, broadly refers to injuries to the skin and clauqiera-initiated subcutaneous tissue in a variety of ways (eg, prolonged bed rest pressure sores, trauma-induced wounds, wounds received during or following a surgical procedure and the like) and with diverse characteristics. Examples include, but are not limited to, bruises, scrapes, burns, sunburn, incision wounds, excision wounds, surgical wounds, necrotizing fasciitis, ulcers, venous stasis ulcers, diabetic ulcers, bedsores, aphthous ulcers, pressure ulcers, scars, alopecia areata, dermatitis, allergic contact dermatitis, atopic dermatitis, berloque dermatitis, diaper dermatitis, dyshidrotic dermatitis, psoriasis, eczema, erythema, warts, anal warts, angioma, cherry angioma, athlete's foot, atypical moles, basal cell carcinoma, purpura of
254
Bateman, bullous pemphigoid, candida, chondrodermatitis helicis, Clark's nevus, cold sores, condylomata, cysts, Darier's disease, dermatofibroma, discoid lupus erythematosus, nummular eczema, atopic eczema, dyshidrotic eczema, hand eczema, erythema nodosum Fordyce, folliculitis keloidalis nuchae, folliculitis, granuloma annulare, Grover's disease, rash, herpes simplex, herpes zoster (herpes), hidradenitis suppurativa, urticaria, hyperhidrosis, ichthyosis, impetigo, keratosis pilaris, keloids, keratoacanthoma, lichen planus, lichen planus like keratosis, lichen simplex chronic, lichen sclerosus, papulosis lymphomatoid, lupus skin, lyme disease, lichen striatus, myxoid cysts, mycosis fungoides, molluscum contagiosum, moles, nail fungus, necrobiosis lipoidica diabeticorun, nummular dermatitis, onychocytosis, onychomycosis, pityriasis lichenoides, pityriasis rosea, pityriasis rubra pilaris, plantar warts, poison ivy, poison oak, pompholyx, pseudofolliculitis barbae, anal itching and pitirasis alba.
Biological activity evaluation
The biological activity of the compounds and compositions described herein can be tested using any suitable in vivo or in vitro test. For example, the compounds and compositions can be evaluated using in vitro or in vivo tests, subjective patient evaluations, and mechanical tests used to measure and evaluate physical parameters of the skin. Various
255 Factors can be used to determine the effectiveness of a compound or composition provided herein. Such factors include changes in the depth of wrinkles, changes in the frequency of wrinkles, changes in the frequency of acne, elasticity and firmness of the skin, and customer satisfaction and compliance.
The mechanical properties of skin change not only with aging but also upon exposure to various environmental factors such as UV irradiation and air pollution. This exposure can lead to decreases in collagen synthesis as well as damage due to processes such as glycation or oxidative stress. Fibroblasts are major cell types present in the dermis that are capable of producing collagen fibers - the main component of the extracellular matrix (ECM) of dermal connective tissue. Fibroblasts are also thought to be connected to the collagen network and provide dermal support for the epidermis and give rise to elastic properties of a tissue.
A change in the elastic properties of cells can be determined using atomic force microscopy to calculate the relative Young's modulus (a parameter that describes the elastic properties of cells). This method is described in, for example, International Journal of Peptide Research and Therapeutics (2014), 20 (1), 77-85. Another exemplary method uses infrared thermography in combination with a mechanical deformation system to measure skin elasticity and firmness (see, for example, US Patent Application No. 2013/0079643). The elasticity of the
256 Skin can also be measured using Cutometer® (Courage + Khazaka electronic GmbH, Germany) by lightly pressing a test probe onto the skin resulting in a temporary vacuum. The skin is lifted, stretched and then released. These deflections can be optically recorded and evaluated as demonstrated in US patent application no. 2005/0054578 (see, for example, example 13). Methods for determining skin moisturizing effects are shown in US Patent Application No. 2013/0171274 (see, for example, example 5).
The photoaging effects of the skin can be determined by evaluating the ultraviolet (UV) light-induced photodimerization of thymine, the expression of proinflammatory cytosine (IL) 1-a interleukin, the scavenging properties of skin free radicals by quantifying the Oxidative stress biomarker malondialdehyde (MDA) as well as anti-glycation activity (glycation reduces the ability of collagen fiber to regenerate, leading to skin wrinkling). Examples of related tests are shown in, for example, Clinical, cosmetic and investigational dermatology (2013), 7, 1-9. Expression of proinflammatory matrix metalloproteinases (MMPs), production of reactive oxygen species (ROS), and NF-κΒ signaling (all indicators of UVB-induced photoaging) can be determined by methods described in, for example, PLoS One (2013), 8 (9), e73877. Other non-limiting examples of such trials can be found in the American Journal of Chinase Medicine
257 (2010), Journal of Dermatological Science, Supplement (2006), 2 (1), S65-S74, WO 2008/156345 and US Patent No. 8,741,357.
Wrinkle prevention can be assessed using hairless mice exposed to chronic sun-simulating ultraviolet (UV) irradiation as demonstrated in European journal of pharmacology (2001), 411 (1-2), 169-174, International journal of dermatology (2006 ), 45 (4), 460-8, BMB reports (2013), 46 (9), 465-70, US Patent No. 8,088,369 (eg, Examples 1 and 2) and WO 2008/001921.
Mechanical and optical methods can also be used to measure wrinkles. Non-limiting examples of such instruments and methods include high-resolution PRIMOS (GFMesstechnik, Germany), which can quantify periorbital wrinkles (crow's feet), perioral wrinkles (around the mouth and lips), nasiolabial wrinkles (cheeks, forehead wrinkles and / or frown wrinkles) and glabella wrinkles (between the eyebrows) by 3D optical measurement of the skin; and Antera 3D® (Miravex Limited, Ireland) that allows a view of the skin in 2 and 3 dimensions as well as multi-spectrum analysis of epidermis and dermis. The scan can provide information on how rough the skin is, how deep the wrinkles are, and the degree of sun damage and redness. FOITS (Fast Optical in vivo Topometry of Human Skin) (Schrader Institute, Germany) is a non-contact method of 3D wrinkle analysis. This 3D wrinkle method methodology allows the
258 quantification of skin surface topography and excludes skin color tone and surface reflection artifacts. The Breuckmann in-vivo-3D scanner (AICON, Michigan, USA) uses an image metrology principle based on structured light projection and a combination of phase shift and gray code technology. The Visioscan® (Courage + Khazaka electronic GmbH, Germany) uses a high resolution UVA light camcorder to study the skin surface directly. The images show the structure of the skin and the level of dry skin. The computer program analyzes the distribution of gray levels and allows the calculation of four clinical parameters to quantitatively and qualitatively describe the skin surface as an index: skin smoothness, skin roughness, scaling and wrinkles.
Other non-limiting examples of devices include the Corneometer®, which can be used to determine the level of hydration of the skin surface (stratum corneum); the Mexameter®. which can be used to measure the two components mainly responsible for skin color; melanin and hemoglobin (erythema) by reflectance; Tewameter®, which assesses the skin's water barrier function; CutiScan®, which measures the mechanical properties of the skin (viscoelasticity and anisotropy); and Visiopor®, which uses a specific UV light to visualize fluorescent acne lesions.
259
Administration _____ and _____ cosmetic _____ and dermopharmaceutical compositions
Also provided herein are cosmetic or dermopharmaceutical compositions which undertake: (a) an effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tauromer, or dermatologically acceptable salt thereof; and (b) a dermatologically acceptable carrier.
The compounds provided herein may also be useful, in combination (administered together) with other known ingredients.
Based on the intended use, the compositions may be products for the care, treatment, cleansers and / or protectors for facial or body skin; anti-wrinkle or anti-aging compositions; skin firming compositions; skin lightening compositions; compositions for irritated skin; sunscreen compositions, artificial tanning (self-tanning) compositions, or after-sun care compositions; scalp care compositions; shaving preparation compositions; depilatory compositions; or makeup products for the skin of the face or body.
The cosmetic or dermopharmaceutical compositions of the present description can be prepared and used in the form of an aerosol, cream, emulsion, solid, liquid, dispersion, foam,
260 oil, gel, lotion, mousse, ointment, powder, patch, ointment, solution, pump spray, stick, washcloth, soap, or other forms commonly employed in the technique of topical administration and / or cosmetic and skin care formulation. The compositions can be in an emulsion form. In addition, the compounds provided herein used in the compositions provided herein can be used in cosmetic color compositions, such as foundation, blush, eye shadow, mascara, concealer, eyeliner, lip color, lip color. nails and so on. Other cosmetic compositions may include perfumes, lipsticks, fingernail and toenail varnishes, eye and facial makeup, wipes, deodorants, hand sanitizers, baby products, bath oils, bubble baths and butters. The cosmetic and dermopharmaceutical compositions of the present disclosure may be formulations for subcutaneous injection.
If desired, the formulations of the disclosure can be incorporated into a gel formulation (eg, US Patent Nos. 4,474,752 and 6,911,211).
The compounds provided herein are intended for cosmetic and / or dermopharmaceutical use and can be administered as crystalline or amorphous products. Cosmetic or dermopharmaceutical compositions as provided herein may include solids, semisolids, liquids, solutions, colloids, liposomes, emulsions, suspensions, complexes, coacervates, and
261 aerosol sprays. Dosage forms, such as, for example, powders, liquids, suspensions, suppositories, aerosols, controlled release, or the like, are provided herein. Dosage forms can be obtained, for example, as solid plugs, powders, lipid nanoparticles or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, formation of complex, freeze drying, spray drying or evaporative drying. Microwave or radio frequency drying can also be used.
Liquid cosmetic or dermopharmaceutical compositions can be prepared, for example, by dissolving, dispersing, etc. A compound as provided herein and optional cosmeceutical / cosmetic / dermatological auxiliaries in a carrier (eg, water, saline, aqueous dextrose, glycerol, glycols, ethanol, or the like) to form a solution, colloid, liposome, emulsion, complexes (including inclusion complexes), coacervate or suspension. If desired, the cosmetic and / or dermatological composition may also contain auxiliary substances, such as wetting agents, emulsifying agents, cosolvents, solubilizing agents, pH buffering agents, and the like (eg, sodium acetate, sodium citrate, cyclodextrins, and derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, hydroxyethylpiperazine, and the like).
In some embodiments, the cosmetic composition or
262 Dermopharmaceutical comprises a combination of a compound of formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, lie, lid, lie, Hf, III, Illa, lllb, lile , llld, and / or IV and one or more additional ingredients, carriers, excipients, or diluents including, but not limited to, absorbents, anti-irritants, antibacterials, anti-acne agents, antioxidants, coloring agents / pigments, emollients (humectants), emulsifiers, agents film formers / carriers, fragrances, leave-in exfoliants, prescription drugs, preservatives, cleansing agents, silicones, skin-identical / skin-repairing agents, gliding agents, sunscreen actives, surfactant / detergent cleansing agents, penetration enhancers, and thickeners.
Ingredient lists, which are well known in the art, are described, for example, in "Cosmetics: Science and Technology," edited by MS Balsam and E. Sagarin, 2nd edition, 1972, Wiley Pub. Co .; "The Chemistry and Manufacture of Cosmetics" by MG DeNavasse; and "Harry's Cosmeticology," JB Wilkinson et aL, 7<sup>to</sup> edition, 1982, Chem. Pub. Co .; the descriptions of which are incorporated herein by reference in their entirety.
In some embodiments, diluents, carriers, and excipients may include, but are not limited to, polyethylene glycols (such as, PEG200, PEG300, PEG400, PEG540, PEG600, PEG1450, or mixtures thereof) and coconut oils (such as propylene glycol dicaprate , coco-caprylate / caprate, propylene glycol dicarpilate / dicaprate, caprylic / capric triglyceride, triglyceride
263 caprylic / capric / lauric, caprylic / capric / linoleic triglyceride, tricaprine, tricap ri I na, glyceryl trioleate, neopentyl glycol dicaprylate / dicaprate, caprylic triglyceride / capric / palmitic / stearic or mixtures thereof).
Absorbents are substances which are added to cosmetic / dermatological products to capture dissolved or finely dispersed substances soluble in oil and water. Cosmetic / dermatological chemical absorbents can also be used as cosmetic / dermatological thickeners in a wide variety of formulations including face creams, lipsticks, shampoos, and calamine lotions.
In some embodiments, absorbents may include, but are not limited to, alcohol (ethyl alcohol, methanol, isopril alcohol, SD alcohol [specially denatured alcohol], and benzyl alcohol), alumina (aluminum oxide, aluminum chlorohydrate, aluminum hydroxide , magnesium aluminum silicate, aluminum silicate, aluminum starch octenylsuccinate, aluminum sulfate, ammonium chloride, bentonite, bismuth oxychloride, boron nitride, calcium carbonate, carnauba wax, coal, china clay, clay, Copernicia cerifera wax, corn starch, fuller's earth, hydrolyzed corn starch, iron powder, kaolin, lithium magnesium sodium silicate, magnesium, magnesium carbonate, magnesium hydroxide, Montmorillonite, Nylon-12, Rice Starch, Silica, Silicate, Silk Powder, Silt, Sodium Carbonate, Sodium Polyacrylates, and Zeolite.
264
Anti-irritants are substances that are added to cosmetic / dermatological products to reduce certain signs of inflammation, such as swelling, tenderness, pain, itching, or redness. Many ingredients perform the function of anti-irritants or anti-inflammatories. Many antioxidants also work as anti-irritants because one of the skin's responses to free radical damage is irritation and inflammation. These ingredients help skin deal with sun exposure, pollution, skin care routines (topical disinfectants, sunscreens, and exfoliants can be skin irritants) and seasonal environmental extremes [Exogenous Dermatology (2004), 3 (4 ), 154-160; and Toxicology Letters (2003), 146 (1), 65-73],
In some modalities, anti-irritants may include, but are not limited to, Acacia Senegal, acetylsalicylic acid, Achillea millefolium, adenosine, adenosine triphosphate, Aesculus hippocastanum, allantoin, Aloe barbadensis, aloe barbadensis leaf juice extract, aloe extract, aloe juice, aloe vera, alpha bisabolol, Althaea rosea, Althea officinalis, aminobutyric acid, andlroba oil, Anthemis nobilis flower extract, Arachis hypogaea extract, Arctim lappa, Adenosine triphosphate, Avena sativa, Azulene, Barberry, β-hydroxy acids (BHA) (such as salicylic acid, β hydroxybutyric acid, tropic acid and tretocanic acid), β-glucan, β-sitosterol, bisabolol, black tea, Boerhavia diffusa root extract, borage seed extract, borage seed oil, Borago officinalis extract, Borago officinalis seed oil, root of
265 Burdock, butcher's broom extract, calcium gluconate, marigold extract, Calluna vulgaris flower extract, canyon oil, Centaurea cyanus, chitosan, chrysanthemum extract, coenzyme Q<sub>10 </sub>(ubiquinone), colloidal oats, comfrey extract, echinacea, cornflower, cornus extract, bilberry seed extract, curcumin, decarboxycarnosine HCL, dipotassium glycyrrhizinate, dogwood, epidermal growth factor (EGF), gallate of epigallocatechin, extract of Epilobium angustifolium, erotioneine, evening primrose oil, extract of Evodia rutaecarpa, extract of feverfew, Filipéndula rubra, extract of fireweed, Fu ling, genistein, Gentiana lútea (Gentian) root extract, ginger extract, ginger oil, glabridine, glycyrrhetic acid, Glycyrrhiza glabra, Glycyrrhiza uralensis root extract, green tea, gromwell, honey, honey extract, honeysuckle flower extract, Horse chestnut extract, hydrocortisone, llex paraguariensis, Ju hua, jujube fruit extract, juniper berry, Juniperus communis, kava-kava extract, kawa extract, Kigelia africana extract, L-ascorbic acid, Laminaria ochroleuca extract, Lamium album flower extract, Lappa extract, Leontipodium alpinum extract, Licorice extract, Licorice root, Linoleic acid, Lithospermum erythrorhizon, Lonicera caprifolium flower extract, Lonicera japanica, Lonicera flower extract japan, lotus seed extract, oil or seed extract of Luffa cylindrica, mallow, extract of Malva sylvestris, marigold, marshmallow, mate extract, flower extract of
266 feverfew, meadowsweet extract, Morinda citrifolia, nettle extract, niacinamide, noni juice, oat β-glucan, oat bran extract, oatmeal, Oenothera biennis oil, oleanolic acid, oleanolic acid, seed opium poppy, P. elisabethae, pansy extract, Perilla ocymoides, petrolatum, fruit extract Phyllanthus emblica, extract of Picea excelsa, extract of Poria cocos, extract of Portulaca oleraceam, propolis, Prunella vulgaris, Pseudoptergorgia elisabethae, red clover, resveratrol, Ruscusiculeus, salicylic acid, Salix alba extract, Salix nigra (willow) bark extract, Sapindus mukurossi husk extract, saponin, saw palmetto extract, Scutellaria baicalensis extract, sea whip extract, self-healing, Serenoa serrulata extract, silver-tipped white tea leaf extract, cap extract, slippery elm bark, soap extract, sodium ascorbyl phosphate, Sonojell, extract of soybean, soy isoflavones, soybean oil, soy protein, Spiraea ulmaria, stearyl glycyrrhenate, Symphytum officinale extract, tamanu oil, Tanacetum parthenium, Tazorac, Terminalia sericea, Terminalia sericea extract, tetrahydrobisdemethoxycurcumin, tetrahydrodemethoxycurcumin, tetrahydrodemethoxydiferuloylmethane, tetrahydrodiferuloylmethane, tetra h id ro-methoxycurcumin, Trifolium pretense, turmeric, extract of bark of Ulmus fulva, extract of Ulva lactuca, extract of Ulva lactuca, Vanilla planifolia, Viola extract
267 tricolor, white nettle, white willow, wild ginger, willow bark, willow herb, witch hazel, Xi xin, yarrow extract, yerba mate extract, cassava extract, zinc, zinc oxide, Zingiber officinale roscoe, Zingiber zerumbet , Zingiberaceae and Zizyphus jujuba fruit extract.
Antibacterial ingredients are substances which are added to cosmetic / dermatological products to destroy or inhibit the growth of bacteria; in the case of skin care products, in particular the bacteria that cause blemishes.
Anti-acne ingredients are substances that are added to cosmetic / dermatological products to help reduce and control acne and acne-related problems, such as sebum production. Some agents work by increasing the change of skin cells by promoting the extrusion of the capped material into the follicle.
In some embodiments, antibacterial and / or anti-acne agents may include, but are not limited to, Alchemilla vulgaris, Aleurites moluccana seed oil, aluminum sulfate, amygdalic acid, anise, Anthemis nobilis flower extract, Arctostaphylos uva leaf ursi, Azadiractha indica, bearberry, benzalkonium chloride, benzoin extract, benzoyl peroxide, Berberis aristata, β-hydroxy acids (BHA) (such as salicylic acid, β-hydrobutyric acid, tropic acid and tretocanic acid), borate, boric acid, calendula extract, Centella asiatica, chamomile, extract
268 Chamomilla recutita flower, chaparral extract, chaulmoogra oil, chitosan, chlorhexidine, chloroxylenol, Cinnamomum, cinnamon, colloidal silver, Commiphora myrrha extract, Cymbopogon citrates, Epilobium angustifolium extract, eucalyptus oil, eucalyptus oil, far , farnesyl acetate, Gentiana lute (gentian) root extract, geranium oil, Geranium pretense, glucose oxidase, goldenseal, gotu kola, hoelen, hops, Humulus lupulus extract, Hydnocaprus anthelmintica, Hydrastis canandenis, hydroctyl extract, hyssop, lllicium vernum, jujube fruit extract, lactoperoxidase, lady's mantle extract, Larrea divaricata, Larrea tridentata, lemon, lemon grass extract, Lentinus edodes extract, Leptospermum scoparium oil, magnesium, magnesium gluconate, magnesium hydroxide, manuka oil, marigold, feverfew oil, Melaleuca alternifolia, Melia azadirachta, Mentha piperita, menthol, chin, Mitracarpe scaber extract, myrrh extract, myrtle extract, Myrtus communis extract, Nardostachys jatamansi, neem oil or extract, oak root extract, oregano, Origanum vulgare flower extract, P. elisabethae, palmarosa oil, Pelargonium graveolens oil, peppermint, pine oil, pineapple extract, Pinus sylvestris extract, propolis, Pseudoptergorgia elisabethae, pyridoxine hydrochloride (HCL), quercus, Quercus infectora extract, quillaja extract , Ranunculus ficaria extract, raspberry seed extract, raspberry seed oil, red raspberry extract, resorcinol, Rubus
269 idaeus, Saponaria officinalis extract, silver, soap, ascorbyl sodium phosphate, sodium silicate, tuberose, star anise, sulfur, Taraktogens kurzii, tea tree oil, Terminalia serícea extract, tretinoin, triclosan, Uva ursi extract, vetiver oil or extract, white oak bark extract, willow herb, zinc phenolsulfonate, Zizyphus jujuba fruit extract.
Antioxidant ingredients are substances which are added to cosmetic / dermatological products to reduce free radical damage and environmental stress on the skin [Clinics in Dermatology (2008), 26 (6), 614-626; Skin Therapy Letter (2008), 13 (7), 5-9; and Journal of Drugs in Dermatology (2008), 7 (2), S7-S12J. Antioxidants are useful in two ways: They prevent the degradation of natural ingredients (proteins, sugars, lipids) in the cosmetic product. Antioxidants also protect skin cells from being damaged and slowing down the aging process. Antioxidants have also been shown to boost skin radiance, minimize age spots, sun spots, and expression lines.
In some embodiments, antioxidants may include, but are not limited to, Acai, Acetyl Carnitine HCL, Agar, Agrimonia Eupatoria Leaf Extract, Ahnfeltia concinna Extract, Ahnfeltia Extract, Alanine, Alaria esculenta, Alfalfa Extract, Algae , algae extract, algin, α-lipoic acid, a-gocopherol, Anacystis nidulans extract, Angelica archangelica root oil, Angelica root extract polymorpha sinensis, anise,
270
Anthemis nobilis, anthocyanin, Arctium lappa, Arctostaphylos uva ursi leaf, argan oil, Argania spinosa, arginine, artemia extract, Ascophyllum nodosum, ascorbyl glucosamine, ascorbyl glucoside, ascorbyl methylsilane pectinate, ascorbyl methylsilane pectinate Asparagopsis armata extract, aspartic acid, astaxanthin, astaxanthin extract, Astragalus mamebranaceus, Astragalus sinicus, avocado oil, Azulene, banana extract, basil leaf oil, beet root extract, Bertholletia excelsa extract, β-hydroxy acids (BHA) (such as salicylic acid, β-hydroxybutyric acid, tropic acid, and tretocanic acid), β-vulgaris root extract, β -carotene, β-glucan, Betula alba, butylated hydroxytoluene, bioflavonoids, birch bark extract, birch leaf extract, black elderberry, black carob extract, black raspberry, black tea, blackberry, fucus extract, Boerhavia diffusa root extract, borage seed oil, Borago officinalis extract, Borago officinalis seed oil, bilberry, Brassica campestris, Brazil nut extract, Buddleja davidii extract, burdock root, caffeic acid, caffeine , Calcium Ascorbate, Calendula Extract, Calendula officinalis Flower Extract, Camellia Japanica, Camellia Oleifera, Camellia Sinensis, Carnitine, Carnosic Acid, Carnosine, Carnosol Acid, Catalase, Caulerpa taxifolia extract, chamomile, Chamomilla recutita flower extract, chaparral extract, chlorella, cholecalciferol, Chondrus crispus, Cichorium intybus, Cinnamomum, cinnamon, Citrus unshiu,
271
Citrus unshiu, cocoa extract, Codium tomentosum extract, coenzyme Q<sub>10</sub>, Coffea arabica (coffee) seed oil, Coffea arabica extract, collagen amino acids, copper gluconate, copper peptides, Corallina officinallis extract, Cornus extract, coumarin, bilberry seed extract, bilberry seed oil , cucumber extract, fruit extract of Cucumis melon (melon), extract of Cucumis sativus, cucurbit pepo seed extract, Cucurbitae peponis, curcumin, Cymbopogon Martini, Da-tocopherol, Daucus carota, siringilidenmalonato diethylhexyl rutinil disodium disulfate, dogwood, Angelica polymorpha sinensis, sweet, durian, extract Durvillaea antarctica, Elaeis guineensis, elderberry, ellagic acid, extracts of Enteromorpha compressa, epigallocatechin gallate, ergocalciferol, ergothioneine, Eriobotrya jaonica, escin, ethyl vanillin , Euterpe oleraca, fae, Fagus sylvatica extract, farnesol, farnesyl acetate, dill seed extract, Ferrule foetida, ferulic acid, Filipendula glaberrima, flavonoid, flax, flaxseed oil, Foeniculum vulgare extract, folic acid, Fu ling, Fucus vesiculosus extract, galactoarabinan, γ-linolenic acid (GLA), Ganoderma lucidum extract, Gardenia florida extract, Gellidiela extract oil, genistein, geranium extract, Geranium pretense, Ginkgo biloba leaf extract, glutathione, glycine soybean oil, grape seed extract, grape seed oil, green tea, gromwell, Haematococcus pluvialis extract, Hamamelis virgininana, hamamelitanina, Haslea extract
272 ostrearia, hawthorn extract, hesperidin, hesperidin methyl chalcone, hexylresorcinol, hibiscus, Himanthalia elongate extract, Hippophae rhamnoides, histidine, honey, honey extract, hops, horsetail extract, Huang qi, extract of Humulus lupulus, hydrogenated olive oil, hydrogenated palm glycerides, hydrolyzed silk, hydroquinone, Hypericum extract, idebenone, llex paraguariensis, lllicium vernum, Irish moss extract, Isoflavone, Isoleucine, Jojoba Butter, Seaweed Extract, Kigelia Africana Extract, Kiwi Fruit Extract, Kojic Acid, Kojic Dipalmitate, Kudzu Root, Lascorbic Acid, L-Carnitine, L-Cysteine, Milk Thistle Extract, Laminaria digitata extract, Laminaria longicruris, Laminaria saccharine, Lamium album flower extract, lappa extract, Larrea divarica extract, Larrea tridentate, Laurus nobilis, lemon juice, Leontopodium alpinum extract, linden blossom extract, linoleic acid, lithospermum erythrorhizon, loquat extract, lotus seed extract, lupine, lupine oil, extract of Lupinus albus extract, lutein, Lycium barbarum fruit extract, lycopene, Usina, magnesium ascorbyl palmitate , magnesium ascorbyl phosphate, Malva sylvestris extract, manganese gluconate, Mangifera indica root, marigold, marijuana, Mastocarpus stellatus, mate extract, feverfew flower extract, feverfew oil, Meciago sativa, methionine, methylsulfonylsulfate, Microcystis aeruginosa, milk pea root, Morinda citrifolia, Nacetyl-L tyrosine, Nastrurtium officinale extract, gum natto, juice
273 Noni, Nordihydroguaiaretic Acid, Nymphaea tetragon, Oat β-glucan, Oat Bran Extract, Olea Europea Fruit Oil, Unsaponifiable Olea Europea Oil, Oleanolic Acid, Olive Oil / Olive Fruit Oil, Orizanol, oxidoreductase, Padina pavonica extract, Paenoia suffruticosa extract, palm oil, Palmaria palmata extract, Panax ginseng root extract, pansy extract, Passiflora edulis seed oil, peony root extract, Perilla ocymoides, Persea gratissima oil, Persicaria hydropiper, phenylalanine, phenylethyl resorcinol, floretin, Phyllanthus emblica fruit extract, pineapple extract, Pinus sylvestris extract, Pisum sativu, extract of plum, Polygonum cuspidatu root extract, polysaccharide, pomegranate extract, Poria cocos extract, ascorbyl tocopheryl potassium phosphate, proline, Prunella vulgaris, Prunus Americana, Prunus domestica seed extract, Pueraria lobata, pullulan, pumpkin, pumpkin seed extract, Punic granatum extract, Pycnogenol, pyridoxine hydrochloride (HCL), quercetin, rapeseed oil, raspberry seed extract, raspberry seed, red algae, red clover, red raspberry extract, resveratrol, retinol, retinyl palmitate, Robinia pseudacacia extract, Rosa canina, Rosa centifolia, Rosa centifolia flower, Rosa eglanteria, Rose hip, Rosa roxburghii extract, Rose rubinosa, Rose hip, Musk oil, Rosemary extract, Rosemary oil, Rosmarinus officinalis extract, Rubus idaeus, Rubus occidentalis, Rubus
274 ursinus, Rubus ursinus x idaeus, Rubus villoscus, rutin, Saccharomyces copper ferment, Saccharomyces iron ferment, Saccharomyces lysate, Saccharomyces magnesium ferment, Saccharomyces manganese ferment, Sachharomyces postasium ferment Saccharomyces, Saccharomyces Silicon Ferment, Safflower Seed Oil, Sambucus Canandensis, Sambucus cerulean, Sambucus nigra, Sapindus mukurossi husk extract, saponin, Sargassum filipula extract, Scutellaria baicalensis extract, sea buckthorn, Seamollient, seaweed, selenium, self-cure, sericin, serine, Shao-yao, silk, silk tip white tea leaf extract, extract of cap, soap extract, sodium ascorbate, sodium ascorbyl phosphate, sodium citrate, sodium metabisulfite, Solanum lycopersicum extract, soy extract, soy isoflavones, soy oil, soy protein, spirulina, squalane, squalene, St. John's wort, you anise star, superoxide dismutase, seed extract Tamarindus indica, tannic acid, Terminalia catappa, hydroxyhydrocinnamate pentaerythrityl tetradibutyl, ascorbate Tetrahexyldecyl, tetrahidrobisdemotoxicurcumina, tetrahidrobisdemetoxidiferuloilmetano, tetrahidrodemetoxicurcumina, tetrahidrodemetoxidiferuloilmetano, tetrahidrodiferuloilmetano, tetrahidrometoxicurcumina, acid thioctic, thiodipropionic acid, thiotaurine, threonine, thyme extract, thyme oil, Thymus serpillum extract, Thymus vulgaris, Tnhymus vulgaris oil, Tilia
275 cordata, tocopherol, tocopherol acetate, tocopheryl acetate, tocopheryl linoleate, tocotrienols, tomato extract, Trifolium pretense, tryptophan, turmeric, extract of Ulva lactuca, Undaria pinnatifida, fruit extract of Vaccinium macrocarpon, valine, fruit extract of Vanilla planifolia, Biola tricolor extract, vitamin A, vitamin C, vitamin D, vitamin E, vitamin F, Vitis vinifera, walnut extract, watercress extract, serum, white tea leaf extract, hazelnut, yeast, yerba mate extract, yucca extract, zinc and zinc oxide.
Coloring agents / pigments are any dye, pigment or substance that imparts color when added or applied to a food, drug, cosmetic / dermatological, or human body and which are considered safe and FDA approved for use in food, drugs and cosmetics. Most organic dyes are synthetic and are available as either water soluble, oil soluble or insoluble (= lacquer) agents in all shade classes. Inorganic dyes are co-busts of insoluble metal compounds, which are either derived from natural sources (eg, Chinese clay, carbon deposits) or synthesized.
In some embodiments, coloring / pigment agents may include, but are not limited to, aluminum powder, barium sulfate, beet root extract, βvulgaris root extract, blue 1, blue lacquer 1, bronze powder, caramel, carmine, chrome hydroxide green, chrome oxide green, D&C colors
276 (drugs & cosmetics), Ext. D&C colors (external drugs & cosmetics, FD&C colors (food, drugs & cosmetics), ferric ammonium ferrocyanide, ferric ferrocyanide, iron oxides, manganese violet, mica, red lacquer 27, red 33 , red lacquer 6, titanium dioxide, groceries, yellow 5, yellow lacquer 6, zinc oxide and zinc stearate.
Emollients are flexible, wax-like, thickening, lubricating substances which are added to cosmetic / dermatological products to prevent water loss and have a soothing and calming effect on the skin.
In some embodiments, emollients may include, but are not limited to, 10-hydroxydecanoic acid, acetyl glyceryl ricinoleate, acetylated castor oil, acetylated hydrogenated cottonseed glyceride, acetylated lanolin alcohol, acetylated lanolin alcohol, acetylated palm, agar, Ahnfeltia concinna extract, ahnfeltia extract, Alaria esculenta, algae extract, algin, almond oil, aglycan oligosaccharide, amodimethicone, Anacystis nidulans extract, apricot kernel oil, arachidic acid, arachidonic acid, arachidyl alcohol, arachidyl propionate, Arachis hypogaea extract, argen oil, brine shrimp extract, Ascophyllum nodosum, Asparagopsis armata extract, Astrocaryum seed butter murumuru, avocado oil, babassu oil, batyl alcohol, beeswax, behentrimonium chloride, bisdiglyceryl polyacyladipate, bis-PEG-18 methyl ether dimethyl silane, seed oil
277 borage, Borago officinalis extract, Borago officinalis seed oil, Brassica campestris, Butyrospermum fruit, Buyrospermum parkii, Buxus chinensis, C esters<sub>1O</sub>-<sub>3</sub>or cholesterol / lanosterol, C benzoate<sub>12</sub>.<sub>15</sub> alkyl, Ci acid triglyceride<sub>2</sub>.i8, Ci acid triglyceride<sub>8</sub>-<sub>3</sub>6, Candelilla wax, Cannabis sativa L oil, Caprylic / Capric triglyceride, Caprylyl methicone, Carrot oil, Carthamus tinctorius oil, Carya illinoensis oil, Castor succinate isostearate, Castor oil, Caulerpa taxifolia extract, Cephalin, microcrystalline wax, cetearyl alcohol, cetearyl ethylhexanoate, cetearyl octanoate, cetyl acetate, cetyl alcohol, cetyl dimethicone copolyol, cetyl esters, cetyl hydroxyethyl cellulose, Cetyl palmitate, chlorella, cholesterol, Chondrus crispus, cocoa butter, cocoglycerides, coconut oil, Cocus nucifera, Codium tomentosum extract, Corallina officinalis extract, corn oil, Corylus Americana, Corylus avellana, cyclohexasiloxane, cyclomethicone, cyclopentasiloxane, cyclotetrasiloxane, decyl oleate, dicaprilyl carbonate, diethylhexyl carbonate, diethylhexyl malate, diisopropyl adipate, diisopropyl dimer dilinoleate, Diisostearoyl Trimethylolpropane Siloxy Silicate, Diysostearyl Dimer Dilinoleate, Diysosaryl Malate, Dilinoleyl Dimer Dilinoleate Dimer, Dimethicone, Dimethicone Copolyol, Dimethicone Ditercane / Hepthionel Polymer, Dimethiononol Crosslinked Polymer diglyceryl disodium phosphate, glyceryl disodium phosphate, docosahexaenoic acid,
278 Dromiceius Acid, Durvillaea Antarctic Extract, Egg Yolk, Eicosapentaenoic Acid, Elaeis Guineensis, Emu Oil, Enteromorpha compressa Extract, Ethyl Macadamiate, Ethylhexyl Stearate, Euphorbia Wax Oil, Onagra Oil γ-linolenic acid (GLA), Gellidiela acerosa extract, glicereth-26, glicereth-26 phosphate, glicereth-6 laurate, glyceriol monostearate, glycerol triacetate, glycerol trioleate, glyceryl beanate, glyceryl cocoate, glyceryl dibehanate, glyceryl dipalmitate, glyceryl distearate, glyceryl isopalmitate, glyceryl isostearate, glyceryl glyceryl stearate, glyceryl stearate, glyceryl stearate SE, glycine soybean oil, glycine soybean seed extract, glycine soybean sterols, glycol stearate, glycolipid, grape seed oil, Haslea ostrearia extract, hazelnut oil, Helianhtus annuus seed oil, Helianthus oil, hemp seed oil, hexyl laurate, hexyldecanol, Himanthalia elongate extract, hydrogenated coco-glyceride, hydrogenated olive oil, hydrogenated palm glycerides, hydrogenated polydecene, hydrogenated polyisobutene, hydrogenated vegetable glyceride citrate, hydrolyzed jojoba esters, hydrolyzed jojoba protein, hydroxylated lecithin, Irish moss extract, isononyl isononanoate, isopropyl isostearate, isopropyl lanolate, isopropyl myristate, Jaen wax, jojoba butter, jojoba esters, jojoba oil, wax
279 jojoba, seaweed extract, kukul nut oil, Laminaria longicruris, Laminaria saccharina, lanolin, lanolin alcohol, lauryl lactate, lecithin, linoleic acid, lupine, lupine oil, Lupinus albus extract, macadamia nut oil , Mangifera indica (Mango) Seed Butter, Mastocarpus stellatus, Prairie Foam Seed Oil, Methicone, Methyl Glucose Sesquistearate, Methyl Trimethicone, Methylsilanol Manuronate, PEG7 Methylsilanol Glyceryl Cocoate, Microcystis aeruginosa, Mineral Oil, Murumurous Seed Butter, Myristyl Mlstate, Neopentyl Glycol Dicaprylate / Dicaprate, Octyl Stearate, Octyldodedeoyl Octodecyl, Deoyl Dedelodenoyl Deodarylene , fruit oil of European Olea, unsaponifiable oils of European Olea, olive oil / olive fruit oil, Orbignya martiana, Orbignya oleifera, Oryza sativa oil, Padina pavonica extract, palm kernel acid, palm oil, Palmaria palmata extract, palmitic acid, liquid paraffin, peanut oil, pecan oil, pectin, PEG 90M, PEG-10 dimethicone, polymer PEG-10 dimethicone / vinyl dimethicone crosslink, mat! of PEG-10 rapeseed, PEG-100 stearate, PEG-12 dimethicone, PEG-20 methyl glucose sesquistearate, PEG-40 hydrogenated castor oil, PEG-60 almond glycerides, PEG-60 hydrogenated castor oil, PEG-7 glyceryl cocoate, PEG-8, copolymer of PEG / PPG17 / 6, PEG / PPG-18/18 dimethicone, PEG / PPG-20/15 dimethicone, pentaerythrityl tetraoctanoate, oil by Persea gratissima,
280 petrolatum, phenyl trimethicone, phosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, phytosterol, pistachio seed oil, Pistacia vera seed oil, polyethylene, polyglyceryl monostearate 2, polyglyceryl-3-methylglyceryl distearate, isostearate , polyglyceryl-6 isostearate, polymethylsilsesquioxane, PPG-3 benzyl ether myristate, propylene glycol isostatrate, propylene glycol laurate, Prunus amygdalus dulcís, Prunus dulcís, pumpkin seed extract, quinoa oil, rapeseed oil, red algae, rice bran oil, rice oil, Ricinus communis, Rosa canina, Rosa centifolia, Rosa centifolia flower, Rosa eglanteria, Rosa mosqueta, Rosa rubiginosa, rose hip, rose hip oil, rutin, saccharide isomerate, safflower seed oil, Sargassum filipulandula extract, Seamollient, sesame oil, Sesamum indicum, sesquioleate, shea butter, silicon, siloxane, Simmondsia chinensis, PEG-7 olive oil carboxylate, sodium polyacrylate, Sonojell, soybean oil, matting! Soybean, Spirulina, Squalene, Squalene, Stearates, Stearic Acid, Stearyl Alcohol, Stearyl Methicone, Safflower Seed Oil, Sweet Almond, Sweet Almond Oil, Synthetic Beeswax, Theobroma Cocoa Seed Butter, Tribehenin, Esters of trribehenin PEG-20, tricapriline, tridecyl stearate, triethoxicaprililsilan o, trietoxisililetil pol id i metí Isi I oxieti I hexyl dimethicone, triglyceride, trihydroxystearin, triisocetyl citrate, trilaurine, trimethylsiloxysilicate, trioctanoin, trioctyldodecyl citrate,
281 Triticum vulgare oil, Undaria pinnatifida, vitamin F, Vitis vinifera, walnut oil, wheat germ glycerides, wheat germ oil, and Ximenia americana oil.
Film-forming / supporting agents are substances which are added to cosmetic / dermatological products to help leave a flexible / cohesive and continuous coverage on the skin. This film has water binding properties and leaves a soft feeling on the skin.
In some embodiments, the film-forming / supporting agents may include, but are not limited to, acrylate, acrylate copolymer, crosslinked acrylate / Ci polymer<sub>0</sub>-3rd alkyl acrylate, acrylate / dimethicone copolymer, adipic acid / neopentyl glycol / trimellitic anhydride copolymer, crosslinked polymer of allyl methacrylates, carnauba wax, cellulose gum, Copernicia wax, dextrin, diisopropyl adipate glyceryl, hydrolyzed wheat protein, hydroxyethyl cellulose, carob, neopentyl glycol diheptanoate, PEG_40 hydrogenated castor oil, polyacrylamide, polyacrylate-17, polyglucuronic acid, polyglyceryl methacrylate, polyisobutene, polymethyl methacrylate, polyquaternium-10, polyquaterniums, polyvinyl alcohol, polyvinylpyrrolidone, propylene carbonate, crosslinked polymer of PVM / MA (polyvinyl methyl ether / maleic acid) decadiene, copolymer of PVP [poly (vinylvin) , PVP / dimethylaminoethyl methacrylate, sodium carbomer, polyacrylate
282 sodium, styrene / acrylates copolymer, cross-linked triethoxycapilsilane polymer, VA (vinyl acetate) / chronates, VA / chronate copolymer, VP (vinylpyrrolidone) / eicosen copolymer and VP / hexadecene copolymer.
Fragrance ingredients are a single or a mixture of volatile and / or fragrant vegetable oils (or synthetically derived oils) that impart aroma and odor to cosmetic / dermatological products. The level of fragrance to use varies according to the type of product. In some modalities, a face cream may contain approximately 0.01% fragrance by weight.
In some embodiments, fragrances (eg, fragrant and synthetic plant extracts) may include, but are not limited to, Acacia farnesiana extract, Aerocarpus santalinus, amyl cinnamate, amyl salicylate, amyris oil, Anethum graveolens, Angelica archangelica root, anisaldehyde, anise, balsam mint extract, balsam from Peru, bay leaf oil, bergamot oil, bitter orange blossom, bois de rose oil, bois oil, Boswellia carterii, Butylphenyl methylpropional, Cananga extract, Cananga odorata, Cardamom, Cedarwood, Cherry extract, Citrus aurantifolia, Citrus aurantium, Citrus aurantium extract, Citrus medica limonium, Sage extract, Commiphora myrrha extract, Coriander, Cucurbitea peponis, cyclamen aldehyde, dill extract, ethyl vanillin, eugenol, farnesol, farnesyl acetate, Galbaniflua splint, fir needle oil, floralozone, Foeniculum vulgare extract, excerpt from
283 frankincense, galbanum, gardenia florida extract, grapefruit oil, guaiac wood, guaiacum officinale, hediona, hexyl cinnamal, hyssop, lilium vernum, iris florentine extract, jasmine oil, jasminium grandiflorum, jonquil extract, laurus nobilis, lactate lauryl, bleach oil, Lavandula angustifolia, Lavandula officinalis, lavender extract and oil, lemon, lemon balm, citronella oil, Levisticum officinale root extract, lime oil and extract, limonene, linalool, Litsea cubeba, tangerine oil or extract, marjoram, Melissa officinalis, Mentha piperita, Mentha spicata, Mentha viridis, menthol, mentho, mentoxypropanediol, menthol lactate, methyldihydrojasmonate, oil or extract of mimosa , mint, wax, Narcissus poeticus, neroli, neroli oil, olibanum extract, orange blossom, orchid, Origanum majorana, lily root, patchouli, pentadecalactone, mandarin petitgrain, Pogostemon cablin, Rosa damascena oil, Rosa galilea flower extract, rose flower, rose flower oil, rose oil, rosemary extract, rosemary oil, rosewood oil, sandalwood oil, Santalum seed extract album , sausurrhea oil, sclareolide, spearmint oil, star anise, tangerine oil, Thymus vulgaris oil, Vanilla planifolia fruit extract, verbena extract, vetiver and ylang ylang oil or extract.
Exfoliation involves the removal of older dead skin cells on the outermost surface of the skin and can be accomplished through mechanical or chemical means. The
284 Mechanical exfoliation involves the use of body cleansing or polishing agents, which are solid materials from natural origins (fine dust from seeds or shells of different vegetables), or are obtained by chemical synthesis (tiny beads of styrene or polyethylene). Cosmetic / dermatological products containing cleaning agent are used to remove the stratum corneum from the superficial skin (horny layer) by mechanical abrasion, leaving behind a smooth, fresh skin surface. Cleaning agents are selected based on the body part to be treated. Chemical scrubs are often referred to as leaving scrubs. The exfoliating ingredients that are left in place are substances that are added to cosmetic / dermatological products to give a subject a low concentration of acid on a daily basis. They are usually applied after cleansing and are for oily, acne-prone, and sun-damaged skin. They can also help with lightening discolored and scarred areas.
In some embodiments, exfoliants left in place may include, but are not limited to, α-hydroxy acids (AHAs) (such as glycolic acid, lactic acid, malic acid, citric acid, hydroxycaprylic acid, hydroxycapric acid, and tartaric acid), ammonium glycolate, amlgdalic acid, fruit extract of Ananas sativus, β-hydroxy acids (BHA) (such as salicylic acid, β-hydroxybutyric acid, tropic acid and tretocanic acid), bromelain, acid
285 mandelic, papain, papaya extract, pawpaw extract, pineapple extract, polyhydroxy acid (PHA) such as gluconolactone and lactobionic acid and urea.
In some modalities, prescription drugs may include, but are not limited to, adapalene (Differin®, Teva, Pimpal®, Gallet, Adaclene, Adapen ™, Adeferin ™), all-trans retinoic acid (Tretinoin, Aberela®, Airol ®, A-Ret ™, Atralin®, Avita®, Retacnyl ^^, Refissa®, Renova®, Retin-A®, Retino-A *, ReTrieve®, or Stieva-A ™), aminophylline (Aminophyl, Procellix, Phyllocontin ®, Celluthin, Cellulean®), Azelaic Acid (AzClear Action, Azelex®, SynCare, Finacea®, Finevin®, Skinoren®, Melazepam, Azelex®, Azaclear®, Aziderm®), bimatoprost (Lumigan®, Latisse®), hydroquinone (Lustra-AF®, Unblemish, Lustra®, Sunvanish ™, PCA Pigment Gel®, Sledgehammer ™), isotretinoin (Accutane®, Roaccutane® , Amnesteem®, Claravis ™, Absorica ™, Isotroin, Epuris ™, Sotret®) and Tazarotene (Tazorac®, Avage®, Zorac® and Fabior ™).
Preservatives are substances which prevent bacterial, microbial or fungal contamination of cosmetic / dermatological products, thereby increasing the shelf life of the product and consumer safety. Some of these agents also have stabilizing effects capable of preserving the function of various active ingredients including antioxidants (vitamins), emulsifiers and surfactants.
In some embodiments, preservatives may include, but are not limited to, 1,2-hexanediol, benzoic acid,
286 Benzotonium, Borax, Bronopol, Butylparaben, Caprylyl Glycol, Chlorophene, Chloroxylenol, Chlorophenesin, Dehydroacetic Acid, Diazolidinyl Urea, DMDM Hydantoin, Ethylhexylglycerin, Ethylparabenyl, Butylyl-Butyl, Ivorin , methyldibromo glutanitrile, methylisothiazolinone, methyl paraben, o-cimen-5-ol, phenoxyethanol, phenoxyisopropanol, phytosphingosine, polyamine propyl biguanide, potassium sorbate, propyl paraben, quaternium-15, sodium benzoate, sodium citrate, sodium dehydroacetate, sodium hexametaphosphate, sodium lactobionate, sodium metabisulfite, sodium sulfite, sorbic acid and sty .
In some embodiments, cleaning agents may include, but are not limited to, alumina, aluminum silicate, apricot kernel, azuki beans, diatomaceous earth, polyethylene, polyethylene glycol glycol (PEG), sea salt, sodium chloride, and powder. of walnut shell.
Silicone ingredients are substances which are added to cosmetic / dermatological products to create a silk-like feel on the skin, impart emolliency and are a water-binding agent that holds up well, even when the skin gets wet. Silicones also act as a skin protector, conditioner, peeler, film former, moisturizer, thickener, and emulsifier. Because silicones are very soft, they are often used to reduce irritation from
287 hard surfactants. Some cosmetic / dermatological compositions can be used to heal wounds and to improve the appearance of scars [Journal of Wound Cara (2000), 9 (7), 319-324].
In some embodiments, silicones can include, but are not limited to, acrylates / dimethicone copolymer, amodimethicone, b / s-PEG-18 methyl ether dimethyl silane, b / s-phenylpropyl dimethicone, caprylyl methicone, cetyl dimethicone, copolyol of cetyl dimethicone, cetyl PEG / PPG-10/1-dimethicone, diisoestearoyl trimethylolpropane siloxy silicate, dimethicone, dimethicone copolyol, dimethicone crosslinked polymer, dimethicone crosslinked polymer / PEG10 / 15, dimethicone / vinyl dimethicone crosslinked polymer, dimethiconol, isopropyl titanium triistearate / triethoxycarpylsilane crosslinked polymer, methicone, methyl trimethicone, methylsilanol manuronate, PEG-7 methylsilanol glyceryl dimethylone, crosslinked polymer vinyl dimethicone, PEG-12 dimethicone, PEG / PPG-18/18 dimethicone, PEG / PPG-20/15 dimethicone, phenyl trimethicone, polymethylsilsesquioxane, polysilicon-11, silica dimethyl silylate, silicone, siloxane, simethicone, stearyl dimethicone, stearyl methicone, triethoxycapilyl silane, triethoxycaprylylsilane crosslinked polymer, trimethyl isyloxysi lycate and crosslinked vinyl dimethicone / methicone silsesquioxane polymer.
The term "identical skin agents" or "skin repair agents" refers to substances between cells of
288 skin (technically referred to as the intercellular matrix) that keep skin cells connected and help maintain the fundamental external structure of the skin. They can be added to the compositions provided herein to help keep the skin moisturized and hydrated without causing unnecessary inflammation or irritation.
In some modalities, identical / skin repairing agents may include, but are not limited to, acetyl hexapeptide3, acetyl octapeptide-3, adenine, aquaporins, aspartic acid, β-sitosterol, Butyrospermum parkii, Buxus chinensis, cane oil, carrot, ceramide 1, ceramide 2, ceramide 3, ceramide 6-II, cetearyl octanoate, cholesterol, chondroitin sulfate, creatine, cysteine, cysteine [sic], decylene glycol, dextran, dimethylamlnoethanol (DMAE), elastin, Fibronectin, Fructose, Glucose, Glutamine, Glycerin, Glycerin [sic], Glycerol, Glycine, Glycogen, Glycolipid, Glycosaminoglycans, Glycosphingolipid, Hyaluronic Acid, Hydrogenated Palm Oil Glycerol, Hydroxyproline, Inolin, Hydroxyproline jojoba, lactobionate, lanolin, lanolin alcohol, lecithin, leucine, Usina, Mangifera indica (mango) seed butter, melibiosam, methionine, milk protein, mucopolysaccharide, Nacetyl-L tyrosine, natural moisturizing factor (MFN), fruit oil from Olea europaea, inseparable from Olea europaea oil, olive oil / olive fruit oil, palm oil, palmitic acid, palmitoyl oligopeptide, phenylalanine, phosphatidylcholine,
289 phosphatidylethanolamine, phospholipic, phytosphingosine, polysaccharide, proline, pumpkin seed extract, RNA, saccharide isomerate, saccharides, Saccharomyces cerevisiae, serine, Simmondsia chinensis, sodium chondroitin sulfate, sodium dilauramidoglutamide, hyaluronate sodium hyaluronate pyrrolidone sodium (PCA), sphingolipids, squalene, squalene, stearates, stearic acid, sucrose, thiotaurine, threonine, tribehenine, trihydroxystearin, tryptophan, urea, valine and wheat protein.
The term "slip agent" is used to describe a range of ingredients which can help other ingredients spread on the skin and penetrate the skin. Gliding agents may also have wetting (hygroscopic) properties.
In some embodiments, slip agents may include, but are not limited to, amodimethicone, or / s-PEG-18 methyl ether dimethyl silane, b / s-phenylpropyl dimethicone, butylene glycol, cetyl dimethicone, cetyl dimethicone copolyol, cetyl PEG / PPG-10 / 1dimethicone, cyclohexasiloxane, cyclomethicone, cyclopentasiloxane, cyclotetrasiloxane, decylene glycol, diysostearoyl trimethylolpropane siloxy silcate, dimethicone, dimethicone copolyol, dimethicone crosslinked polymer, dimethiconol, dipropylene glycol, hexylene glycol, hydrolyzed silk, iododecane, methicone, methyl trimethicone, methylsilanol manuronate, methylsilanol cocoate PEG-7 glyceryl, PEG-10 dimethicone, crosslinked polymer of PEG-10
290 dimethicone / vinyl dimethicone, PEG-12 dimethicone, PEG / PPG-18/18 dimethicone, PEG / PPG-20/15 dimethicone, pentylene glycol, phenyl trimethicone, polymethylsilsesquioxane, PPG-3 benzyl ether myristate, silica dimethyl silylate, silk powder, siloxane, simethicone, sorbitol, stearyl dimethicone, stearyl methicone, triethoxycapilylsilane, trimethylsiloxysilicate, xylitol and zinc stearate.
Sunscreen assets are substances which are added to cosmetic / dermatological products to protect the skin against UV rays. They can be organic molecules, which absorb high-energy ultraviolet rays and release energy as lower-energy rays, thereby preventing harmful ultraviolet rays from the skin from reaching the skin. They can be inorganic particulates that reflect, scatter, and absorb UV light. They can also be organic particulates that mostly absorb light as organic chemicals, but contain multiple chromophores, can reflect and scatter a fraction of light as inorganic particulates, and behave differently in formulations than organic chemicals.
In some embodiments, sunscreen assets may include, but are not limited to, avobenzone, benzefenone-3, benzophenones, bumetrizol, butyl methoxydibenzoylmethane, ecamsul, ensulizol, methoxycinnamate, ethylhexyl, homosate, menthyl anthranilate, meradmate, Mexoryl SX octinoxate, octisalate, octrocrylene, octyl methoxycinnamate, octyl salicylate, oxybenzone, padimate O, para-aminobenzoic acid (PABA), Parsol 1789, terephthalidin acid
291 Sulfonic Dialcaphor, Tinosorb M, Tinosorb S and Titanium Dioxide.
Emulsifiers are substances which are added to cosmetic / dermatological products to help maintain different ingredients (such as oil and water) without separating into an emulsion. There are 2 types of emulsifiers. Oil-in-water (o / w) emulsifiers keep oil droplets packed in water, while water-in-oil (w / o) emulsifiers keep water droplets packed in oil. W / O emulsifiers are used for a greasy feeling (for example, sunscreen and night creams). O / W emulsifiers are used more in moisturizing products (eg, body lotions, day creams).
Surfactants are substances that are added to cosmetic / dermatological products to degrease and emusify oils and greases and suspend dirt, allowing them to be washed, as laundry products do. Sometimes they are referred to as "detergent cleaning agents." Based on their cleaning power, surfactants are classified as primary and secondary or cosurfactants. Based on the chemical structure, there are anionic, amphoteric, nonionic and quaternary agents. Surfactants form the basis of all personal cleansers and can also have moisturizing, conditioning, degreasing, emulsifying and thickening effects.
In some embodiments, emulsifiers, surfactants, and detergents may include, but are not limited to, lauret sulfate.
292 ammonium, ammonium lauryl sulfate, arachidyl glucoside, behenic acid, or / s-PEG-18 methyl ether dimethyl silane, C<sub>2O</sub>-4o paret-40, cocamidopropyl betaine, cocamidopropyl dimethylamine, cocamidopropyl hydroxysultaine, coco-glucoside, coconut oil, decyl glucoside, dicetyl phosphate, dihydrocolet-30, disodium cocoaffodiacetate, disodium cocoyl glutamate, lauraminopropinoate disodium, of hydrogenated vegetable glycerides, isohexadecane, isostearamide DEA, lauraanfocarboxiglicinato, lauret23, lauret-4, lauret-7, lauryl PEG-9 polydimetilsiloxetiI dimethicone, lauryl alcohol, lauryl glycoside, magnesium lauret sulfate, magnesium olet sulfate, myristic acid, nonoxynols, oleic acid, olet 10, palm kernel acid, palmitic acid, almond glycerides from PEG-60, shea butter glycerides from PEG- 75, PEG 90M, PEG-10 dimethicone, PEG-10 dimethicone / vinyl dimethicone crosslinked polymer, PEG-10 rapeseed sterol, PEG-100 stearate, PEG-12 dimethicone, PEG-120 methyl glucose dioleate, PEG-20 methyl glucose sesquystearate, PEG-40 stearate, PEG-60 hydrogenated castor oil, PEG-7 glyceryl cocoate, PEG-8, PEG-80 sorbitan laurate, PEG / PPG-17/6 copolymer (polyethylene glycol / polypropylene glycol-17 copolymer / 6), PEG / PPG-18/18 dimethicone, PEG / PPG-20/15 dimethicone, poloxamer 184, poloxamer 407, poloxamers, polyglyceryl-4 beeswax, polyglyceryl-6 isostearate, polysorbate 20, polysorbate 60, polysorbate 80, otasium cetyl phosphate, potassium hydroxide, Otasium myristate, PPG-12 butet-16, PPG-26293
Butet-26, Salvia officinalis, Saponaria officinalis extract, soap, C<sub>14</sub>.<sub>ie</sub> sodium olefin sulfonate, sodium cetearyl sulfate, sodium cocoamphoacetate, sodium cocoate, sodium cocoyl glutamate, sodium cocoyl isethionate, sodium dilauramidoglutamide, sodium hexametaphosphate, sodium hydroxide, sodium lauret sulfate, lauret-13 carboxylate sodium, sodium lauroamphoacetate, sodium lauroyl lactylate, sodium lauroyl sarcosinate, sodium lauryl glucose carboxylate, sodium lauryl sulfate, sodium methyl cocoyl taurate, sodium methyl taurate, sodium miret sulfate, sodium palm quernelate, sodium palmate, sodium PEG-7 olive oil carboxylate, sodium tridecet sulfate, stearet-20, TEA-lauryl sulfate (triethanolamine-larul sulfate) and tribehenin esters PEG-20.
Thickeners are substances which are added to cosmetic / dermatological products to improve the consistency, volume and viscosity of cosmetic products, thereby providing more stability and better performance. Although some thickeners also have emulsifying or gelling properties, most thickeners have the ability to retain water on the skin and therefore act as humectants. Thickeners can be completely natural like waxes, but also synthetic or semi-synthetic.
In some embodiments, thickeners may include, but are not limited to, Acacia Senegal, Acetyl Glyceryl Ricinoleate, Acetylated Castor Oil, Acetylated Hydrogenated Cottonseed Glyceride, Acetylated Palm Kernel Glycerides,
294 acrylates / stearet-20 methacrylate copolymer, agar, Ahnfeltia concinna extract, ahnfeltia extract, Alaria esculenta, algae, algae extract, algin, alkyl amides, Althaea rosea, Althea officinalis, alumina, aluminum hydroxide, aluminum stearate, copolymer ammonium acryloyl dimethyltaurate / VP, Anacystis nidulans extract, arachidic acid, arachidonic acid, arachidyl alcohol, arachidyl propionate, arrowroot, brine shrimp extract, Ascophyllum nodosum, Ascorbyl Methylsilanol Pectinate, Asparagopsis Armata Extract, Beeswax, Behenic Acid, Behentrimonium Chloride, Behenyl Alcohol, Polyacyladipate, Bismuth Oxychloride, C Benzoate<sub>12</sub>.<sub>15</sub> alkyl, triglyceride of C acids<sub>12</sub>.<sub>18</sub>, C<sub>13</sub>. i<sub>4</sub> Isoparaffin, C-acid triglyceride<sub>18</sub>.<sub>36</sub>, candelilla wax, caprylic / capric triglyceride, carbomer, carbopol, carnauba wax, carrageenan, Caulerpa taxifolia extract, cellulose, cellulose gum, cephalin, wax alba, ceresin, cetearet-20, cetyl alcohol, cetearyl ethylhexanoate, glucoside cetearyl, cetearyl octanoate, cetyl alcohol, cetyl dimethicone copolyol, cetyl hydroxyethyl cellulose, cetyl palmitate, cetyl PEG / PPG-10 / 1dimethicone, chlorella, Chondrus crispus, cocamide DEA and MEA, cocoglycerides, Codium tomentosum extract, Copernicia cerifera wax, Corallina officinalis extract, Cyamopsis tetragonoloba, DEA olet-10 phosphate, diethanolamine (DEA), di-PPG-3 myristyl ether adipate, dimethicone crosslinked polymer / dimethicone crosslinked polymer / vinyl dimethicone, dilinoylethyl dimer, dilinoleate dimer, hexacaprilat / hexacapipentaerythrityl, diglyceryl phosphate
295 disodium, disodium glyceryl phosphate, docosahexaenoic acid, dulse, Durvillaea Antarctic Extract, Eicosapentaenoic Acid, Enteromorpha compressa Extract, Erythropoietin (Epo), Ethylhexyl Stearate, Euphorbia cerifera Extract, Tierra de Fuller, Gellidiela acerosa, gliceret-26, gliceret-26 phosphate, gliceret-6 laurate, glycerol monostearate, glycerol triacetate, glycerol trioleate, glyceryl behanate, glyceryl cocoate, glyceryl dipalmitate, glyceryl distearate, glyceryl sopalmitate, glyceryl stearate, glyceryl myristate, glyceryl palmitate, glyceryl glyceryl stearate, glyceryl stearate, glyceryl stearate, , glycolipid, guar gum, guar hydroxypropyltrimonium chloride, gums, Haslea ostrearia extract, hepatocyte growth factor (HGF), Himanthalia elongate extract, hydrogenated coco-glyceride, hydrogenated didecene, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, hydroxyethyl cellulose, hydroxypropyl guar, hydroxypropyl starch phosphate, interleukin (Ll), Irish moss extract, isohexadecane, isoproyl, lanolate isopropyl palmitate, isopropyl titanium triisoesearate / triethoxycaprilyl silane crosslinked polymer, isostearamide DEA, isostearic acid, soap wax, seaweed extract, Laminaria digitata, Laminaria longicruris, Laminaria saccharine, lauret-23, lauret-4, lauret-7, lauryl PEG-9 po I idimeti Is i I ox iet i I dimethicone, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, lithium magnesium sodium silicate, carob, silicate
296 magnesium aluminum, magnesium stearate, magnesium sulfate, mallow, marshmallow, Mastocarpus stellatus, monoethanolamine (MEA), microcrystalline wax, Microcystis aeruginosa, montane wax, myristyl distaprylate / neopentylglycol-dicarprate, nylon diheptanoate octyl palmitate, octyl stearate, octyldodecanol, octyldodecyl myristate, oleic acid, olet 10, ozocerite, Padina pavonica extract, Palmaria palmata extract, palmitoyl hexapeptide-12, palmitoyl oligopeptide, palmitoyl pentapeptide-3, palmitoyl tetrapeptide-7, palmitoyl tripeptide-5, paraffin, pectin, PEG-100 stearate, PEG-150 distearate, PEG-32, hydrogenated castor oil of PEG-400, pentaerythrityl tetraisoestearate, pentaerythrityl tetraoctanoate, polybutene, polyethylene, polyethylene glycol, polyglycerol monostearate, polyglyceryl tri-stearate, polyglyceryl-3 beeswax, polyglyceryl-3 methylglucose distearate, polyisobutene, polysorbate 20, polysorbate 60, polysorbate 80, polysorbates, PPG-12 butet-16, propylene glycol propionate, propylene glycol isol stearate, pumpkin seed, , crosslinked polymer of PVM / MA decadiene, Pyrus cydonia, Pyrus malus, quaternium-18 hectorite, quince seed, red algae, ricinoleate, Salvia officinalis, extract of Sargassum filipulandula, sclerotium gum, Seamollient, Seaweed, Sesquiolet, Two Silent Information Regulatory Proteins (Sirtuins), Silica, Silicate, Sodium Acrylate / Acryloyldimethyl Taurate Copolymer, Carboxymethyl β-glucan Sodium, Hexametaphosphate
297 sodium, sodium lauroyl lactylate, sodium lauryl sulfate, sodium polyacrylate, Solanum tuberosum extract, sorbitan oleate, sorbitan sesquioleate, sorbitan stearate, sorbitol, spirulina, stearic acid, stearyl alcohol, subtilisin, synthetic beeswax, TEA-lauryl sulfate, titanium dioxide, tragacanth, transforming growth factor (TGF), tribehenin, tridecyl stearate, tridecyl trimellilate, triglyceride, trigonella foenum-graecum seed extract, trihydroxystearin, trilaurin, tri-peptide do-32, trioctanoin, Lindaria pinnatifida, vascular endothelial growth factor (VEGF), vinyl dimethicone / methicone silsesquioxane glyceride, wheat germ glycerides, gum , xylitol, zinc oxide and zinc stearate.
In some embodiments, penetration enhancers can be used to assist the compounds or compositions provided herein to pass through the outer layer (epidermis) of the skin and into the dermis and / or hypodermis of the skin. Penetration enhancers can be selected from one of the following classes of compounds:
1. Fatty alcohols, fatty acids and related compounds.
two. Biologicals, such as lecithins, phospholipids.
3. Amines and amides.
Four. Complex forming agents, such as cyclodextrins.
5. Surfactants including Brij, tweens, spans, and pluronics.
298
6. N-methyl pyrrolidone and related compounds.
7. Ionic compounds, such as sodium ascorbate and hyaluronate.
8. Dimethyl sulfoxide and related compounds.
9. Solvents such as ethanol, acetone, glycols, glycerols, squalene, tween 20, etc.
10. Azona and related compounds.
The cosmetic or dermopharmaceutical compositions provided herein may include cleansers, face masks, toners, moisturizers, sunscreen, tanning oils and lotions, skin lighteners, serums, and exfoliants.
Furthermore, various auxiliaries, such as are commonly used in the art, may be included. These and other such compounds are described in the literature, eg, Rowe, RC; Sheskey, PJ & Quinn, ME (Eds.) (2009). Handbook of Pharmaceutical Excipient. London Chicago: Pharmaceutical Press; Hoepfner E., et al. (2002). Fiedler Encyclopedia of Excipients for Pharmaceuticals, Cosmetics and Related Areas, Aulendorf, Germany: Cantor; Kemper, FH, et al. (2000). Blue List Cosmetic Ingredients, Aulendorf, Germany: Cantor; and Smolinske, SC (1992). Handbook of Food, Drug and Cosmetic Excipients, Boca Ratón, FL: CRC Press.
Ingredients, additives, products or materials and auxiliaries, which can be used in the compositions discussed herein, are referred to by their commonly used chemical names or by the international nomenclature (recognized by the
299
European Union), commonly referred to as an INCI name given in any edition of the International Cosmetic Ingredient Dictionary and Handbook, (hereinafter INCI Dictionary), or any edition of the International Buyers' Guide, all published by the Personal Care Products Council (PCPC ), Washington DC. Numerous commercial providers of materials listed by INCI name, trade name, or both can be found in any edition of the INCI Dictionary and in numerous trade publications.
Cosmetic or dermopharmaceutical compositions provided herein can be administered to any skin type including normal skin, dry skin, oily skin, combination skin (a combination of both oily and dry or normal skin, for example, certain areas of the face are oily and other dry), sensitive skin and acne prone skin.
The term "administration" or "administer" refers to a method of providing a dosage of a cosmetic or dermopharmaceutical compound or composition to a subject, where the method is epicutaneous (topical) or subcutaneous. Methods of administration, dosage programs, compounds and compositions described can be determined according to the criteria generally taken into account in the establishment of a cosmetic and / or dermatological treatment adapted, for example, to a type of skin of the patient. The compositions can be administered in a way that covers the entire area to be treated.
300
.. 'Ά
As used herein, "topical use" and "apply topically" directly means layering or spreading on the skin, hair, or nail, for example, by the use of hands or an applicator such as a wipe.
The term "topical composition" as used herein refers to any composition suitable for topical application to mammalian keratinous tissue, such as in particular human skin. In particular, the topical compositions according to the present description are cosmetic compositions that can be applied topically to mammalian keratinous tissue, in particular to human skin.
The term "dermatologically acceptable" is used to refer to compounds and compositions that retain biological effectiveness and which are suitable for use in contact with the skin or hair of humans and minor animals without undue toxicity, incompatibility, instability, irritation, allergic response, and Similar.
The term "dermatologically acceptable carrier", "dermatologically acceptable diluent" or "dermatologically acceptable carrier" are well known in the art and are selected based on the end use application and refer to a non-toxic, inert and / or composition component. or physiologically compatible. Except insofar as any conventional medium or agent is incompatible with the active ingredient, its use in cosmetic and dermopharmaceutical compositions is contemplated.
301
The term "dermatologically acceptable salt refers to salts that retain the biological effectiveness and properties of the compounds provided herein and which are suitable for use in contact with the skin or hair of humans and minor animals without undue toxicity, incompatibility, instability , irritation, allergic response and the like. Non-limiting examples include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edsilate, stolate, eslate, fumarate, glyceptate, gluconate , glutamate, glycolilarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methyl nitrate, methylsulfate, mucate, napsilate, nitrate, pamoate, pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, theoclate, tosylate and trietiodide. Cosmetically acceptable basic / cationic salts include and are not limited to, aluminum, benzathine, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, meglumine, potassium, procaine, sodium, and zinc. However, other salts may be useful in the preparation of compounds according to this description or of their dermatologically acceptable salts. Organic or inorganic acids also include, but are not limited to, hydric, perchloric, sulfuric, phosphoric, propionic, glycolic, methanesulfonic, hydroxyethanesulfonic, oxalic,
302
2-naphthalenesulfon, p-toluenesulfonic, cyclohexanesulfamic, saccharinic and trifluoroacetic.
Administration of the compounds described herein or the dermatologically acceptable salts thereof may be via any of the accepted modes of administration for agents serving similar utilities including, but not limited to, topical, intravaginal, rectal, intranasal, intralesional, atrial, conjunctiva, by irrigation and oropharyngeal.
In some embodiments, the unit dosage of compounds of formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, Ha, Hb, lie, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV for topical delivery is approximately 1.0 pg / cm<sup>2</sup> at about 100 pg / cm<sup>2</sup>.
In some embodiments, the unit dosage of compounds of formula I, la, Ib, le, Id, le, If, Ig, Ih, Η, II, Ha, Hb, He, lid, lie, llf, III, Illa, lllb, Hlc, llld, and / or IV for topical delivery is approximately 1.5 pg / cm<sup>2</sup> at about 95 pg / cm<sup>2</sup>.
In some embodiments, the unit dosage of compounds of formula I, la, Ib, le, Id, le, If, Ig, Ih, Η, II, lia, Hb, He, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV for topical delivery is approximately 2.0 pg / cm<sup>2</sup> at about 85 pg / cm<sup>2</sup>.
In some embodiments, the unit dosage of compounds of formula I, la, Ib, le, Id, le, If, Ig, Ih, Η, II, lia, Hb, He, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV for topical delivery is approximately 2.5 pg / cm<sup>2</sup> at about 75 pg / cm<sup>2</sup>.
In some embodiments, the unit dosage of
303 compounds of formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, Ha, Ilb, lie, lid, He, Hf, III, Illa, Hlb, lile, llld, y / o IV for topical delivery is approximately 5 pg / cm<sup>2</sup> at about 50 pg / cm<sup>2</sup>.
In some embodiments, the unit dosage of compounds of formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, Ha, Hb, lie, lid, He, Hf, III, Illa, Hlb, lile, llld, and / or IV for topical delivery is approximately 10 pg / cm<sup>2</sup> at about 25 pg / cm<sup>2</sup>.
In some embodiments, the compositions are provided in unit dosage forms suitable for single administration.
In some embodiments, the compositions are provided in unit dosage forms suitable for twice daily administration.
In some embodiments, the compositions are provided in unit dosage forms suitable for administration three times a day.
The present description is also directed to a composition comprising up to 75% by weight of a compound of formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, lia, Hb, He, Hd , He, Hf, III, Illa, Hlb, lile, llld, and / or IV, or a combination thereof.
In some embodiments, a composition can comprise from about 0.01 to about 10% of the compound in solution.
In some embodiments, the composition will comprise about 0.01 to about 5% of the compound in
304 solution.
In some embodiments, the composition will comprise about 0.05 to about 0.5% of the compound in solution.
In some embodiments, the composition will comprise about 0.05 to about 0.2% of the compound in solution.
In some embodiments, the composition will comprise about 0.05 to about 0.15% of the compound in solution.
In some embodiments, the composition will comprise about 0.1 to about 0.45% of the compound in solution.
In some embodiments, the composition will comprise about 0.1 to about 0.25% of the compound in solution.
In some embodiments, the composition will comprise about 0.1 to about 0.2% of the compound in solution.
In some embodiments, the composition will comprise about 0.15 to about 0.40% of the compound in solution.
In some embodiments, the composition will comprise about 0.15 to about 0.25% of the compound in solution.
305
In some embodiments, the composition will comprise about 0.15 to about 0.20% of the compound in solution.
In some embodiments, the composition will comprise about 0.2 to about 0.35% of the compound in solution.
In some embodiments, the composition will comprise about 0.25 to about 0.3% of the compound in solution.
It will be noted that the concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It will further be understood that for any particular subject, specific dosage regimens can be adjusted over time according to the individual need and professional judgment of the person administering or supervising the administration of the compositions and that the concentration ranges set forth in These are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
Compositions comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, Hb, He, lid, He, llf are provided herein. , III, Illa, Hlb, lile, llld, and / or IV that can be used to improve the condition and aesthetic appearance of the skin.
In one embodiment, a composition comprising one or more
306 compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, lie, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV can be used to alter the aesthetic appearance of the skin associated with or affected by skin aging.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, lie, llf , III, Illa, lllb, lile, llld, and / or IV can be used to alter the aesthetic appearance of skin associated with or affected by one or more wrinkles, dry skin, sensitive skin, or dermatological symptoms caused by ineffective homeostatic regulation healthy skin.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to alter the aesthetic appearance of the skin associated with or affected by, or to treat or prevent, a skin condition / disorder (for example, a condition / skin disorder accompanied by a loss of skin elasticity).
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to improve the barrier function and viability of the skin.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, He, lid, He, llf , III, Illa, lllb, Hlc, llld, and / or IV can be used
307 to alter the aesthetic appearance of the skin associated with or affected by wrinkles, sagging and / or a loss of skin elasticity.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, lia, llb, lie, lid, lie, llf , III, Illa, lllb, Ule, llld, and / or IV can be used to alter the aesthetic appearance of the skin associated with or affected by, or to treat or prevent, acne eg acne may be selected from one or more of simple acne, comedonic acne, papulopustular acne, papulocomedonic acne, nodulocystic acne, acne conglobata, Keloid acne of the neck, recurrent military acne, necrotic acne, neonatal acne, occupational acne, acne rosacea, senile acne, solar acne, or medication related acne.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, lia, llb, He, lid, lie, llf , III, Illa, lllb, lile, llld, and / or IV can be used to alter the aesthetic appearance of the skin associated with or affected by impairments in skin viscoelasticity.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, Ha, llb, He, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to alter the aesthetic appearance of the skin associated with or affected by one or more wrinkles and / or full of expression, lean skin, a lack of elasticity and / or skin tone, thinning of the dermis, degradation of collagen fibers, easy skin, thinned skin and internal skin breakdown following exposure
308 to ultraviolet radiation.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, .Ii, II, Ha, llb, He, lid, lie, Hf, III, Illa, lllb, lile, llld, and / or IV can be used to decrease the appearance of expression lines and / or wrinkles on the skin.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, Hf , III, Illa, lllb, lile, llld, and / or IV can be used to create a more youthful appearance of the skin.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, He, lid, He, Hf , III, Illa, lllb, lile, llld, and / or IV can be used to decrease the appearance of bags and / or rings around the eyes.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, Hf , III, Illa, lllb, lile, llld, and / or IV can be used to reduce the appearance of hyperpigmentation.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, Hf , III, Illa, lllb, Hlc, llld, and / or IV can be used to increase or restore the elasticity, resilience and / or flexibility of the skin.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii,
309
II, lia, llb, He, lid, He, llf, III, Illa, lllb, lile, llld, and / or IV can be used to improve or increase one or more of thickness, elasticity, flexibility, radiance, brightness and fatness of the skin. The method comprising administering to a subject an effective amount of a compound according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He , llf, III, Illa, lllb, lile, llld, and / or IV.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to improve the fineness of the skin texture.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, lie, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to improve the appearance of wrinkled, fine lines, dry, flaky, aged or photodamaged skin.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to alter the aesthetic appearance of skin associated with or affected by skin discolorations.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to whiten, lighten and / or bleach the skin.
In one embodiment, a composition comprising one or more
310 compounds according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, li, II, Ha, Hb, He, lid, He, llf, III, Illa, lllb, lile, Hld, and / or IV can be used to alter the aesthetic appearance of the skin associated with or affected by, or to treat or prevent, hyperpigmentation.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, li, II, lia, Hb, He, lid, He, llf , III, Illa, lllb, lile, Hld, and / or IV can be used to alter the aesthetic appearance of skin associated with or affected by, or to treat or prevent, photodamaged skin.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, H, II, Ha, Hb, He, lid, He, llf , III, Illa, lllb, lile, Hld, and / or IV can be used to treat or prevent deposition of pigment on the skin caused by UV exposure.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, li, II, Ha, llb, He, lid, He, llf , III, Illa, lllb, lile, Hld, and / or IV can be used to treat or prevent vitiligo (skin condition in which there is a loss of brown color (pigment) from areas of the skin).
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, lf, Ig, Ih, H, II, lia, Hb, He, lid, He, llf , III, Illa, lllb, lile, Hld, and / or IV can be used to treat or prevent a wound healing disorder in a mammal. For example, a compound or composition provided herein can be used as a medicine to prevent and / or treat
311
.. 'Ά an ulcer in a mammal.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, llb, lie, lid, He, llf , III, Illa, lllb, lile, llld, and / or IV can be used to promote the proliferation and / or mobility of skin keratinocytes and / or dermis fibroblasts (eg, to increase skin regeneration).
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, lia, Hb, He, lid, He, Hf , III, Illa, lllb, lile, llld, and / or IV can be used to enhance epidermal cell repair activity, eg, in a human.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, Hb, lie, Hd, He, llf , III, Illa, lllb, Hlc, llld, and / or IV can be used to increase fibroblast proliferation, keratinocyte proliferation and / or collagen expression.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, Hb, He, Hd, He, Hf , III, Illa, lllb, Hlc, llld, and / or IV can be used to reduce collagenase activity.
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, Ii, II, Ha, llb, He, Hd, He, Hf , III, Illa, lllb, lile, Hld, and / or IV can be used to improve the thickness of the epidermis.
312
In one embodiment, a composition comprising one or more compounds according to formula I, la, Ib, le, Id, le, If, Ig, Ih, li, II, lia, llb, He, lid, lie, llf , III, Illa, lllb, lile, llld, and / or IV can be used to inhibit melanin production.
In some embodiments, the compositions are cosmetic compositions.
In some embodiments, the compositions are dermopharmaceutical compositions.
Kits are also provided herein. Typically a kit includes one or more compounds or compositions described herein. In certain embodiments, a kit may include one or more delivery systems, eg, for dispensing or administering a compound as provided herein, and directions for kit use (eg, instructions for treating a patient).
Definitions
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by someone of ordinary skill in the art to which this description belongs. All patents, applications, published applications and other publications are incorporated by reference in their entirety.
The term "comprise", as used herein, is synonymous with "includes", "contains" or "characterized by" and is inclusive or open-ended and does not exclude elements, or method steps
313 additional, not declared.
Examples Example 1
This example demonstrates the anti-aging benefits of the present disclosure in human female subjects.
Three groups of women were recruited to evaluate and compare the efficacy of three anti-aging test products (targeting the periorbital eye area) intended to reduce the appearance of fine lines, wrinkles in the outer corner of the eyes (crow's feet) during a 12 week period. Wrinkle assessment was instrumentally conducted using a Visioscan image analysis system. The effectiveness of the test product was evaluated using panelist self-assessment via questionnaire responses comprised of 3-4 questions (Q1, Q2, Q3 & Q4). Each stage in the progression of treatments was photographically documented using a scientifically matched high-resolution photography technique. Image analysis was used to quantify changes in expression lines and crow's feet condition observed in scientifically matched photographs.
Selection of the subject:
Number: six subjects (two per group) to complete the study.
Gender: women
314
Race: Caucasian / Asian / Hispanic
Age range: 40 to 60 years
Test samples:
Topical 0.15% Compound # 222 in Oil (a 50/50 mixture of Propylene Glycol Dicaprylate / Dicaprate and Caprylic / Capric Trlyglyceride) (Cohort 1)
Topical 0.15% of compound # 222 in PEG400 (Cohort 2)
Topical 0.05% Compound # 222 in PEG400 (Cohort 3)
Before baseline measurements were taken, the areas of involvement were marked on the facial surface using a standard template, to ensure that the instruments were repositioned in the same location at each visit. Biophysical measurements (assessment of living skin surface via Visioscan) were conducted by a trained technician. High resolution pre-treatment scientifically matched photographs were taken.
All subjects were instructed to use the test material once a day as part of their daily skin care routine. Right after the baseline assessments, subjects were given the product with the following Instructions:
GROUP 1 - Compound # 222 Topic 0.15% in oil (cohort 1): Subjects were instructed to hold the bottle at an angle, so that the spinning ball was at the bottom and apply the spinning ball to the periorbital area, including the area of crow's feet, 2-3 times, starting from the area under the eye (and above the
315 cheekbone) and moving towards the outer tip of the eyebrow. After 2-3 runs, they were able to see moisture on the treated area. This procedure was repeated for the other eye.
Groups 2 & 3 - Compound # 222 Topical 0.15% on PEG (Cohort 2) and Compound # 222 Topical 0.05% on PEG (Cohort 3): Subjects were instructed to hold the vertical dispenser with one hand and with the tip of the index finger. On the pump (similar to holding a spray can), pour a small amount of the product into the palm of your other hand by pumping once or twice. The product was then applied to the periorbital area, including the crow's feet area, of both eyes with their index finger.
After 2, 4, 8 and 12 weeks of daily use of the test products, the test subjects returned to the study site with the test product applied. After acclimatizing to ambient conditions, scientifically matched high-resolution photographs were taken and biophysical measurements (assessment of living skin surface via Visioscan) were repeated using the standard template to identify test sites on the face. Furthermore (during the acclimatization period) participants were asked to fill out a self-assessment questionnaire.
Living skin surface evaluation - Visioscan: The Visioscan (Courage and Khazaka) took a direct image of living skin using a measuring head containing a CCD camera and two metal halogen lamps positioned opposite each other in order to ensure uniform illumination of the measuring field on the skin
316 (Skin Pharmacol Appl Skin Physiol (1999), 12 (1-2), 1-11 and Cosmetic & Toiletries magazine (2009; 124 (6), 51-54). The gray level distribution of the pixels in the image they correspond to different phenomena (white pixels represent flaking on the skin, dark pixels represent lines and wrinkles.) The computer program with the Visioscan automatically calculates parameters of skin smoothness, skin roughness, flaking and wrinkles. Visioscan images were taken at the following points in time: Baseline day 0 (start of study) week 2, week 4, week 8, and week 12 (end of test).
High resolution scientifically matched photography with PhotoGrammetrix image analysis<sup>MR</sup>: Exclusively detailed high-resolution digital photographs were taken before and after, with a fixed camera background, angles, adjustments, lighting, panel positioning, color bars, white balance, standardized and digitally certified without retouching. Each stage in the progression of the product treatment was photographically documented. This set of photographs provided a visual record of the effectiveness of the products. Full face, front view, left 45 °, and right 45 ° photographs were taken at the following points in time: Baseline day 0 (start of study) week 2, week 4, week 8, and week 12 (end of the proof).
The source data were Visioscan and PhotoGrammetrix image analysis readings along with subjective ratings, the
317 which were totaled and reported as average scores. The photographs were placed side by side in order to compare the before and after photographs of application of the test product in the eye area. Wrinkle reduction analysis source data consisted of quantifying crow's feet area in relative units (px), collected at baseline and evaluations at weeks 2, 4, 8 and 12. The data obtained via Visioscan and the PhotoGrammetrix image analysis were quoted as% of baseline differences at each of the points in time previously described. A paired t-test analysis was conducted in order to compare the results of post-test product application measurements to baseline measurements where applicable. Stay significance was established if p <(a = 0.05) was calculated.
Table 2 - Self-Assessment Questionnaire - Topical Compound # 222
0.15% in oil (cohort 1)
<td colspan="6">1. My wrinkles in the eye area have improved since the start of the study. Q1</td>
<td>Answer:</td><td>Totally agree</td><td>Agree</td><td>Neither agree nor disagree</td><td>Disagreement</td><td>Strongly disagree</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td colspan="2">Panelist ID No.</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 1</td><td colspan="2"> 5</td><td colspan="2"> 4</td>
318
<td>Subject # 2</td><td> 2</td><td> 2</td>
<td>Average score:</td><td> 3.50</td><td> 3.00</td>
<td> 1</td><td> 0%</td><td> 0%</td>
<td>Score vs. two</td><td> 50%</td><td> 50%</td>
<td> % 3</td><td> 0%</td><td> 0%</td>
<td>Responders: 4</td><td> 0%</td><td> 50%</td>
<td> 5</td><td> 50%</td><td> 0%</td>
<td colspan="3">2. Compared to the start of the study, the appearance of my skin around my eyes is ... Q2</td>
<td>Answer: Better</td><td>Little better Same</td><td>Little worse Worse</td>
<td>Score: 1</td><td> 2 3</td><td> 4 5</td>
<td>Panelist ID no .:</td><td>Day 7</td><td>Day 14</td>
<td>Subject # 1</td><td> 3</td><td> 3</td>
<td>Subject # 2</td><td> 2</td><td> 2</td>
<td>Average score:</td><td> 2.50</td><td> 2.50</td>
<td> 1</td><td> 0%</td><td> 0%</td>
<td>Score vs. two</td><td> 50%</td><td> 50%</td>
<td> % 3</td><td> 50%</td><td> 50%</td>
<td>Responders: 4</td><td> 0%</td><td> 0%</td>
<td> 5</td><td> 0%</td><td> 0%</td>
3. Compared to the start of the study, how does your skin feel about the treated area around your eyes and the appearance of wrinkles? Q3
Answer:
Very satisfied
Satisfied
Neither satisfied nor dissatisfied
Unsatisfied
Very unsatisfied
319
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td><sup>4</sup></td><td><sup>5</sup></td>
<td colspan="2">Panelist ID No.</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 1</td><td colspan="2"> 3</td><td colspan="2"> 3</td>
<td colspan="2">Subject # 2</td><td colspan="2"> 2</td><td colspan="2"> 1</td>
<td colspan="2">Average score:</td><td colspan="2"> 2.50</td><td colspan="2"> 2.00</td>
<td rowspan="5">Score vs. % Responders:</td><td> 1</td><td colspan="2"> 0%</td><td colspan="2"> 50%</td>
<td> 2</td><td colspan="2"> 50%</td><td colspan="2"> 0%</td>
<td> 3</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td> 4</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td colspan="2">4. Compared to the nest with light tingling, in the area treat</td><td colspan="4">the study, did you feel any discomfort, different from going during the study? Q4</td>
<td>Answer:</td><td>No</td><td>Yes, occasional discomfort that lasts less than an hour</td><td>Yes, occasional discomfort that lasts more than an hour</td><td>Yes, each day lasts less than an hour</td><td>Yes, each day lasts less than an hour</td>
<td>Scoring:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td>Paneli's ID</td><td>sta no .:</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 1</td><td colspan="2"> 1</td><td colspan="2"> 1</td>
<td colspan="2">Subject # 2</td><td colspan="2"> 2</td><td colspan="2"> 2</td>
<td colspan="2">Average rating:</td><td colspan="2"> 1.50</td><td colspan="2"> 1.50</td>
<td>Score vs.</td><td> 1</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
320
<td rowspan="4">% Responders:</td><td> 2</td><td> 50%</td><td> 50%</td>
<td> 3</td><td> 0%</td><td> 0%</td>
<td> 4</td><td> 0%</td><td> 0%</td>
<td> 5</td><td> 0%</td><td> 0%</td>
Table 3. Self-Assessment Questionnaire - Topical Compound # 222
0.15% in PEG (cohort 2)
<td colspan="6">1. My wrinkles in the eye area have improved since the start of the study. Q1</td>
<td>Answer:</td><td>Totally agree</td><td>Agree</td><td>Neither agree nor disagree</td><td>In disagreement</td><td>Strongly disagree</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td>Pane ID</td><td>ist no .:</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 3</td><td colspan="2"> 3</td><td colspan="2"> 2</td>
<td colspan="2">Subject # 4</td><td colspan="2"> 4</td><td colspan="2"> 4</td>
<td colspan="2">Average score:</td><td colspan="2"> 3.50</td><td colspan="2"> 3.00</td>
<td rowspan="5">Score vs. % Responders:</td><td> 1</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td> 2</td><td colspan="2"> 0%</td><td colspan="2"> 50%</td>
<td> 3</td><td colspan="2"> 50%</td><td colspan="2"> 0%</td>
<td> 4</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td colspan="2">2. Compared to the start of eyes is ... 02</td><td colspan="2">study, the appearance of my foot</td><td colspan="2">around any of my</td>
<td>Answer:</td><td>Best</td><td>A little better</td><td>Same</td><td>Little worse</td><td>Worst</td>
321
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td><sup>4</sup></td><td><sup>5</sup></td>
<td colspan="2">Panelist ID No.</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 3</td><td colspan="2"> 2</td><td colspan="2"> 2</td>
<td colspan="2">Subject # 4</td><td colspan="2"> 3</td><td colspan="2"> 3</td>
<td colspan="2">Average score:</td><td colspan="2"> 2.50</td><td colspan="2"> 2.50</td>
<td rowspan="5">Score vs. % Responders:</td><td> 1</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td> 2</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td> 3</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td> 4</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td colspan="2">3. Compared to eye onset and wrinkle appearance</td><td colspan="4">study how do you feel about the treated area around your >? Q3</td>
<td>Answer:</td><td>Very satisfied</td><td>Satisfied</td><td>Neither satisfied nor dissatisfied</td><td>Unsatisfied</td><td>Very unsatisfied</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td>Pane ID</td><td>ist no .:</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 3</td><td colspan="2"> 2</td><td colspan="2"> 2</td>
<td colspan="2">Subject # 4</td><td colspan="2"> 3</td><td colspan="2"> 4</td>
<td colspan="2">Average score:</td><td colspan="2"> 2.50</td><td colspan="2"> 3.00</td>
<td rowspan="4">Punctuation vs. % Answer back- dores:</td><td> 1</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td> 2</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td> 3</td><td colspan="2"> 50%</td><td colspan="2"> 0%</td>
<td> 4</td><td colspan="2"> 0%</td><td colspan="2"> 50%</td>
322
<td></td><td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td colspan="6">4. Compared to starting the study, have you felt any discomfort, other than light tingling, in the treated area during the study? Q4</td>
<td rowspan="2">Answer:</td><td rowspan="2">No</td><td rowspan="2">Yes, occasional discomfort that lasts less than an hour</td><td colspan="2">Yes. Discomfort Yes. Every day</td><td rowspan="2">Yes, every day that lasts longer from one hour</td>
<td>occasional lasting over an hour</td><td>which lasts less than one hour</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td>Pane ID</td><td>ist no .:</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 3</td><td colspan="2"> 2</td><td colspan="2"> 4</td>
<td colspan="2">Subject # 4</td><td colspan="2"> 1</td><td colspan="2"> 1</td>
<td colspan="2">Average score:</td><td colspan="2"> 1.50</td><td colspan="2"> 2.50</td>
<td rowspan="5">Punctuation vs. % Answer back- dores:</td><td> 1</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td> 2</td><td colspan="2"> 50%</td><td colspan="2"> 0%</td>
<td> 3</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td> 4</td><td colspan="2"> 0%</td><td colspan="2"> 50%</td>
<td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
Table 4. Self-Assessment Questionnaire - Topical Compound # 222
0.05% in PEG (cohort 3)
1. My wrinkles in the eye area have improved since the start of the study. Q1
Answer: Totally
Agree
Not agree
In
Totally
323
<td></td><td>agree</td><td></td><td>nor disagree</td><td>disagreement</td><td>in disagreement</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td colspan="2">Panelist ID No.</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 5</td><td colspan="2"> 2</td><td colspan="2"> 1</td>
<td colspan="2">Subject # 6</td><td colspan="2"> 2</td><td colspan="2"> 2</td>
<td colspan="2">Average score:</td><td colspan="2"> 2.00</td><td colspan="2"> 1.50</td>
<td>Punctuation</td><td> 1</td><td colspan="2"> 0%</td><td colspan="2"> 50%</td>
<td>vs. %</td><td> 2</td><td colspan="2"> 100%</td><td colspan="2"> 50%</td>
<td>Answer-</td><td> 3</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td>dores:</td><td> 4</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td></td><td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td colspan="4">2. Compared to the start of the study, the appearance of my foot</td><td colspan="2">around my eyes is ... Q2</td>
<td>Answer:</td><td>Best</td><td>A little better</td><td>Same</td><td>Little worse</td><td>Worst</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td colspan="2">Panelist ID No.</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 5</td><td colspan="2"> 1</td><td colspan="2"> 1</td>
<td colspan="2">Subject # 6</td><td colspan="2"> 2</td><td colspan="2"> 2</td>
<td colspan="2">Average score:</td><td colspan="2"> 1.50</td><td colspan="2"> 1.50</td>
<td>Punctuation</td><td> 1</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td>vs. %</td><td> 2</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td>Answer back-</td><td> 3</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td>dores:</td><td> 4</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
324
<td></td><td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td colspan="2">3. Compared to the nest with its eyes and the appearance of ar</td><td colspan="4">I read study, how do you feel about the treated area around wrinkles? Q3</td>
<td>Question:</td><td>Very satisfied</td><td>Satisfied</td><td>Neither satisfied nor dissatisfied</td><td>Unsatisfied</td><td>Very unsatisfied</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td colspan="2">Panelist ID No.</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
<td colspan="2">Subject # 5</td><td colspan="2"> 1</td><td colspan="2"> 1</td>
<td colspan="2">Subject # 6</td><td colspan="2"> 3</td><td colspan="2"> 2</td>
<td colspan="2">Average score:</td><td colspan="2"> 2.00</td><td colspan="2"> 1.50</td>
<td rowspan="5">Punctuation vs. % Answer back- dores:</td><td> 1</td><td colspan="2"> 50%</td><td colspan="2"> 50%</td>
<td> 2</td><td colspan="2"> 0%</td><td colspan="2"> 50%</td>
<td> 3</td><td colspan="2"> 50%</td><td colspan="2"> 0%</td>
<td> 4</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td> 5</td><td colspan="2"> 0%</td><td colspan="2"> 0%</td>
<td>4. Comparison tingling lig</td><td colspan="5">a With the start of the study, have you felt any discomfort, different from uero, in the area treated during the study? Q4</td>
<td>Answer:</td><td>No</td><td>Yes, occasional discomfort that lasts less than an hour</td><td>Yes, occasional discomfort that lasts more than an hour</td><td>Yes, every day that lasts less than an hour</td><td>Yes, every day that lasts less than an hour</td>
<td>Punctuation:</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td>
<td colspan="2">Panelist ID No.</td><td colspan="2">Day 7</td><td colspan="2">Day 14</td>
325
<td colspan="2">Subject # 5</td><td> 1</td><td> 1</td>
<td colspan="2">Subject # 6</td><td> 1</td><td> 1</td>
<td colspan="2">Average score:</td><td> 1.00</td><td> 1.00</td>
<td>Punctuation</td><td> 1</td><td> 100%</td><td> 100%</td>
<td>vs. %</td><td> 2</td><td> 0%</td><td> 0%</td>
<td>Answer back-</td><td> 3</td><td> 0%</td><td> 0%</td>
<td>dores:</td><td> 4</td><td> 0%</td><td> 0%</td>
<td></td><td> 5</td><td> 0%</td><td> 0%</td>
Table 5. Roughness reduction [SEr] via Visioscan - Compound # 222 topical 0.15% in oil (Cohort 1)
<td>Panelist ID no .:</td><td>Baseline</td><td>Day 7</td><td>individual% difference</td><td>Day 14</td><td>Individual% difference</td>
<td>Subject # 1</td><td> 2.50</td><td> 2.46</td><td> -1.60%</td><td> 2.25</td><td> -9.82%</td>
<td>Subject # 2</td><td> 1.90</td><td> 1.48</td><td> -21.90%</td><td> 1.29</td><td> -31.93%</td>
<td>Average:</td><td> 2.20</td><td> 1.97</td><td></td><td> 1.77</td><td></td>
<td colspan="2">% Of diference</td><td> -10.36%</td><td></td><td> -19.36%</td><td></td>
Table 6. Roughness reduction [SEr] via Visioscan - Compound # 222 Topical 0.15% in PEG (cohort 2)
<td>Panelist ID no .:</td><td>Baseline</td><td>Day 7</td><td>Individual% difference</td><td>Day 14</td><td>Individual% difference</td>
<td>Subject # 3</td><td> 2.21</td><td> 1.95</td><td> -11.79%</td><td> 1.90</td><td> -13.83%</td>
326
<td>Subject # 4</td><td> 1.51</td><td> 1.39</td><td> -7.84%</td><td> 1.35</td><td> -10.63%</td>
<td>Average:</td><td> 1.86</td><td> 1.67</td><td></td><td> 1.62</td><td></td>
<td colspan="2">% Of diference</td><td> -10.19%</td><td></td><td> -12.53%</td><td></td>
Table 7. Roughness reduction [SEr] via Visioscan - Compound # 222 Topical 0.05% in PEG (cohort 3)
<td>Panelist ID no .:</td><td>Baseline</td><td>Day 7</td><td>Individual% difference</td><td>Day 14</td><td>Individual% difference</td>
<td>Subject # 5</td><td> 2.58</td><td> 1.83</td><td> -29.07%</td><td> 1.77</td><td> -31.40%</td>
<td>Subject # 6</td><td> 1.52</td><td> 1.44</td><td> -5.26%</td><td> 1.24</td><td> -18.42%</td>
<td>Average:</td><td> 2.05</td><td> 1.64</td><td></td><td> 1.51</td><td></td>
<td colspan="2">% Of diference</td><td> -20.24%</td><td></td><td> -26.59%</td><td></td>
Example 2
Four groups of women were recruited to evaluate and compare the efficacy of four anti-aging test products (targeting the periorbital eye area) turned on to reduce the appearance of fine lines, wrinkles on the outer canthus of the eyes (crow's feet area) over a period of 12 weeks. Wrinkle assessment was instrumentally conducted using a Visioscan image analysis system. The effectiveness of the test product was evaluated using panelist self-assessment via questionnaire responses. Each stage in the progression of treatments was documented photographically using scientifically matched high-resolution photography technique. He
327 Image analysis quantified the changes in expression lines and crow's feet condition observed in scientifically matched photographs.
Selection of the subject:
Number: eighty-three subjects (twenty or twenty-one per group) to complete the study.
Gender: women
Race: Caucasian / Asian / Hispanic
Age range: 40 to 60 years
Test samples:
Topical 0.15% Compound # 222 in Oil (a 50/50 mixture of Propylene Glycol Dicaprylate / Dicaprate and Caprylic / Capric Triglyceride) (Cohort 1)
Topical 0.05% Compound # 222 in Oil (a 50/50 mixture of Propylene Glycol Dicaprylate / Dicaprate and Caprylic / Capric Triglyceride) (Cohort 2)
Topical 0.15% Compound # 222 in PEG400 (Cohort 3) Topical 0.05% Compound # 222 in PEG400 (Cohort 4)
The testing and evaluation protocol was the same as in Example 1.
Figures 1 and 2 show the average change in roughness from baseline and percent reduction in skin wrinkles of test subjects after topical treatment of the periorbital areas by compound # 222 in the 4 cohorts.
Table 8 below shows more detail of cohort 1 in
328 week 8 and week 12 as compared to baseline.
Table 8. Change in roughness and change in depth of wrinkles via Visioscan - Compound # 222 Topical 0.05% in oil (cohort 2) in week 8 and 12.
Week 8
Week 12
<td>Number of test subjects</td><td> 21</td><td> 21</td>
<td>Change in roughness</td><td></td><td></td>
<td>Average (SD)</td><td> -0.85 (0.59)</td><td> -1.01 (0.59)</td>
<td>Median [Min, Max]</td><td> -0.67 [-2.00, -0.02]</td><td> -0.79(-1.79, -0.21]</td>
<td>% change in roughness</td><td></td><td></td>
<td>Average (SD)</td><td> -32.9% (15.8)</td><td> -39.3% (14.6)</td>
<td>Median [Min, Max]</td><td> -33.9% [-57.7, -0.9]</td><td> -40.9% [-59.8, - 10.3]</td>
<td>Change in wrinkle depth (x10<sup>4</sup>)</td><td></td><td></td>
<td>Average (SD)</td><td> -0.89 (0.63)</td><td> -0.92 (0.76)</td>
<td>Median [Min, Max]</td><td> -0.79 [-2.10, 0.05]</td><td> -0.85 [-2.47, 0.49]</td>
<td>% change in wrinkle depth</td><td></td><td></td>
<td>Average (SD)</td><td> -58.0% (24.2)</td><td> -54.1% (35.5)</td>
<td>Median [Min, Max]</td><td> -59.3% [-86.8, 4.1]</td><td> -63.5% [-88.2, 38.9]</td>
<img file="MX368248B_D0251.tif" />
329
Contents59
292 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92 Sheet 93 Sheet 94 Sheet 95 Sheet 96 Sheet 97 Sheet 98 Sheet 99 Sheet 100 Sheet 101 Sheet 102 Sheet 103 Sheet 104 Sheet 105 Sheet 106 Sheet 107 Sheet 108 Sheet 109 Sheet 110 Sheet 111 Sheet 112 Sheet 113 Sheet 114 Sheet 115 Sheet 116 Sheet 117 Sheet 118 Sheet 119 Sheet 120 Sheet 121 Sheet 122 Sheet 123 Sheet 124 Sheet 125 Sheet 126 Sheet 127 Sheet 128 Sheet 129 Sheet 130 Sheet 131 Sheet 132 Sheet 133 Sheet 134 Sheet 135 Sheet 136 Sheet 137 Sheet 138 Sheet 139 Sheet 140 Sheet 141 Sheet 142 Sheet 143 Sheet 144 Sheet 145 Sheet 146 Sheet 147 Sheet 148 Sheet 149 Sheet 150 Sheet 151 Sheet 152 Sheet 153 Sheet 154 Sheet 155 Sheet 156 Sheet 157 Sheet 158 Sheet 159 Sheet 160 Sheet 161 Sheet 162 Sheet 163 Sheet 164 Sheet 165 Sheet 166 Sheet 167 Sheet 168 Sheet 169 Sheet 170 Sheet 171 Sheet 172 Sheet 173 Sheet 174 Sheet 175 Sheet 176 Sheet 177 Sheet 178 Sheet 179 Sheet 180 Sheet 181 Sheet 182 Sheet 183 Sheet 184 Sheet 185 Sheet 186 Sheet 187 Sheet 188 Sheet 189 Sheet 190 Sheet 191 Sheet 192 Sheet 193 Sheet 194 Sheet 195 Sheet 196 Sheet 197 Sheet 198 Sheet 199 Sheet 200 Sheet 201 Sheet 202 Sheet 203 Sheet 204 Sheet 205 Sheet 206 Sheet 207 Sheet 208 Sheet 209 Sheet 210 Sheet 211 Sheet 212 Sheet 213 Sheet 214 Sheet 215 Sheet 216 Sheet 217 Sheet 218 Sheet 219 Sheet 220 Sheet 221 Sheet 222 Sheet 223 Sheet 224 Sheet 225 Sheet 226 Sheet 227 Sheet 228 Sheet 229 Sheet 230 Sheet 231 Sheet 232 Sheet 233 Sheet 234 Sheet 235 Sheet 236 Sheet 237 Sheet 238 Sheet 239 Sheet 240 Sheet 241 Sheet 242 Sheet 243 Sheet 244 Sheet 245 Sheet 246 Sheet 247 Sheet 248 Sheet 249 Sheet 250 Sheet 251 Sheet 252 Sheet 253 Sheet 254 Sheet 255 Sheet 256 Sheet 257 Sheet 258 Sheet 259 Sheet 260 Sheet 261 Sheet 262 Sheet 263 Sheet 264 Sheet 265 Sheet 266 Sheet 267 Sheet 268 Sheet 269 Sheet 270 Sheet 271 Sheet 272 Sheet 273 Sheet 274 Sheet 275 Sheet 276 Sheet 277 Sheet 278 Sheet 279 Sheet 280 Sheet 281 Sheet 282 Sheet 283 Sheet 284 Sheet 285 Sheet 286 Sheet 287 Sheet 288 Sheet 289 Sheet 290 Sheet 291 Sheet 292
45 members in 25 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 201462039786 | United States of America | P | |
| 201462039786 | United States of America | P | |
| 62039786 | United States of America | – | |
| 2015046120 | United States of America | W | |
| 2015046120 | United States of America | W | |
| 62039786 | – | – | – |
| PCTUS2015046120 | – | – | – |
| US201462039786P | – | – | – |
| WO2015US46120 | – | – | – |
Members45
| Document | Office | Kind | |
|---|---|---|---|
| CA2958580A1 | Canada | A1 | |
| WO2016029021A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2016206540A1 | United States of America | A1 | |
| AU2015305373A1 | Australia | A1 | |
| IL250663D0 | Israel | D0 | |
| KR20170066342A | Republic of Korea | A | |
| EP3206686A1 | European Patent Office (EPO) | A1 | |
| CN107106549A | China | A | |
| JP2017525767A | Japan | A | |
| US9795550B2 | United States of America | B2 | |
| CL2017000410A1 | Chile | A1 | |
| MX2017002285A | Mexico | A | |
| EP3206686A4 | European Patent Office (EPO) | A4 | |
| US2018193244A1 | United States of America | A1 | |
| RU2017108750A | Russian Federation | A | |
| BR112017003959A2 | Brazil | A2 | |
| RU2017108750A3 | Russian Federation | A3 | |
| MX368248BThis record | Mexico | B | |
| US10434052B2 | United States of America | B2 | |
| EP3206686B1 | European Patent Office (EPO) | B1 | |
| DK3206686T3 | Denmark | T3 | |
| PT3206686T | Portugal | T | |
| LT3206686T | Lithuania | T | |
| MA40454B1 | Morocco | B1 | |
| HRP20192161T1 | Croatia | T1 | |
| RS59797B1 | Serbia | B1 | |
| HUE046741T2 | Hungary | T2 | |
| SI3206686T1 | Slovenia | T1 | |
| PL3206686T3 | Poland | T3 | |
| ES2762559T3 | Spain | T3 | |
| CN107106549B | China | B | |
| US2020222295A1 | United States of America | A1 | |
| RU2727039C2 | Russian Federation | C2 | |
| IL250663A | Israel | A | |
| IL250663B | Israel | B | |
| JP6766047B2 | Japan | B2 | |
| KR102165385B1 | Republic of Korea | B1 | |
| AU2015305373B2 | Australia | B2 | |
| CY1122603T1 | Cyprus | T1 | |
| US11077046B2 | United States of America | B2 | |
| US2022087917A1 | United States of America | A1 | |
| BR112017003959B1 | Brazil | B1 | |
| CA2958580C | Canada | C | |
| US11839679B2 | United States of America | B2 | |
| ZA201701460B | South Africa | B |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Grant or registrationFG | FG |
Numbers
- Publication
- 368248
- Publication, DOCDB
- 368248
- Publication, EPODOC
- MX368248
- Application
- 2017002285
- Application, DOCDB
- 2017002285
- Application, EPODOC
- MX20170002285
Titles2
- Spanish
- GAMMA-DICETONAS PARA TRATAMIENTO Y PREVENCION DE PIEL ENVEJECIDA Y ARRUGAS.
- English
- GAMMA-DICETONES FOR TREATMENT AND PREVENTION OF AGED SKIN AND WRINKLES.
Classification
- CPC, 20
- A61K8/35
- A61K8/4986
- A61K31/44
- A61K8/41
- A61K8/4913
- A61K8/492
- A61K8/4946
- A61K8/69
- A61K8/70
- A61K8/49
- A61K8/4926
- A61K8/494
- A61K8/4953
- A61K8/4973
- A61K8/498
- A61Q19/007
- A61Q19/02
- A61Q19/08
- A61K2800/10
- A61P17/00
- IPC, 1
- A61Q19 08